

Open MDMA: An Evidence-Based Mixed-Methods Review, Theoretical Framework, and Manual for MDMA Therapy

Mark Groeneveld¹

Thomas Harper, M.S.W.²

The book is mostly complete and in decent shape aside from a need of editing, an occasional to-do, and a few marked sections that are in varying degrees of messy unfinishedness. SAFETY RECOMMENDATIONS ARE UNDERGOING MAJOR REVISIONS.

¹Corresponding author; Email: mgroeneveld@protonmail.ch

²Master of Social Work

This work is licensed under [CC BY 4.0](#).

If you share this document, please use this link to ensure people have the latest version: doi.org/10.31234/osf.io/aps5g. This site also tallies downloads, informing us how many people are using the guide and how worthwhile it is to update it with new research.

We'd love to hear your thoughts at mgroeneveld@protonmail.ch. You can submit anonymous feedback [here](#).

We accept donations sent to mgroeneveld@protonmail.ch on Zelle, Venmo, or PayPal. We spent about 761 hours on this project, not including much of the acquisition of relevant skills and knowledge, and have no outside funding.

Contents

Preface	v
1 Introduction	1
1.1 The Essentials	1
1.2 Introduction	2
1.3 Our Pitch	4
1.4 Summary for Mental Health Professionals	6
2 The Science of Mental Illness	9
2.1 Epistemic Status	9
2.2 Defense Cascade	15
2.3 Trauma and its Effects	18
2.4 Mechanism of Healing	22
2.5 Complex Systems, Worsening Symptoms, and Destabilization	25
2.6 Health Conditions Associated with Trauma	28
2.7 Efficacy of MDMA Therapy	28
3 Preparation	33
3.1 Safety and Medical Information	33
3.2 Professional Guidance vs. Self Guidance	46
3.3 How to Find a Therapist or Guide	50
3.4 Dosage and Testing	66
3.5 Dissociation and Avoidance During the Session	67
3.6 Organizing Community Care	69
4 Pre-Session to Post-Session	73
4.1 Pre-Session Checklist	73
4.2 The MDMA Therapy Session	77
4.3 Troubleshooting	80
4.4 Afterglow	84
4.5 Assessing Whether the Session Worked	84
4.6 Making Sense of the Experience	84

5	Between Sessions	89
5.1	[unfinished/poor-quality] The Big Picture / Long Term Process of Healing .	89
5.2	Continued Reconsolidation	90
5.3	[need to re-cite] Making Positive Life Changes	93
5.4	Managing Adverse Symptoms Outside the Session	98
5.5	Session Frequency	102
5.6	Prompts for Uncovering Maladaptive Schemas	104
6	Beyond Therapy	111
6.1	[need to rethink theory] Expanding the Circle of Compassion	111
6.2	Cognitive Flexibility and Truth-Seeking	113
	Glossary	117
A	Psychoeducation	119
B	Shame Triggers Writing Exercise	121
C	Attachment Theory	123
D	Self-Determination Theory	125
E	Life Changes for Improved Mental Health	127
F	Autobiographical Accounts of Internalized MDMA Therapy	129
G	Suggested Avenues of Future Research	133
	Bibliography	157

[unfinished] Preface

This is, admittedly, an odd book that doesn't fit traditional categories. We combined the tasks of reviewing, theorizing, and advocacy of certain moral goals, all in the packaging of a practical manual. We even included a significant amount of personal experience! Our aim is democratizing access to high quality MDMA therapy by mixing exceptional scientific rigor, comprehensive practical guidance, high ethical standards, and transparency about our biases and what is known and not known in the field. I suspect researchers and medical professionals rarely have the right set of incentives to create such documents. I created it because my life was at stake, and I felt that creating this unique set of actionable but accurate knowledge was my only option for survival. Scientific rigor, theoretical consistency, triple checking every conceivable error, covering every possible contingency, intellectual honesty, transparency, and making the best of non-optimal situations in ways the medical system doesn't approve of are critical survival tools for me ¹. The book is my version of *Where there is no Doctor*, but made for a world in which even well-trained mental health professionals need far better information than they currently have.

Much public medical information seems to be shitty in large part because it's optimized for avoidance of liability. We spent almost no effort optimizing for liability! Hopefully this doesn't come back to bite us in the ass. Please read our disclaimers because they indicate genuine uncertainty or perception of risk. We could also be wrong about things!

The book started as my attempt to figure out what was actually happening during my own MDMA therapy journey, which I started after getting no help from almost every treatment licensed mental health professions can offer. I had a very difficult time figuring out what mental illness is, what MDMA therapy does, and how to optimize MDMA therapy for efficacy and safety. As I learned, rigorous answers to these questions have only started to appear in the 2000s and 2010s, and haven't yet widely diffused out of academia to on-the-ground practitioners or even therapist training programs. This knowledge base is also widely distributed in the research literature, and as far as I can tell, hasn't been put together in one place before, especially one accessible to a significant portion of the public. This is unfortunate because many people are desperate for mental health treatment and are attempting MDMA therapy with inadequate information. I thought a manual could help with these problems.

My deepest desire for this work is aiding the wellbeing and cooperation of all beings through the unlearning of maladaptive reactions and beliefs and practicing compassion.

¹As with most coping strategies that people with complex trauma develop, these are somewhat neurotic in many aspects of my life. They have been quite helpful here though. I also have other motivations for writing.

However, I have my own maladaptive beliefs, and have certainly projected them into this work in unhelpful ways despite attempting to avoid that. I've tried to be critical of the things I'm enthusiastic about, but inevitably my biases have pushed me to be overly critical of some things and credulous about others. Likewise, I try to strike a balance between practical applicability and scientific robustness but recognize that that balance means this document is optimally adapted to neither case. In addition, the scope of this document presents some problems. I have deep experience with some aspects of MDMA therapy, and have excellent broad knowledge of the research, but am not an expert on any of the individual pieces of the process or theory of MDMA therapy. Hence, while I have done my best to critically evaluate the evidence and our references, I certainly have missed some nuances only visible to certain subject-matter-experts. My core assumptions and my confidence for them are laid out in Section 2.1. The core ideas of the guide are likely solid, however, some of our citations will inevitably not reproduce in further experiments. Reproducible science is difficult to do or identify.

The strength and novelty of this book lies in the synthesis of multiple theoretical frameworks (memory reconsolidation/predictive-processing and the defense cascade) for describing MDMA therapy, fleshing out the interface of MDMA therapy and predictive processing, and comprehensive review and guidance for most aspects of MDMA therapy that is somewhat accessible to both clients and professionals. It contains almost no individually-original research or insights. Its rigorous science-based approach will also appeal to readers averse to the New Age and shamanic/neo-shamanic beliefs that pervade psychedelic scenes. I think our combination of personal experience and nuanced-research also allow us to present a better balance of the nuance and complex tradeoffs involved in MDMA therapy.

I would like to thank: The scientists and therapists who developed this body of knowledge and practice. My friend Jessica Sojorne Libere, for initial MDMA therapy guidance. My partner for encouragement, support, and editing. r/mdmaththerapy for numerous case examples. One anonymous reviewer.

May this work benefit all beings.

Mark

Author Contributions:

MG developed the initial concept, overall structure, and first draft. TH and MG then shared writing, editing, concept development, and research. Total contribution of hours was about 75% MG and 25% TH. TH wrote the sections How to Find a Skilled and Well-Matched Therapist or Guide, most of Professional Guidance vs. Self Guidance, Organizing Community Care, Making Positive Life Changes, Prompts for Uncovering Common Maladaptive Schemas, Attachment Theory, and some odds-and-ends. MG wrote most of the rest. We shared editing equally.

Biases, Conflicts of Interest, and Author Background:

See Table 1.

Table 1: Author biases, conflicts of interest, and backgrounds.

MG	TH
<ul style="list-style-type: none"> • Has disorganized attachment to MDMA. Resents the mental health establishment for decades of misdiagnoses and ineffective treatment. • Strong belief that everyone should cultivate compassion for all beings. • Scored 14.5/40 (not at all a cultist) on Evan's "Are you a Psychedelic Cultist" quiz [169]. • Used MDMA therapy to self-treat severely disorganized attachment, and suspected childhood sexual abuse. Started with 3 professionally-guided sessions then did a further 20 solo sessions. • Thoroughly familiar with the broad, interdisciplinary set of MDMA therapy research. • No financial stake in the project other than likely-negligible future donations for, or sales of this book. 	<ul style="list-style-type: none"> • Attached to their identity and work as a therapist. • Strong belief in the benefits of cultivating compassion. • Scored 11.5/40 (not at all a cultist) on Evan's "Are you a Psychedelic Cultist" quiz [169]. • Hasn't used MDMA or guided any MDMA therapy sessions. Is a therapist highly regarded by their clients. Also has two decades of experience in community organizing around mental health. • Deeply familiar with the professional practice of therapy, therapy best-practices, and the failures of the mental health industry. • MG paid them for writing and editing. No other financial stake in the project other than likely-negligible future donations for, or sales of this book.

Chapter 1

Introduction

1.1 The Essentials

This document is long and somewhat technical. We think the essential sections include:

- What is [Trauma](#) and Why do its Effects Stick Around ([2.3](#)), [Defense Cascade](#) ([2.2](#)), and Mechanism of Healing ([2.4](#))
- The first list in the safety section summarizing risks ([3.1](#)) and Professional Guidance vs. Self Guidance ([3.2](#))
- Dosing ([3.4](#)), Handling [Dissociation](#) and [Avoidance](#) During the Session ([3.5](#)), Pre-Session Preparation ([4.1](#)), The MDMA Therapy Session ([4.2](#)), and Troubleshooting ([4.3](#))

At an absolute bare minimum please read the first list in the safety section summarizing risks ([3.1](#)) and The MDMA Therapy Session ([4.2](#)).

We also had excellent results (low rate of hallucinations, accurate, clear, helpful) using the Claude 3.7 Sonnet (We had much worse results with ChatGPT-4o.) large language model to answer questions about this document using these instructions: "You should helpfully answer the user's questions about MDMA therapy based on the attached document. The user may not understand the technical content of the paper, so you should make it easier to understand when appropriate. Feel free to interpolate/extrapolate the information in the document and make reasonable assumptions; you don't need to regurgitate it verbatim. Don't say 'the document says/recommends/presents/etc.'; that is assumed." Removing the bibliography from the PDF before uploading it will reduce the document size and allow you more questions before you hit usage limits. Claude can probably also translate and respond in your choice of language.

This guide doesn't offer personalized medical/therapeutic advice, guarantee healing, assure the prevention of negative (possibly severe) outcomes, or prevent legal problems if used in a place where MDMA is illegal. Instead, this guide is our framework for increasing the efficacy and safety of MDMA therapy, grounded in research, community insights, and author experiences. We have spent considerable effort trying to make the best guide we can, but we could be wrong about some important things. If you doubt something we say, cross-check

our references with other high quality sources of information. We don't currently have any professional licenses, but we do have a lot of lived experience, skepticism, drive for rigor, capacity for critically evaluating research literature, and some training and professional experience. These disclaimers are serious; it isn't just disingenuous boilerplate legal stuff. While this guide has universal aspects, it doesn't cover all frameworks for doing MDMA therapy. Although MDMA therapy has been practiced by underground therapists for decades, comprehensive scientific study is relatively recent, leaving some aspects unexplored [252]. Possessing [psychedelics](#) is a felony in many jurisdictions [262]. Licensed mental health professionals theoretically risk their licensure by offering psychedelic therapy in contexts where it isn't legal. In practice, we only know of two instances of this happening, both involving inappropriate therapist-client boundary crossing [200, 293].

1.2 Introduction

MDMA creates powerful feelings of compassion, connection, and safety [110]. When used with skill, these emotional states are highly effective tools for healing and adaption. However, there are no quick fixes for all but the most simple issues. We think that, even in optimal conditions, MDMA therapy and the best cases of traditional psychotherapy can take multiple years to heal severe mental illness. Additionally, almost all models of MDMA therapy currently under investigation emphasize the necessity of between-session therapy or at-home therapeutic exercises to fully treat complex mental illness [29]. We think MDMA can provide an on-ramp to these activities if they have traditionally been difficult or useless for you. Uncovering and healing the effects of [trauma](#) can be psychologically [destabilizing](#) until the newly-surfaced emotions have been processed [247]. Therapeutic destabilization can be intense for those with the severe trauma [220]. We believe MDMA therapy presents a significant increase in the potential cost-quality curve of therapy and provides a much-needed tool for cases that haven't responded well to other approaches [231]. The potential benefits of therapy can be described in different ways:

- Healing mental illness or addiction
- Connecting to yourself, those you love, and the world.
- Developing equanimity, patience, compassion, introspection, resilience, alignment of behavior with goals, and cognitive and emotional flexibility.
- Unburdening from hypervigilance, fear, chronic stress, loneliness, addiction, shame, guilt, etc.
- Helping you focus on the things that you can change and let go of the things you can't.

Put another way, we think the processes in this document (also achieved through the best cases of traditional psychotherapy) can help you achieve the following characteristics of securely attached adults, developed by D. P. Brown and Elliott [44]:

Seeks emotional closeness with others; Able to establish emotional intimacy; Comfortable with mutual dependence; Comfortable being alone; Positive self-image and other image; Warm and open with others; Accepts criticism without significant distress; Strong sense of self; Self-esteem; Self-observational skills; Self-reflective skills; Able to trust in relationship; Relationships tend to be stable, lasting; Open with others about feelings; Positive feelings about relationships; Balanced experience of emotions-neither too little nor too much; Values attachment

The core process of healing is conceptually simple: activate a maladaptive pattern; contradict that pattern (with other knowledge, the present moment, or MDMA-induced feelings) until the pattern dissipates; repeat until satisfied [89]. Almost all of this manual is just instructions on how to facilitate this process with MDMA or other techniques, and how to manage support for yourself during the longer process of healing.

This manual has four use cases: 1) individuals interested in MDMA therapy for themselves, whether they want professional assistance or not, 2) mental health professionals seeking a thorough understanding of MDMA therapy, and who might want a resource to give to their clients, and 3) researchers interested in the interface between MDMA, memory [reconsolidation](#), and the [defense cascade](#). Unfortunately, it's difficult to write for all audiences in the same document. We primarily wrote to the therapy client or solo user because that is the foundation of our personal expertise. Consequently, the mental health professional will have to combine the information in this document with their existing training, and possibly also with training programs for [psychedelic-assisted](#) therapy, though we are quite unclear on this last point. If psychedelic therapy training programs are anything like academic degree programs in therapy, we expect a severe lack of scientific rigor and the uncritical promulgation of unvalidated hypotheses.

As detailed in Section [2.1](#), we think the core theories this manual relies on are solid. However, any pharmaceutical or therapeutic intervention relies on a multitude of small or not-so-small choices (1.6mg/kg or 1.4mg/kg of MDMA?, Directive or non-directive therapy?, What type of therapist training?) that have not been rigorously studied. Any manual or practice, including ours, thus inherently depends on quite a lot of educated guesswork to fill in the gaps between the main support beams of rigorously validated theory and practice. We always clearly distinguish between more established science and educated guesswork by marking opinions as "we think," "we believe," etc. We aim to provide a majority of the "full stack" of knowledge needed to successfully do MDMA therapy, though we don't include about much about the fundamentals of being a good mental health professional. So you can't rely on this alone to teach yourself to be an MDMA therapy guide.

As of the early 2020s, we are somewhere in a psychedelic hype bubble [345]. There are many reports and anecdotes of psychedelics treating a wide variety of health conditions. The hype bubble makes it difficult to figure out which claims are true and which are false. There are also many claims of psychedelics solving a wide variety of issues including war, oppression, etc. We don't believe that just taking the medicine will necessarily change people's beliefs and actions related to these issues. However, we do think some of the insecurities partly driving these problems can be unlearned by explicitly activating those feelings during an MDMA session.

We avoid providing a simple list of instructions to follow because the practice of MDMA therapy is sometimes complex, we are not able to provide individualized medical advice, and many uncertainties about the practice remain unresolved.

There is an extensive glossary after the appendices. We use some terms differently than some other authors, and the glossary describes our choices. We used a python script to link the first occurrences of glossary terms in each section to the glossary. This works pretty well, but there may be an occasional inappropriately-linked term.

1.3 Our Pitch

Mental illness is one of the largest causes of suffering [339]. Besides being painful, difficult, and expensive for the people who experience it, it carries a heavy economic, emotional, and logistical cost for close companions of those who experience it. On top of all this, we hypothesize that the widespread prevalence of mental illness effects such as cognitive distortion, emotional rigidity, and emotions of deep insecurity and threat may be among the engines driving tribalism and political polarization across the globe. Even when mental illness isn't a factor in tribalism, we hypothesize that the learned maladaptive and false beliefs that are key components of humanity's tribal tendencies [125, 178] can be unlearned by the same mechanism that mental illness can be unlearned. While some individuals are able to access effective mental healthcare, both access and effectiveness are inadequate for most of the vast population of individuals who experience mental illness.

We are developing an evidence based user guide to therapeutic MDMA use. Therapeutic use of MDMA is one of the most promising developments in psychopharmacology [231]. This guide has the potential to meaningfully reduce mental illness by addressing several of the most prevalent, highest impact barriers to effective care. By doing this, we hope to:

- Alleviate direct suffering
- Assist individuals in building their capacity to function effectively in the world.
- Increase the ability of individuals to feel and behave compassionately toward all beings.

Ultimately, we believe this has the potential to improve the capacity of entire communities to act collaboratively towards constructive ends. Although the usefulness of therapeutic MDMA for individuals who do not experience mental illness has not been established with the same research base, we are also hopeful that it could eventually become a resource for anyone who wishes to experience a greater sense of meaning, connection, and fulfillment in their life. We believe this guide provides the foundational knowledge necessary to leverage MDMA to create transformative increases in compassion and connectedness, relevant to many positive social outcomes as well as to mental healthcare. This project aims to amplify the broad-scale effectiveness of therapeutic MDMA use by helping overcome three categories of barriers:

- **Trust:** Feelings of trust towards the therapeutic process are an important resource for getting individuals into mental health treatment who need it, and feelings of trust

between therapists and clients are an essential mechanism for the effectiveness of therapy [340]. One of the most exciting aspects of therapeutic MDMA usage is that it allows [traumatized](#) individuals to experience a sense of safety and connectedness that is otherwise physiologically and psychologically inaccessible to them, even in trustworthy circumstances [110]. Additionally, many cultures and subcultures experience a normalized hostility regarding even the acknowledgement of mental illness, creating a challenge for clients who are in need of care and for clinicians who attempt to provide effective care in these communities. It can also be extremely difficult for individuals of a particular identity group to feel trust towards a clinician who shares few of their identities and little of their direct experience. Because of this, the ability to achieve that trust more reliably with the support of MDMA may be an enormous asset in increasing the accessibility of effective care. Because of its emphasis on rigor and accessibility, the guide we are producing has the potential to increase the comfort of a wide variety of individuals who would not otherwise be willing to use MDMA, and the comfort of a wide variety of clinicians who would not otherwise be willing to support them.

- **Financial and logistical:** We believe MDMA is useful for increasing cost-effectiveness for many clients. This can happen through increased efficiency of therapy—it has already shown promise in clinical trials for treating cases resistant to conventional methods. It can also happen through gradually shifting a large amount of therapeutic work to at-home sessions the client conducts by themselves or with a “sitter” who needs far less training than a fully licensed clinician, if such a method is found to be safe and effective within certain parameters (as some underground practitioners we know have already anecdotally seen, and has been reported by Colbert and S. Hughes [66] and Hills [152]). We hope MDMA-assisted psychotherapy will make significant improvements to the cost/quality curve of psychotherapy.
- **Clinician training:** In our professional experience, many licensed clinicians lack access to the best and most up-to-date training on a variety of therapies because of financial barriers. Additionally, because MDMA usage is and has long been illegal, clinicians who ask their supervisors and senior colleagues about how to support this form of clinical work are often rebuffed. Many clinicians are unwilling to provide clinical support to individuals who embark on its therapeutic use on their own, due to this lack of training and support, as well as due to the legal ambiguities of such care. Depending on how flexible the FDA rules for clinical support are when and if MDMA is legalized, it is possible that providing a high quality open access manual at this early stage of the legalization process could have a positive impact on the culture of mental health providers around MDMA support. This has the potential to prevent rent-seeking experts from making an expensive certification the standard in clinical MDMA support before widespread access to therapeutic MDMA can even be established.

We are writing a rigorous, comprehensive, and accessible guide to therapeutic MDMA use. It starts with a clear exposition on the science of trauma and healing, articulating a proposed mechanism by which MDMA therapy most likely achieves its effectiveness. It continues on to a thorough discussion of the practice of MDMA therapy, covering safety, dosage, what

to expect physically and psychologically, and the role of clinical support. This includes discussion of complicating factors such as addiction, poly-drug use, and [contraindications](#). We have included detailed instructions on using MDMA to confront the painful and self-defeating feelings that underlie a wide range of implicit social biases. Finally, we include a discussion of therapies and therapeutic supports appropriate for augmenting MDMA therapy, as well as several appendices of supplementary resources to assist therapeutic MDMA users in getting the most out of their experience.

Many people are already doing professionally-guided or solo MDMA therapy outside legal frameworks [152, 252]. The available information on the subject for these professionals, their clients, and DIYers is usually poor quality, locked behind expensive training programs, or both. Often the institutions providing training advocate for a mix of evidence based and non-evidence based practices, which requires that individuals who wish to take an evidence based approach must do extensive research on their own. Our manual will provide a much-needed source of high-quality, accessible information on this subject. This can increase the accessibility and quality of MDMA therapy and decrease its risks.

1.4 Summary for Mental Health Professionals

We have noticed many MDMA therapy clients have unanswered questions, feel distressed, or are confused about parts of their professionally-guided MDMA therapy sessions. Additionally, many therapists lack critical information about MDMA. We hope to remedy this by providing better information to therapists, guides, and clients.

MDMA adds a source of intense safety, compassion, and connection to a therapeutic session without the strong loss of self, hallucinations, or [traumatizing](#) experiences that LSD, DMT, or mushrooms can sometimes create. These emotional states make the engagement and unlearning of maladaptive patterns easier and more productive. MDMA's properties often makes therapeutic progress simpler than traditional psychotherapy; people are often able to make major therapeutic progress when all they do is 1) use the medicine in a relatively safe environment and 2) have some type of emotional (not just intellectual) engagement with maladaptive thought patterns or trauma responses. A therapeutic framework or highly attuned therapist often is not necessary. That being said, a structured and safe container (skilled, attuned, and ethical therapist or guide; prep and follow-up sessions) definitely increase the chances of benefit and reduce risk. MDMA's capacity for powerful and rapid therapeutic progress is also associated with a capacity for intense [destabilization](#) in those with severe complex trauma.

MDMA broadens the [window of tolerance](#), such that some degree of panic, [resistance](#), or [dissociation](#) is not a barrier to effective unlearning of maladaptive patterns during the session. Higher degrees of panic, resistance, or dissociation may still pose difficulty [267].

MDMA has a few serious medical and drug [contraindications](#), and additional caution and support is warranted in clients with dangerous or difficult to manage symptoms such as a history of psychosis, mania, suicidal ideation, and possibly severe lack of impulse control. Other than that it is generally safe and non-addictive in therapeutic contexts. See Section 3.1 for more information.

We think the following are highly important for a practitioner to be proficient in:

- Identifying and working with dissociation. See Sections 2.2 and 3.5.
- Identifying destabilization and helping their client manage it. See Sections 2.5 and 5.4.
- Maintaining especially high ethical boundaries and practices because idealizing transference may be intense. See Section 3.3. A number of licensed therapists and underground [psychedelic](#) guides have appeared in the news for taking advantage of their clients [241].

Further, Poulter and Ot'Alora [257] recommends that personal experience being and MDMA therapy client is helpful, but not necessary for therapists. Clients often want to know that their therapist understands what they will experience. Personal experience also conveys more knowledge of the MDMA therapy experience than can be conveyed in words.

Recommended Reading Material

- *The Secrets of Supershrinks: Pathways to Clinical Excellence* This article explores the concept of "supershrinks" - therapists who consistently achieve superior outcomes regardless of their theoretical orientation or specific techniques [227]. The authors argue that exceptional performance in therapy, as in other fields, is primarily the result of deliberate practice and ongoing feedback rather than innate talent or experience alone. They propose a three-part formula for improving therapeutic effectiveness: determining one's baseline of effectiveness, engaging in deliberate practice, and consistently seeking and incorporating client feedback. By tracking outcomes, comparing performance to national norms, and actively working to improve skills through targeted practice and reflection, the authors suggest that all therapists can significantly enhance their effectiveness and client outcomes.
- *Unlocking the Emotional Brain, Eliminating Symptoms at their Roots Using Memory Reconsolidation* This book may have popularized the connection between [prediction](#) error, memory reconsolidation, and therapeutic improvement. We think it is so useful that it should be required reading for all mental health professionals. Ecker [88] provides an important complementary resource addressing common misunderstandings and clarifies some fundamental mechanisms.
- *Fear and the [defense cascade](#): clinical implications and management* This paper lays out an integrated biological framework for dissociation, [fight-or-flight](#), and threat-induced alertness/tenseness. As noted in the paper, the Clinical Interventions section is speculative, and we have low confidence in its theoretical correctness.

Chapter 2

The Science of Mental Illness

2.1 Epistemic Status

Robust scientific models are, as the pseudonymous blogger duo ¹ Slime Mold Time Mold [302] (one of whom is a cognitive scientist and statistician) state, is “a proposal for a set of entities, their features, and the rules by which they interact, that gives rise to the phenomena we observe.” They also make a wide variety of accurate [predictions](#) in the area of their relevance. Physics represents an exceptionally high degree of alignment to this standard; it has such a complete model of atoms that their behavior can be predicted to many decimal points of precision. It also has a highly detailed and precise list of the entities involved (neutrons, protons, electrons, strong force, weak force, electromagnetic force) and the rules by which they interact. Few fields can match that level of completeness. In comparison, the political scientist Brian Klaas argues on their blog that the social sciences (psychology in our case) mostly use models that occasionally make good predictions in a narrow area, but rarely over a wide area [177] (see also Briggs [39]). Slime Mold Time Mold [302] further points out that psychological models don’t have convincing lists of well-defined parts and mechanisms and generally have no plausible connection to what neurons are doing in the brain. Working with these epistemically ungrounded abstractions is often a necessary first step to figuring out the set of mechanistic rules that govern the system one is investigating. However, a great number of these abstractions turn out to be false. That’s ok in the process of science, but, in our opinion, these provisional models have taken on a great deal of undeserved prominence in popular culture and clinical practice. These problems aren’t limited to the social sciences either. The neuroscientist Erik Hoel synthesizes a variety of papers in their blog to argue that even neuroscience is beset by severe systemic problems [153]. He specifically argues that neuroscience has no conclusively accepted overarching model of brain function (Predictive processing is a compelling candidate and is the model we use [57].).

These issues show up in a variety of ways in mental health science and practice:

- Mental illness is typically diagnosed according to somewhat arbitrary clusters of subjectively-

¹The next two paragraphs largely rely on blog posts by several scientists. This is not traditionally-citable material, but we felt 1) this discussion is important to set the stage for the rest of the book, 2), these posts contain unusually high quality material by practicing scientists, and 3) we don’t have the capacity to sufficiently learn and synthesize this area of knowledge ourselves.

assessed (either by the client or the clinician) symptoms [181]. Mental illnesses are rarely objectively measurable or attributable to specific, well-understood causes. The current categorization of mental illnesses is significantly incorrect. Models similar to The Hierarchical Taxonomy Of Psychopathology (HiTOP) seem to offer better categorization than the DSM.

- Most other constructs in psychology are also similarly ungrounded, or only defined in terms of other ungrounded constructs.
- Mechanisms of action for psychiatric drugs, even when they have been rigorously shown to be helpful (though many haven't been evaluated for long term efficacy and risk [193]), are typically only known as far as: drug \rightarrow specific effects on neurotransmitters \rightarrow ??? (part of the missing overarching model of neuroscience) \rightarrow observed changes in behavior/mood/etc. It is often tempting to say a drug works because of the "known effects on neurotransmitters" when the "???" may be just as, or more important. When a high quality (pre-registered, active-placebo-controlled, unblinding and expectancy effects measured and adjusted for, independent data analysis, unbiased staff, open data and code, multi-site, etc.) clinical trial does find an effect, that effect is statistical. It shows that the intervention causes some effect in the average person. It doesn't show the full chain of causation. We think not understanding why a drug really works significantly raises the likelihood that 1) it's not very predictable when the drug will or will not work for any particular person 2) the drug may have unknown but important side effects 3) and the drug may superficially improve some symptoms while creating other, harder to see problems. Additionally, the efficacy and safety of regular long-term use of psychiatric drugs is rarely studied [193].
- Even when brain imaging studies are statistically significant (they frequently aren't), it's often not clear that the measured changes in blood flow to some brain region tell us anything meaningful about the information-processing function of that brain region [15, 81, 166]. For example, it is commonly claimed that MDMA reduces fear by reducing activity in the amygdala [110]. However, this was based on a questionable and weak correlation, and even if MDMA does reduce blood flow to the amygdala, it is not known whether the reduction in blood flow causes reduced fear, is caused by reduced fear, or both are caused by some third factor [51]. The changes in blood flow to the amygdala could be irrelevant to the therapeutic effects of MDMA.
- The replication crisis revealed deep problems with clinical psychology research [314]. Many important assumptions and common practices in the field are probably neither true nor useful.

These problems are all well-known to researchers in the field, and to some clinicians, but generally not to the public. We don't want to imply that psychiatric drugs are useless or that therapy doesn't work. Instead, we're attempting to calibrate expectations. We hope to sidestep some, but not all the above problems by basing this book on the [schemas](#)/predictive-processing and [defense cascade](#) models of mental illness that do have mechanistic explanations. These models don't seem to have percolated very far out of certain specialist labs into

other areas of mental health science, much less the world of clinical practice, though there are exceptions.

In conclusion, we suggest taking any model (including ours, almost everything from psychology, much of neuroscience, most psychiatry, and especially any pop-neuroscience) related to brain function or mental health with a large grain of salt unless there is "a set of entities, their features, and the rules by which they interact, that gives rise to the phenomena we observe [302]." As far as we are aware, exceedingly few models of mental illness, and hardly anything in the field of psychology (See the psychologist Adam Mastroianni's blog post Mastroianni [214]) meet those criteria.

Our Core Assumptions

The following assumptions are the foundation of this book. Note that we don't have the deep expertise to really evaluate the mechanism-of-action of these phenomena. We primarily rely on other researchers' summaries.

- The predictive processing framework largely explains mental illness. Schemas/priors/predictions explain the psychological part of mental illness, but not its genetic or physiological influences (Aizenbud et al. [5], A. Clark [57], J. E. Clark et al. [59], Ecker et al. [89], and Lane et al. [188]). Certainty - high. Predictive processing is widely (though not universally) supported in neuroscience, has detailed mechanistic explanations for its functions (though some of them have not yet been experimentally investigated), and seems to neatly explain a wide variety of phenomena.
- Memory reconsolidation can permanently unlearn maladaptive schemas (Ecker et al. [89], Elsey et al. [92], and Lane et al. [188]). Certainty - high. Studies have established the protein-synthesis mechanism of memory reconsolidation in a variety of animals. Those experiments are not possible in humans because they are hazardous, but human studies have verified many of the purported behavioral signs of reconsolidation. Controversy remains over exactly what conditions facilitate reconsolidation, what types of memory it can change, and some inconsistent experimental results. It also can't be ruled out that therapy facilitates a separate phenomenon whose nuances appear similar to reconsolidation. Elsey et al. [92] conclude: "Nevertheless, we would argue that reconsolidation has provided a framework within which a range of new experimental manipulations and clinical interventions have been formulated and tested. Such investigations have already produced surprising and clinically relevant findings. We are not aware of any a priori hypotheses, besides reconsolidation, that would have predicted such results..."
- MDMA facilitates memory reconsolidation when used appropriately. Certainty - high. MDMA-facilitated reconsolidation remains biochemically unverified. However, we think the phenomenal and behavioral markers of reconsolidation are clear in many cases, based on Feduccia and M. C. Mithoefer [110], numerous case reports we have read, and extensive personal experience. These reports often show a pattern of 1) activating a maladaptive fear schema during the session by talking, thinking, or writing about it, 2) the fear dissipating within a span of minutes to tens of minutes, 3) the fear not

returning when the client enters typically-triggering contexts after the session is over, and 4) the dissipation of fear is effortless and durable. Steps 1 and 2 highly align with the prerequisites of reconsolidation: activation of target schema, activation of contradictory knowledge, and conscious awareness of the contradiction [89]. Steps 3 and 4 highly align with the signs of successful reconsolidation: emotional non-reactivation, symptom cessation, and effortless permanence. Fear-extinction, the only other mechanistic mechanism of action we are aware of, does not align with these steps. MDMA's effects of safety and empathy also decrease [avoidance](#) and facilitate staying present with difficult schemas, one of the prerequisites of reconsolidation.

- The section of the autonomic nervous system termed the defense cascade explains anxiety, panic, and [dissociation](#) (Kozłowska et al. [182]). Certainty - high. To our non-expert eye the general principles of the defense activation seem well-established, non-controversial, and somewhat mechanistic.
- Acute physical injury from MDMA is almost always caused by mixing it with dangerous activities, certain other drugs, or certain medical conditions (Wolfgang et al. [343]). Certainty - high. The primary causes of injury seem well-understood and there haven't been any significant reported adverse effects in trials, where dangerous activity and drug interactions are absent, and participants are screened for cardiovascular problems. There could be rare exceptions that are poorly understood.
- Limited MDMA use does not cause long-term physical problems when used in therapeutic contexts and known medical [contraindications](#) are screened for (D. Nutt et al. [243]). Certainty - medium. We're not aware of any trials investigating this. A panel of drug misuse experts judged that in recreational contexts (where mixing it with other drugs, dehydration, and hyponatremia are much more common than in therapeutic contexts), MDMA-use carries some risk of physical harm to the user, though far less than alcohol. We think a majority of that harm can be attributed to the known risk factors mentioned in Section 3.1. MDMA is also used far less in therapeutic contexts than in recreation.
- MDMA does not directly cause long-term post-session cognitive problems when used in limited therapeutic contexts (Passie [252] and Wolfgang et al. [343]). Certainty - medium/high. One well-done observational study of recreational use gave recreational users a battery of 15 neuropsychological tests [142]. That ruled out high levels of cognitive deficit, but didn't have the statistical power to rule out low-moderate effects. However, the recreational users in that study also used much more MDMA (median of 44 occasions) than is typical in therapeutic use. One small randomized study of MDMA therapy also did not find any significant cognitive effects [233]. Therapeutic surfacing of [traumatic](#) material may still occasionally cause dissociation or panic-induced cognitive impairment.
- The types of mental illness that depend on maladaptive predictions are formally-defined complex systems whose elements are predictions, genes, medical history, and environment. Certainty - high. Theorizing predictive processing and mental illness as a

complex system is well-established [123, 149]. Its practical applications are limited, perhaps because complex systems are difficult to model, and it's extremely difficult or impossible to obtain the full set of parameters for any individual case of mental illness.

- Complex system dynamics largely explain features of therapy like [destabilization](#), sudden unforeseen improvement, and how mental illness is often a stable state that doesn't naturally resolve. Additionally, destabilization is often "part of the process." Certainty - high. Attractor states (e.g. some mental illnesses that don't naturally resolve) and nonlinear dynamics like destabilization and sudden unforeseen changes are core features of complex systems [247]. A variety of research has shown that destabilization is associated with better long-term therapeutic outcomes. This does not imply that destabilization due to abusive or incompetent therapists or guides is helpful. Even necessary destabilization can sometimes be intense enough to cause harmful effects when entered into at the wrong time or poorly managed.
- Therapy-induced psychological destabilization explains the vast majority of adverse symptoms. Certainty - medium/high. We think a large majority of adverse psychological effects of MDMA therapy appear highly compatible with destabilization. We can't rule out other mechanisms, but also don't know of any other mechanisms that would explain such effects in the context of high quality MDMA therapy.
- Sufficient further reconsolidation resolves destabilization. Certainty - high. Individual predictions-along with environmental, genetic, and medical elements-are the set of interconnected complex system elements that dynamically create attractor states [123, 149]. Good mental health and many mental illnesses are, respectively, adaptive and maladaptive attractor states or sets of attractor states. Destabilization seems to consist of 1) vacillation between maladaptive and adaptive attractor states, or as we speculate, 2) transition to a stable attractor state even more maladaptive than the initial one, but that you couldn't previously access because it was surrounded by strong barriers of avoidance (e.g. some cases of uncovering horrific memories of abuse during MDMA therapy). In case 1, further reconsolidation of the predictions that create the maladaptive attractor state will weaken the state and make it less likely to activate, thus decreasing vacillation. In case 2, further reconsolidation will similarly dismantle this other maladaptive attractor state and make it easier to transition to an adaptive attractor state. Unfortunately, destabilization can last a long time even with high amounts of reconsolidation if the maladaptive attractor states are particularly entrenched.

Major Unresolved Issues

- We are not clear why MDMA therapy facilitates prediction error for some schemas but not others, and why the schemas it tends to reconsolidate are casually or therapeutically identifiable as "maladaptive." We also do not understand what exactly "maladaptive" means in this context. A process can only be adaptive or maladaptive in relation to a goal or optimization function. Predictive processing posits that the brain's fundamental optimization function is minimization of prediction error, but it

remains to be seen which particular sources of prediction error that function contains in most people [57]. Some near-immutable intrinsic sources of prediction error for almost everyone may include hunger, thirst, pain, companionship, etc., and the future fulfillment of these. We don't know if MDMA therapy optimizes your schemas according to your existing set of fundamental errors, or to some MDMA-modified set. Depending on various assumptions, MDMA therapy might optimize for violence or manipulateness in the rare humans who lack certain fundamental error sources such as empathy, and who currently have "maladaptive" schemas inhibiting them from violence or manipulateness they would otherwise do.

In our experience, MDMA therapy seems to produce, in the long-term, changes that both the individual and their community feel are healthy and good. In this book we use the terms "maladaptive" and "adaptive" casually in this sense.

- Predictions and the belief component of schemas seem like the same thing. How does the schema's emotional component fit into the predictive processing framework?
- We don't know how much, and for whom, MDMA therapy will be destabilizing, other than thinking that destabilization risk is associated with complex early-life trauma and attachment issues. We also don't know when more MDMA therapy will reduce or increase existing destabilization. It's not even clear to what degree these uncertainties are even conceptually resolvable; they could be computationally intractable even with perfect information, which itself is impossible to acquire. See 2.5 for more information.
- We don't know what risk MDMA therapy poses for those with a history of psychosis.

Reference Quality

We applied a variety of checks on the validity of our references while writing this book:

- Retractions and PubPeer comments: All references via Zotero. We cite one retracted paper and detail our reasoning in footnote 2.
- Reproduction of experimental results by other labs: No systematic evaluation, though we have made changes to the book when we happen across published replication failures.
- Informal qualitative analysis of experimental design: Most references. We highly preferred papers that randomized their participants, had high numbers of participants, controlled for certain confounding variables for non-randomized studies, were recent (experimental and statistical methods have improved over time), were reviews or meta-analyses (these provide more robust results than individual experiments), had high statistical power, and had high citation count (a partial indication that a paper outside our scope of knowledge is well-respected). Not all references meet high standards for all of these criteria. We may still have included them if they were, in our judgement, particularly theoretically compelling or reasonable extrapolations of more established results. Note that there are many indicators of quality that we did not check, but that

are often important, such as effect size heterogeneity in meta-analyses, topic-specific study design nuances, statistical methods, data processing methods, publication bias, researcher bias, etc. However, the meta-analyses we cite often do assess some of these indicators.

- **Contradictory evidence:** Only the 8 important assumptions listed above. We put significant, though non-systematic, work into looking for evidence that contradicts these assumptions.

2.2 Defense Cascade

The Autonomic Nervous System governs a wide variety of involuntary bodily functions, such as heart rate and digestion [182]. In one of its roles, it activates a defense cascade—a sequence of responses—to shield us from threats. Increasing levels of perceived threat activate these responses, though the order of activation depends on individual variability and experience. Additionally, activation is proportional to our estimation of the threat and our ability to handle it. Children activate easily because the threshold of what constitutes a threat to their life is much lower than it is for healthy adults. Lack of parental support, attention, or attunement (see Appendix C) can be life-threatening for children. Here is the defense cascade:

- **Arousal** The most common initial reaction to a potential threat. Think of how a deer becomes alert when they see something moving far away. Vigilance, muscle tension, respiratory rate, and heart rate all somewhat increase, allowing us to quickly assess and respond to possible dangers.
- **Fight-or-Flight** When an imminent danger is identified, like when a deer notices a wolf nearby or chasing them, this response prepares the body to immediately either confront (fight) or escape (flight) the threat. The adaptations of the arousal stage intensify and are augmented by an adrenaline surge, further suppression of pain, and an urge to fight or run.
- **Freeze** When the danger is imminent, but you might yet go unnoticed, the freeze response temporarily pauses a fight-or-flight response. If the predator notices you, freezing can quickly revert to fight-or-flight. While most physiological responses from fight-or-flight remain, opioids cause the muscles to become immobilized and heart rate decreases.
- **Tonic/Collapsed Immobility (Dissociation)** Tonic immobility (playing dead) may dissuade a predator from eating you when you have been caught. Fight-or-flight responses are deactivated, the body is partially-to-fully paralyzed, and the brain produces opioids which numb and disconnect you from reality. Muscles remain tense in case the predator gets distracted, and you have to run or fight again. This state may transition to collapsed immobility (fainting; muscle tension and consciousness partially to fully lost) when the threat further increases.

- **Quiescent Immobility** Tonic/Collapsed Immobility may extend into a lethargic rest and recuperation phase after the threat has gone. Occasionally, this may persist beyond its period of usefulness and become maladaptive.

The defense cascade originally evolved to activate during immediate physical threats like predation, but can also be activated by a wide range of stimuli (sounds, thoughts, places, etc.) associated with past threats. These associative activations are ideally adaptive; defense cascade activation upon sight of a wolf coming in the distance will give you more time to run than if activation occurs only after the wolf has bitten you. Unfortunately, associative activations can also be maladaptive. Think of the soldier who goes into fight mode in response to loud noises even after the war is over. Maladaptive defense cascade activation may be called PTSD (Post [Traumatic](#) Stress Disorder) for fight-or-flight responses, anxiety for arousal responses, or dissociative disorders for immobility responses. As described in the next two sections, MDMA therapy can unlearn maladaptive associations between stimulus and activation.

Note that while others have used the term dissociation for a variety of phenomena, in this book we strictly define dissociation as the production and effects of endogenous (self-produced) opioids [\[182\]](#). The specific effects vary depending on what type of opioids (μ -opioids or κ -opioids) and other neurotransmitters are being produced, but generally include emotional numbing and detachment [\[182, 189\]](#). We suspect there are opioid-mediated dissociative states that don't neatly fit into the defense cascade model. Some individuals "...feel sober, or bored or sleepy as if they could get up and go about their day." during MDMA sessions where the individual can presumably move and think fairly well, but remains emotionally numbed [\[269\]](#). While we can't be sure that this phenomenon is always opioid-mediated, we think it is often because emotional numbing is a known effect of opioids [\[189\]](#), and we aren't aware of any other mechanism that would cause such a degree of numbing as to make an MDMA trip feel boring.

Refer to [Table 2.1](#) for a thorough comparison of the signs of intensified arousal and dissociation.

Table 2.1: Comparison of Hyperarousal [intensified arousal] and Dissociation Signs. Britton [41] compiled this from Ogden et al. [246], Magyari [208], and Treleaven [326]. Reprinted with permission.

Signs of Hyperarousal	Signs of Dissociation
Body/Somatic <ul style="list-style-type: none"> • Agitation, difficulty relaxing • Psychomotor hyperactivity • Tingling • Twitching • Hyperventilation, difficulty breathing • Exaggerated startle • Increased heart rate • Hot flashes, flushing • Sweating • Cold hands + feet • Muscle tension • Chronic pain • Insomnia Cognitive <ul style="list-style-type: none"> • Racing, repetitive, obsessive, intrusive thoughts • Worry, rumination • Rapid or disorganized speech; • Jumping from topic to topic • Executive dysfunction (memory, planning, decisions) 	Body/Somatic <ul style="list-style-type: none"> • Flaccid muscle tone • Extremely still (frozen) • Pale skin tone • Fixed gaze ("thousand yard stare"), glassy eyes Cognitive <ul style="list-style-type: none"> • Few thoughts, "mind is blank" • "Can't think" • Concept loss • Slow responses • Difficulty evaluating surroundings • Executive dysfunction (memory, planning, decisions) • Slowed/slurred or disorganized speech • "Spacey," "ungrounded" • Hypernowness, no past or future Self <ul style="list-style-type: none"> • Disconnected from body, emotions, thoughts • Outside body or at distance • Disownership • Don't exist, not here

Continued on next page

Table continued from previous page

Signs of Hyperarousal	Signs of Dissociation
Emotion <ul style="list-style-type: none"> • Emotional volatility, mood swings • Euphoria, mania, grandiosity • Anxiety, panic • Reports of flashbacks, nightmares • Irritability, anger Conative/Motivational <ul style="list-style-type: none"> • Excessive, obsessive striving/effort • Scrupulosity/perfectionism • Apathy/withdrawal Perception <ul style="list-style-type: none"> • Perceptual hypersensitivity • Sounds too loud • Light sensitivity Social <ul style="list-style-type: none"> • Social engagement dysregulated • Inhibition/withdrawal (also disinhibition, disruptive, interrupting) • Inability to make eye contact during inter-views/interactions 	Emotion/Motivation <ul style="list-style-type: none"> • Affective flattening, blunted emotions, loss of emotion • Normal emotions but "can't feel them" or "not mine" • Apathy, feel dead, nothing matters • Lack of meaning, motivation Perception <ul style="list-style-type: none"> • World appears unreal or dreamlike • Objects appear flat/2-dimensional; "cartoon-like" • Distance distortions • Visual hyper-clarity or fog Social + Occupational <ul style="list-style-type: none"> • Social engagement system offline • Not seeking social support • Withdrawn/avoidant • Eye contact difficulty Dissociation vs Meditative Calm <ul style="list-style-type: none"> • Disconnected from thoughts, body, emotions, world, others • "Not here" • Immobility; frozen quality • Sudden resolution of distress • "Feel fine" • "Nothing going on"

2.3 Trauma and its Effects

Our brains are fundamentally learning organs [57]. They continually build and run [prediction](#) and response models (formally called predictive processing) of the world, other people, our bodies, and our own mind for the purpose of fulfilling our innate needs for bodily integrity, community, health, reproduction, etc. Typically, we predict and respond to threats in an

appropriate and unproblematic manner. We don't usually ruminate about falling off cliffs until we are near a cliff edge. Then the closer to the edge we go the more alert and cautious we become. This alertness or fear is not due to [trauma](#) because the response is situationally appropriate. However, not all responses are situationally appropriate. The brain's learning process doesn't necessarily build *true* models of the world, it builds models (an individual model is called a [schema](#)) that are *true enough* (heuristic) to work mostly-well in the contexts they develop in. These heuristics sometimes don't work very well outside the context in which they form (Think of the soldier who goes into fight mode in response to loud noises even after the war is over.). We might describe trauma as events that create heuristics that impair functioning in regular life. Lane et al. [188] describes traumas as distressing events or chronic conditions that overwhelm our ability to cope, where our ability to cope depends on our capabilities and resources. Standing near cliffs is not typically traumatic because the situation is under our control, and we manage the situation to avoid overwhelm. If nothing surprising or threatening occurs, our predictions of what happens around cliffs doesn't change much. Conversely, threatening situations outside our control create strong signals for updating our predictive model because your survival may depend on avoiding or managing that situation in the future. Maybe someone attacks you near the cliff edge, and you almost fall off. Your brain may learn that cliffs (or the combination of cliffs and other people, or the combination of cliffs and just that particular person) are much more dangerous than you previously thought. You may feel alertness or fear from much farther away from the edge than you did before. If the attack was overwhelming enough you may learn that everything about cliffs is dangerous, even the thought of them or pictures of them. We think "high caution around that particular person" or "that person is dangerous and unpredictable" is likely the adaptive response in this scenario. Unfortunately the other responses, such as fear at the thought of cliffs, sometimes occur and can cause problems for you or others. Or instead of learning a somewhat helpful but not very accurate heuristic, you may learn a very accurate heuristic that only becomes a problem when your environment changes, but the heuristic doesn't. These are the types of responses that we call maladaptive schemas and focus on throughout this book.

Here's another example of a schema that became maladaptive:

- Situation: As a young child, Amy was frequently ridiculed by her peers whenever she spoke up in class or shared her opinions.
- Initial Schema: "If I voice my opinions or stand out, I will be ridiculed."
- Resulting Behaviors and Beliefs: Amy grows up avoiding speaking in group settings and tends to keep her thoughts to herself. She might decline leadership positions or avoid roles where she'd be in the spotlight. In discussions, even if she disagrees or has a valuable perspective, she might not voice it. Amy might believe she's not as smart or valuable as others, even if evidence from later in life suggests otherwise.

This schema may operate either in the background or in explicit awareness, guiding Amy's behaviors and beliefs. If she is consciously aware of it she may or may not realize that this pattern is maladaptive.

Common traumas include:

- Different forms of unintentional or occasionally intentional neglect or abuse.
- Lack of emotional attunement from parents [44].
- Your parents' maladaptive schemas
- Disasters, accidents, assault, or war
- Chronic poverty, dehumanization, or dysfunctional social-cultural systems [277]. A lot of abuse and insecurity is normalized as culture.
- Loss of health, home, family, or culture
- A wide variety of other difficult situations

Some of these are single events, where the resulting schema is relatively simple. Someone attacked by a dog as a child may learn an intense fear of all dogs. Many traumas, especially chronic ones experienced during childhood, create complex networks of maladaptive schemas around things like your sense of self, relationships, your own body, etc. These are termed complex post-traumatic stress disorder or [attachment disorders](#). They are often disabling because the schemas are intense and are activated by a wide variety of stimuli or a few particularly pervasive stimuli.

Mentally healthy adults with sufficient resources are resilient to most traumas and usually develop appropriate and healthy schemas to manage those situations in the future [35]. After the threat passes they may have a temporary period of anxiety about the experience called an acute stress reaction, but this typically dissipates within a few days of the event [147]. However, a variety of risk factors reduce the capacity to bounce back and form healthy schemas for that situation. Post-trauma factors for children, adolescents, and presumably also adults to a large degree, include blaming others, thought suppression, distraction, low social support, social withdrawal, poor family functioning, and parental psychological problems [327]. [316] also found that female gender (this may function differently in different cultures), unemployment, and low education are risk factors for adults. Resilience to trauma is complex [35], but we speculate that many of those items are risk factors because they are generally situations of broad resource (emotional, physical, social) insecurity, and are an additional "attractor" toward overly-general high-threat predictions (e.g. "I'm in danger everywhere"). The risk factors may also reduce circumstances that promote nuance (e.g. "My friendships remind me that I'm safe in many circumstances" or "I am already emotionally secure") or may directly inhibit [reconsolidation](#) (e.g. thought suppression). Note that while these factors may provide some prediction of resilience on a population level for certain situations, they might not be very predictive for any specific individual in any particular situation [36].

Our potentially maladaptive schemas usually update when our ability to handle adversity increases (like when we become adults and no longer rely on them for all our needs) or when the original difficulty ends. As further discussed in the following section, the updating process is initiated by "prediction error [89]." Prediction Error is a *consciously (though not necessarily explicitly recognized) experienced contradiction* between the original prediction (e.g. "broccoli tastes bad" experienced as a child eating mushy broccoli) and a new experience (e.g. "broccoli

can taste good" experienced later an adult eating properly-cooked and seasoned broccoli). That prediction error updates your schema with the new information. This is a fundamental process enabling adaption to new situations, but a few things can inhibit this updating process by preventing this conscious contradiction, causing our schemas to keep operating in older, less adaptive ways:

- **Avoidance:** Anything that inhibits consciously experienced contradiction, like drinking alcohol when distressed, inability to tolerate uncomfortable emotions, possibly [Alexithymia](#), escapist habits, addictions, fear that updating a schema will make you vulnerable in some way, denial, projection, rationalization, etc. [149]. There is such a thing as healthy avoidance, which is temporary and helps you cope in non-destructive ways until you have the space to process.
- **Lack of Resources or Skills:** Not having a quiet moment or space to investigate and feel your emotions. Being unsure about the reasons for your reactions or how to handle them. Or you may not have skill in noticing and labeling feelings, sometimes called Alexithymia. Making schemas explicit, like with labeling, can aid the brain's built in contradiction-detection processes.
- **Fight-or-Flight or Dissociation:** These [defense cascade](#) states frequently inhibit prediction error [269].
- **Schemas May Just be Hard to Update in General:** All complex decision systems, such as the brain, must trade off between multiple goals. The psychiatrist Scott Alexander speculates in a blog post that the brain must trade off between two failure modes (these failure modes are well-established in artificial neural networks): overgeneralization and over-specificity [11]. Say that Alice was mean to you one time. An overgeneralized prediction may be that all people are mean all the time. An over-specific prediction may be that Alice is only mean on Mondays, while wearing a blue shirt, when it is sunny out. Neither of these predictions are useful or correct; the correct prediction might be "sometimes people have bad days and take it out on others." Learning the correct prediction is difficult, and the brain must often make hasty guesses because learning a prediction too slowly can be risky in threatening situations. All of this possibly results in a messy system that sometimes generates overly-strong and durable predictions that require unusual circumstances to contradict.
- **Pervasive Threat Expectations Impede Updating** den Bergh et al. [78] hypothesizes that high-level schemas predicting pervasive threat broadly impair awareness of contradictory evidence. S. Alexander [12] provides a more accessible summary of the paper.

When these continually inhibit prediction error for a maladaptive schema, the schema becomes stuck in its maladaptive configuration, replaying and creating problems [89, 266].

Schemas are not just simple stimuli-response pairs. In the model of Lane et al. [188] they have three components that we may be more or less explicitly aware of:

- Emotional responses like fear, anger, or love

- Beliefs like "my partner loves me" or "dogs are unpredictable and dangerous"
- Episodic memories (detailed memories of how specific events unfolded)

Schemas may not contain a clear episodic memory if you were too young to form long-term episodic memories that persist into adulthood. Though the reasons are unclear to us, many people also seem to forget experiences of childhood abuse. These memories can sometimes be later remembered (such as during non-directive therapy) and corroborated. We recommend The Psychedelics and Recovered Memories Project [324] for a nuanced guide on [psychedelics](#) and recovered memories. Schemas caused by such events can be confusing compared to schemas we clearly see a cause for.

About 10% of the population might meet the somewhat arbitrary criteria for mental illness at any given time [344], but we suspect almost everyone has some amount of maladaptive schemas that negatively effect them and those around them. We think these schemas may push us to overreact, deny the truth, misjudge important trade-offs, say hurtful things, etc. We may seek out the connection and safety we desperately need in dysfunctional ways [44]. Or we may get too distracted by our distress to pay attention to the needs of those we love. The stress of chronically activated distressing feelings or chronic defense cascade activation also significantly increases risk for a wide variety of physical diseases and problems as discussed in Section 2.6.

For more information we highly recommend *Unlocking the Emotional Brain: Memory Reconsolidation and the Psychotherapy of Transformational Change* by Bruce Ecker, Robin Ticic, and Laurel Hulley as essential reading for all mental health professionals and anyone else interested in the topic [89]. If you're interested in the general theory of predictions in the brain, we recommend two definitive books by Andy Clark, Ph.D. on predictive processing. *Surfing uncertainty: Prediction, action, and the embodied mind* is the more technical, though not mathematical, of the two books [57]. S. Alexander [8] provides a good accessible summary of it. *The experience machine: How our minds predict and shape reality* is the less-technical mass-market version [58].

2.4 Mechanism of Healing

As discussed in the previous section, a consciously experienced contradiction between an old [schema](#) and a new experience or existing knowledge creates [prediction](#) error [89]. Prediction error triggers an updating process called memory reconsolidation. When schemas are first created, they are *consolidated*. After that, when a consciously experienced contradiction creates prediction error for that schema, the schema enters a state of plasticity where it can be changed. Maintaining that experience of contradiction over a period of time will then gradually update the schema to account for the contradiction. About 5 hours (in animal models) after the initial prediction error, the memory is *re-consolidated*, re-entering a stable state where it can no longer be changed without another consciously experienced contradiction. Throughout this book for convenience we will use "reconsolidate" in a slightly different way to denote the entire process of schema destabilization, updating, and restabilization.

Thus, durable long-term unlearning of stuck or maladaptive schemas is a process of memory reconsolidation. Mismatches can come from a variety of sources: feelings of safety and

connection from an attuned therapist, a second activated memory, secure relationships, everyday life, and a wide variety of other experiences and knowledge. We've observed that in practice, MDMA seems to facilitate or provide effective mismatches for most, if not all maladaptive schemas, in contrast to traditional psychotherapy, where specific mismatches must be found for each schema. Carhart-Harris and K. J. Friston [50] theorizes that [psychedelics](#) potentially relax all high-level schemas (e.g. "I am bad," as opposed to low-level schemas that control, say body temperature, which remain largely unaltered), thus making all types of contradictory information more liable to inducing prediction error and reconsolidation of maladaptive schemas. We don't know exactly what type of contradictory information you might encounter in any particular scenario, but we have a few somewhat overlapping speculations:

- The present moment, which is in all likelihood safe, thus contradicting predictions of danger, which most or all maladaptive schemas may be to some extent.
- Connection might contradict all schemas fundamentally about some sort of disconnection from life, safety, love, etc.
- Partial [non-dual](#) awareness, which might be a form of deep, inviolable connection or safety.
- Other schemas you already have, as is often used in therapy [89].
- Interoception [50]

It could be that multiple of these occur at the same or different times throughout one or more sessions. In all cases, we think MDMA's safety and empathy also makes it easier to stay present with the emotional activation of your highly distressing schemas, a requirement for reconsolidation.

We posit that there are at least three practical ways of using MDMA to aid memory reconsolidation, though in reality, more than one of these may happen during any given MDMA therapy session:

- Using the mismatch facilitated by MDMA, whatever its exact source, to reconsolidate a maladaptive schema during the session by activating and staying present with the schema. This could be as simple as staying present with some fear-based schema, then noticing it dissipate over a span of minutes to 10s of minutes. This is common and the approach we advocate.
- Using the feelings of safety from MDMA to make your implicit ("I have this maladaptive behavior but don't understand why and don't know what the schema is") schemas explicit ("I do the maladaptive behavior because my schema says..."). Explicit schemas are often easier to mismatch through regular therapy after the session because. Absent extraordinary states of mind, finding a mismatch typically requires knowing what the schema is [89]. This is the approach that seems to be associated with the need for post-session "integration" where these insights are used for sober reconsolidation.

- MDMA may show you new knowledge (e.g. "I have an inner well of inviolable safety") that you can then use outside the session as a mismatch for a wide variety of maladaptive schemas. We're aware of a few anecdotes of this occurring.

These processes are conceptually quite simple, but practical use is usually more complex. People's target schemas are often very intense and may require multiple sessions to fully reconsolidate [230], or they may have multiple maladaptive schemas they wish to work on. Additionally, individuals usually only have a partial understanding of the schemas causing their problems, so they often end up needing to work on schemas they weren't initially aware of. Realistically, we think the most severe mental illness may require 1000s of hours of reconsolidation.

Reconsolidation reduces the intensity of distressing feelings of a schema, but as previously discussed, schemas also contain abstract beliefs (e.g. "I am a bad person") [188]. As such, the reconsolidation process may produce changes in self-conception, alterations in your narrative surrounding the schema, shifts in associated beliefs or values, expansion of emotional perspectives, integration of previously separated aspects of the experience, or the development of greater cognitive flexibility in relation to the event. You may not even conceptualize the experience as activation and reconsolidation of a maladaptive schema.

Ecker et al. [89] describe the following signs of a completely reconsolidated schema:

A specific emotional reaction abruptly can no longer be reactivated by cues and triggers that formerly did so or by other stressful situations.

Symptoms of behavior, emotion, somatics, or thought that were expressions of that emotional reaction also disappear permanently.

Non-recurrence of the emotional reaction and symptoms continues effortlessly and without counteractive or preventive measures of any kind.

Reconsolidation is the core mechanism of unlearning maladaptive schemas, but it is not the only part of healing. Learning healthy habits and emotional skills may also critical. We discuss some relevant topics in different parts of this book.

Fear extinction is another strategy commonly used to deal with maladaptive schemas [89]. We mention it here only to discuss why we do not focus on using it. In fear extinction, one attempts to create a secondary schema that activates in response to the same stimuli that activate the maladaptive schema. Ideally, this secondary schema will preferentially activate instead of the maladaptive one. The process is time-intensive as it requires individually training the secondary schema for every stimulus you want it to activate for. It is also fragile because the maladaptive schema remains unaltered and will activate any time you encounter a stimulus you have not sufficiently trained the secondary schema for. As Doss et al. [83] states based on Dunsmoor et al. [86], "Extinction memory is characteristically weaker, more transient, and more contextually specific than the original fear memory, rendering conditioned fear susceptible to return under a variety of circumstances."

We highly recommend Sotala [306]. It describes the fundamental process of reconsolidation better than any other resource we are aware of, short of the book they are reviewing.

2.5 Complex Systems, Worsening Symptoms, and Destabilization

The framework we've laid out is accurate, especially for simple issues, but doesn't capture the full complexity of many mental illnesses. Maladaptive [schemas](#) and the [defense cascade](#) states they activate play a large role in the large majority of mental illnesses, unhelpful reactions, and emotional problems. However, the personal circumstances leading to the learning of particular schemas and mental illnesses are only part of the story. The prevailing model in the field is called the [biopsychosocial](#) model [96]. It describes how many mental illnesses arise through complex interactions of biology (genetics, medical history), psychology ([trauma](#), schemas), and social context (social models of how you should respond to trauma, support networks, living situation). Hayes and L. A. Andrews [149] summarizes a variety of research (citations 13, 17-26 in the original) on this complex-adaptive-systems modeling of mental illness:

...a dynamic system [a person in this case] is a set of interconnected elements that evolve over time and self-organize into higher-order functional units, called attractor states [stable patterns of behavior, beliefs, and emotions], that are preferred and govern system behavior. Self-organization is the process by which lower-order processes [individual schemas, defense cascade activations, elements of life circumstances, gene variants, etc.] interact and higher-order patterns emerge and then influence the lower-order processes in a top-down manner. Attractor states constrain system behavior such that it tends to be "pulled" back to these states when perturbed. An adaptive system is flexible as conditions change, but also able to maintain functional integrity in the face of perturbation. A system that has multiple functional patterns (known as multistability) can flexibly switch between patterns to meet the demands of internal and external challenges.

Attractors that are well-established have strongly interconnected elements, with reinforcing and inhibiting feedback loops that can increase or decrease the probability of activation over time and contexts. When attractor patterns are entrenched, they become rigid and relatively insensitive to challenges or new information [as in most mental illness]. Significant disturbance [like the unlearning of maladaptive schemas] or strong jolts [like [psychedelics](#)] are therefore required to disrupt these patterns. Less developed or [destabilized](#) attractors have a weaker hold, allowing the system to more easily switch to alternative states [like high functionality and healthy emotions].

Presumably, in different situations therapeutic improvement may come from either 1) gradually making a maladaptive state less maladaptive, 2) a clear transition from one state to another existing state, 3) transition through a number of different states, or 4) destabilizing an entrenched maladaptive state then creating a new stable adaptive state.

In simpler terms, therapy is a process of moving from a "stuck" state of mental illness (or two stuck states like in bipolar disorder) to one or more states of mental health [123, 149]. This is accomplished through:

- [Reconsolidating](#) the schemas that reinforce the state of mental illness. This book primarily focuses on this.
- Changing the behavioral, social, or environmental elements that reinforce the state of mental illness. Appendix [E](#) and Sections [3.6](#) and [5.3](#) discuss this.
- Increasing the strength of the schemas, behaviors, and environment that reinforce a state or states of good mental health. Appendix [E](#) and Sections [3.6](#) and [5.3](#) discuss this.
- Shaking the system hard enough that you (hopefully) jump straight from the stable state of mental illness to an existing, but inactive and somewhat stable state of good mental health. We suspect high doses of psychedelics sometimes do this.

In practice, the first process of reconsolidation seems frequently necessary to resolve the issue at hand [89]. All the other processes generally leave the maladaptive schemas reinforcing the state of mental illness inactive but intact. Relapse occurs when the right circumstances reactivate that old state. Additionally, constant effort may be needed to maintain the set of behavioral and environmental elements that maintain a state of mental health. Reconsolidation permanently dismantles many of the reinforcing elements of mental illness. There is no, or only a weakened, latent state of mental illness to relapse into.

We suspect that in some cases a stable state of mental illness is actually only semi-stable, and one can transition to an even worse and potentially more stable state in certain unusual conditions. People occasionally uncover horrifying memories of abuse during MDMA therapy, and after the session end up with much worse symptoms than before. We suspect this new state already existed but was inactive, but was unreachable because of strong [avoidance](#) mechanisms that prevented access to that memory. Psychedelics are famous for their capacity to decrease avoidance. Completely avoiding these memories for the rest of your life is not healthy, as the schemas that abuse creates are generally important and active in peoples' lives. It's conceivable that a skilled therapist who you align well with could help you gently ease into these distressing memories instead of confronting them all at once. However, psychedelic experiences are famously difficult to control, and we think it's likely harder to maintain an easing-in pace during MDMA therapy. This symptom-worsening issue is further complicated in practice because people are sometimes avoiding a multitude of distressing things and possibly multiple associated even-more maladaptive and stable states.

Here is another hypothetical example of nonlinear therapeutic effects in a fragile schema network (Healthy schemas networks remain in adaptive stability, or quickly return to adaptive stability when perturbed.): Occasionally one maladaptive schema may provide some valuable functionality in your life that your other maladaptive schemas would otherwise inhibit. For example, you might have two schemas: 1) "nothing matters" (which disincentivizes doing chores) and 2) "I have to do chores because someone will hurt me if I don't" (which incentivizes doing chores). Schema 2 may help you do chores even when schema 1 would otherwise prevent it. MDMA therapy could possibly reconsolidate schema 2 before schema 1, leaving you unable to do the chores until you also reconsolidate schema 1. Furthermore, for those with complex networks of maladaptive schemas, the state of not doing chores could conceivably exacerbate a third schema like "I deserve to die if I'm not being useful." That

schema may have been influencing your feelings and behavior all along, but had never been intense because you had never felt so useless. Now it escalates to suicidal ideation because the feeling of uselessness is unusually intense. We hope these illustrate that convoluted networks of schemas and dysfunction are sometimes encountered in the reconsolidation process. This can be considerably more complex and opaque in real life.

We don't know any reliable way to reliably reconsolidate complex and fragile schema networks without ever falling into a worse state for a while. One might just need to reconsolidate a lot of maladaptive schemas over a long period of time to gradually shift the network from fragility to resilience. In practice, symptom worsening seems to be much less common than shifts to more adaptive states, given that the MDMA therapy clinical trials showed high average improvements over time [230, 231]. Notably, therapeutic alliance is a moderate predictor of good therapy outcomes when working with a mental health professional [119]. See Greenspace [138] for a good rating scale of therapeutic alliance.

It is difficult to jump from an entrenched state of mental illness to a weaker state of mental health [149]. Therapy can gradually weaken entrenched state or strengthen weak states. Vacillation (critical fluctuations) between two states becomes more frequent as the two states become more equal in strength and minor environmental changes are enough of a jolt to initiate a transition. This destabilization might be distressing, but is often a sign of an immanent shift from the old maladaptive state being primary to the new adaptive state being primarily. Further weakening of the old state or strengthening of the new state should resolve destabilization as the new state becomes even more stable and the old state becomes even harder to transition to. In simple terms, you can think of it as standing up. Sitting and standing are both stable positions. The transition positions between the two are unstable, but must be passed through if you want to walk anywhere. This destabilization process could also theoretically signal an impending shift to an even more maladaptive state. However, a variety of experimental evidence indicates that therapeutic destabilization tends to be marker of later therapeutic improvement rather than worsening [149, 247].

While complex systems dynamics surely explain important parts of the therapeutic process, its practical applications are currently limited [149]. Complex systems are hard to model, the model architecture is unknown (it's probably somewhat different for each case), and many of the parameters of any individual case are extremely difficult or impossible to measure. Furthermore, the "state space" these states exist in isn't just a simple one or two-dimensional landscape of valleys and hills that the "ball" of mental health rolls around in; it has as many dimensions as there are schemas, behaviors, and environmental elements. We don't know how many dimensions are of practical importance in any particular case, but it could easily be enough that the system is too complicated for any human to comprehend. So while it succeeds at qualitatively describing some therapeutic dynamics, it doesn't offer a lot of practical advice on who will destabilize/worsen, when they will destabilize/worsen, how long they will be destabilized/worsened for, and which therapeutic tactic is best at any particular point of any specific case [149, 150]. Consequently, the process of therapy is to a large degree unpredictable. No one knows for sure what distressing material you may or may not uncover, or how reconsolidating certain schemas will cause complex nonlinear shifts in schema networks.

2.6 Health Conditions Associated with Trauma

Certain types of [trauma](#), especially multiple severe traumas in childhood without a mediating [secure attachment](#) relationship, increase the risk for a wide variety of chronic health conditions [145]. This may occur either through harmful coping behavior [112], chronic high stress causing problems with the hypothalamic-pituitary-adrenal axis [203] and immune system, or heightened neural sensitization to normally-unremarkable pain signals [117, 173]. Other mechanisms may exist too, and though we are not sure to what degree each particular problem is caused behavioral vs physiological mechanisms, it has been proven that these correlations exist outside behavioral differences [112]. Childhood traumas are robustly associated with an increased risk of cardiovascular problems (e.g. heart attack, stroke, ischemic heart disease), respiratory problems (e.g. asthma, bronchitis), gastrointestinal problems (e.g. hernia, spastic colitis), metabolic disorders (e.g. diabetes, obesity), neurological problems (e.g. headaches, migraines), musculoskeletal problems (e.g. arthritis, broken bones), ulcers, sexually transmitted diseases, cancer, and autoimmune disorders [159, 242, 341]. Conditions like fibromyalgia, functional dyspepsia, chronic fatigue syndrome, and irritable bowel syndrome are also significantly correlated with anxiety, depression, and childhood trauma history [127, 151, 298]. They can have a major negative impact on quality of life, and are notoriously difficult to obtain satisfying medical care for. We have observed that, due to physician perceptions that the symptoms of some of these disorders are "vague" and "subjective," these conditions can be particularly subject to medical gaslighting, exacerbating ongoing stress for those who experience them. Dementia is also strongly associated with childhood trauma [294]. These are assuredly a limited subset of the full set of disorders associated with childhood trauma. We are not sure to what degree each particular disorder can be reversed by unlearning the underlying [schemas](#) and associated stress or behaviors, but there are many anecdotes of improvements to a variety of disorders following successful therapy [336]. We are hopeful that psychoneuroimmunology may be helpful in addressing this category of conditions, and we are excited to witness the next decades of research on the physiological impacts of trauma and mental illness.

For additional popular-press coverage of the physiological impacts of trauma and how to heal them, we strongly recommend *The Deepest Well* by Nadine Burke Harris, MD [145]. We also recommend the video [You're Not Crazy For Being Sick - Understanding Psychosomatic Illness](#).

2.7 Efficacy of MDMA Therapy

MDMA therapy has shown excellent results for PTSD in clinical trials [230, 231]. However, there is a great deal of controversy and confusion over certain aspects of those trials, and whether the FDA was correct in not approving MDMA until more data is gathered, as reported by the researcher Jules Evans on their blog Evans [102]. A couple issues with data collection and study design at MAPS combined with confusion and process issues at the FDA seem to be primary factors; not necessarily poor efficacy or safety, though a better trial could show worse efficacy or safety. Schenberg [289] analyzes why a Dutch government commission came to the opposite conclusion and decided there actually was enough evidence

of efficacy and safety to legalize MDMA therapy. We discuss some of these issues later in this section.

Both MDMA phase 3 clinical trials (the final round of clinical trials that test efficacy and safety on a large sample size) reported that MDMA-assisted non-directive psychotherapy highly outperformed placebo-with-therapy treatments for PTSD [230, 231]. The first phase III study reported a Clinician-Administered PTSD Scale for DSM-5 (CAPS-5) effect size of $d = 0.91$ with $P < 0.0001$, and the second reported $d = 0.7$ with $P < 0.001$. Those numbers indicate large effect sizes and high statistical reliability. CAPS-5 scores represent therapeutic progress related to the single [traumatic](#) event that participants chose as their therapeutic target. However, another measurement collected in the studies, the Sheehan Disability Scale (SDS), also reported large gains in total life-functionality independent of progress related to that single traumatic event. The first trial reported $d = 0.43$ with $P = 0.0116$ and the second reported $d = 0.4$ with $P = 0.03$. The greater effect size in CAPS-5 compared to SDS may reflect the fact that many participants had complex trauma, and targeting a single trauma in therapy will consequently improve those specific symptoms to a greater degree than the client's overall symptoms, which are an aggregate of multiple traumas. Table 2.2 breaks the CAPS-5 results into clinically-relevant labelled bins.

Table 2.2: Mean (Own work derived from Fig. 3 in J. M. Mitchell et al. [230] and Fig. 3 in J. Mitchell et al. [231]) outcomes from the first and second phase 3 clinical trials (174 total participants). "Clinically Meaningful Response", "Loss of Diagnosis", and "Remission" are labels applied to escalating degrees of improvement.

	MDMA w/ Therapy	Placebo w/ Therapy
No Response	13 %	35 %
Clinically Meaningful Response	87 %	65 %
Loss of Diagnosis	69 %	40 %
Remission	40 %	13 %

Each subsequent dose (the trials included 3 doses) improved outcomes further, likely indicating further doses would further increase healing [230, 231]. Only 5% of participants in the MDMA groups discontinued treatment (half for reasons unrelated to the study), compared to 16% in the placebo groups. MDMA therapy worked across severity of symptoms, presence of other mental illnesses, and history of ineffective treatment. The improvements persisted when the data was reanalyzed by an independent, blinded programmer. Finally, long term follow-up results submitted to the FDA from phase III also suggest that the healing is durable, and the advantage of MDMA over placebo was maintained in the long term [346]. See Wolfgang et al. [343] and Mustafa et al. [237] for a more thorough discussion of efficacy. Note that there are a number of reasons MDMA therapy in clinical practice may be more or less effective than these trials suggest:

- Different expectations of positive results from the client or practitioner.
- Higher or lower therapist compliance with professional ethics. Two of the guides in the trials sexually abused a participant [241].
- Doses tailored to a client's body mass, which did not occur during the trial [230].

- Therapists may have more or less experience with MDMA, or more or less skill as a therapist.
- Therapy outcomes are strongly dependent on the client's working relationship with their therapist [119], yet trial participants had little choice in their therapist, as reported by one of the participants [171].
- Trials have strict inclusion and exclusion criteria that do not reflect the diversity of people seeking therapy.
- Trials may attract a different type of person than the typical therapy client.
- Different levels of support.
- Session pacing and number of sessions tailored to the client's needs rather than the demands of the trial.
- The trials were subject to intense media attention, possibly affecting the participants or clinicians.
- Trial sessions were video recorded [230].

Trials for all types of mental health interventions rarely control for expectancy of good results among participants and researchers, one type of study bias that placebos are supposed to correct for [161]. This results in much of the field using poor quality data that doesn't properly differentiate how much of the treatment effect is due to study bias vs. the intrinsic effects of the treatment itself. This most obviously affects trials where blinding is impossible, like psychotherapy and mindfulness. However, it also affects trials that do attempt blinding, but where the effect of the medicine is noticeable enough that the patients or providers unblind themselves. After unblinding, the patient's and provider's expectations about whether the medication works then alters either how much the treatment actually works or how much they report that the treatment works, confounding the data. [Psychedelic-assisted-therapy](#) trials like the MDMA trials possibly have worse-than-typical unblinding (because the effects of the medicine can be so strong) and researcher bias compared to typical trials for psychiatric drugs [3]. We suggest van Elk and Fried [334] for a thorough discussion of these problems. We still think MDMA therapy is more effective than placebo due to 1) anecdotes appearing to support durable therapeutic improvement in situations where the user was intending a recreational, rather than therapeutic experience, but happened to activate some maladaptive [schemas](#), and 2) anecdotes of successful MDMA therapy outcomes consistently matching the signs of successful [reconsolidation](#) reported by Ecker et al. [89] (emotional non-reactivation, symptom cessation, and effortless permanence).

As previously mentioned, mental illness is a complex interaction of biology (genes and medical history), psychology (schemas, in our view), and social context [96]. We think reconsolidation can likely resolve the "psycho" part of "[biopsychosocial](#) [50, 89]," which we suspect plays a major part in the large majority of mental illness cases. Determining to what degree any particular issue is caused (either self-assessed or clinician-assessed) by maladaptive schemas is difficult, in no small part because the poor state of current mental

health practice and science. For instance, the current categorization of mental illness in the DSM is in large part just arbitrary clustering of different symptoms [181]. If you have significant uncertainty about your particular issue, it may be worth trying MDMA therapy if you meet the safety criteria (See Section 3.1) and the cost is reasonable. It offers some chance of addressing the problem if it is schema-based, and very low risk if you don't have any emotional issues, though [destabilization](#) is a significant challenge if your problem is schema-based. We do know that MDMA therapy won't cure:

- Autism is genetically- and environmentally-determined [317]. However, autistic people often have anxieties that seem amenable to resolution [71].

Chapter 3

Preparation

3.1 Safety and Medical Information

MDMA therapy is generally well-tolerated, but there are dangerous drug interactions, medical [contraindications](#), side effects, and psychological risks [343]. These risks are mostly well-understood. As detailed later, most MDMA-related problems are caused by [272, 280, 343]:

- Prolonged, intense physical activity in high temperatures combined with dehydration. This may cause heat exhaustion or heat stroke. High water consumption not balanced with salt can also cause dangerously low sodium levels. Alcohol co-use strongly exacerbates the risk of these problems. Potentially deadly.
- Taking MAOIs (including ayahuasca) within 2 weeks of a session. Potentially deadly.
- Co-use with other psychiatric medications is unlikely to be dangerous, but may increase side effects or decrease (SSRIs in particular) the therapeutic effect.
- Co-use with amphetamines, stimulants, and opioids may be particularly risky.
- Liver or cardiovascular problems. Risk unclear.
- Exceedingly high doses. Risk unclear. A cautious upper bound may be 200 mg.
- Extremely high lifetime use can cause heart problems. It could also conceivably cause other, poorly understood problems.
- Possibly poorly-understood interactions with certain health conditions.
- Adulterated pills. This can be checked with test kits, though laboratory testing is much better. Risk unclear and varies by adulterant.
- Therapeutic [destabilization](#) is a common and healthy phase of therapy for those with severe [trauma](#). Unfortunately, the presence of a major risk factor for destabilization, severe early childhood trauma, is difficult to self-assess without (and sometimes even with) professional assistance. [Psychedelic-assisted](#) therapy tends to speed up both

healing and destabilization. Destabilization is sometimes overwhelming and can cause major problems when poorly managed or entered into at an inappropriate moment in your life. It may also on rare occasion exacerbate dangerous symptoms like psychosis or suicidal ideation.

Putting this in perspective, one panel of drug-misuse experts estimated that, even in recreational contexts where users are likely not as cautious as they should be of risks, MDMA poses a significantly lower overall health risk than marijuana, and far less than alcohol [243]. However, we suspect anyone undergoing MDMA therapy likely has a higher chance of therapeutic destabilization than the average recreational user. We also suspect that combining altered states of consciousness, the physiological drug effects of MDMA, confrontation of sometimes-extreme trauma memories, and the [psychogenic](#) illness that many with extreme trauma have may unpredictably improve or worsen an especially wide variety of health conditions.

When applying scientific studies to one's own life and health, it is important to remember that the data we glean from these studies flattens a wide variety of individual responses by combining them into readable averages. You as an individual may experience something very different from the average participant of any given study, and that may be totally normal and fine. Some examples include: you may be much more or less sensitive to the psychological or physical impacts of MDMA. The medicine may impact you for a greater or lesser amount of time than it impacts the average person. You may experience more healing, faster, than the average study participant, or you may not be helped by MDMA at all. Many normal human variations, like low or high body weight, recent pregnancy, or menstrual cycle status clearly have an impact on many mental health interventions (especially when it comes to effective dosage), but are not typically studied at all.

One of the great frustrations of mental healthcare research is that every real life situation is infinitely complex, and a corresponding infinity of confounding factors have the potential to influence outcomes. We encourage you to discuss with your clinician any difference in what you are experiencing (during any mental health intervention) from what the average response is that you might have expected from the research. It's important to both keep an eye on any health and safety concerns that might be related to your response, while also remembering that the range of normal and healthy responses to any mental health intervention is much broader than the averages suggest.

The following information is a high-level summary designed to be useful in typical practice. Far more detailed collections of information on MDMA can be found in the pharmaceutical investigator brochures from Multidisciplinary Association for Psychedelic Studies [236] and PharmAla Biotech [254].

Acute Effects

M. E. Liechti et al. [197] recorded side effects during a session and 24 hours afterward that we list in Table 3.1. On occasion some of these symptoms can last up to 3 days. These were found in individuals who were not diagnosed as mentally ill, though some of the individuals could have been engaging with intense maladaptive [schemas](#) that don't rise to the level of mental illness or are not classified as a mental illness in the DSM. Therefore, much of these symptoms

are possibly due to the MDMA itself rather than [defense cascade](#) activation and maladaptive schemas. Colcott et al. [67] also reported that non-cardiac chest pain/discomfort is an acute side effect. In the absence of MDMA-specific advice, the cardiologist Nicole Bhave, MD offers this general advice for what type of chest pain you should go to the emergency room for [124]:

...it most often boils down to the severity of the pain and the heart attack symptoms we mentioned above. If the pain is so severe that you feel like you can't function, or if you are experiencing central or left-sided chest pain — especially if you have nausea or a cold and clammy feeling alongside it — it is always safest to go to the emergency room. With chest pain, it's best to be cautious.

We're not aware of these side effects causing major problems in therapeutic contexts, though it's common to feel fatigued and low-mood enough that one needs to spend the whole following day or two resting. In recreational contexts the side effects are usually not significant enough to impair dancing or socializing. Using MDMA in therapy to [reconsolidate](#) the schemas of intense fear that cause most mental illness may additionally activate states of agitation, panic, or [dissociation](#) and their associated symptoms (See Section 2.2). Large amounts of reconsolidation also cause a period of exhaustion called [therapy hangover](#). There is no data on the phenomenon, but we think it lasts anywhere from a few hours to a day or two.

Table 3.1: Adapted from Table 3 of M. E. Liechti et al. [197]. Values indicate the percent of participants reporting that symptom. Blank cells either indicate the data was not collected, the MDMA value was within 1 unit of the placebo value in the original data, or the MDMA value was lower than the placebo value. The original data showed that the values reported here were generally much higher in the MDMA group than the placebo group, indicating that these symptoms are mostly caused by MDMA.

Symptom	Acute %	24 Hours %
Difficulty concentrating	80	38
Jaw clenching	78	27
Lack of appetite	73	53
Dry mouth/thirst	72	46
Impaired balance	66	9
Restless legs	55	15
Sensitivity to cold	55	16
Dizziness	51	9
Palpitations	47	9
Restlessness	46	16
Being cold	46	12
Sweating/sweaty palms	42	16
Forgetfulness	38	15
Heavy legs	36	16
Fatigue		55
Weakness	35	32
Hot flushes	32	20
Tremor	31	11
Paresthesia (tingling sensation)	30	
Inner tension	27	11
Brooding	22	24
Nausea	20	
Lack of energy	20	32
Exhaustibility	20	26
Frequent urge to urinate	19	20
Headache		36
Anxiety	15	
Irritability	11	7

Drug Interactions

If you regularly take another medication, we suggest consulting M. Liechti and Schmid [195] (more accessible) or Sarparast et al. [286] (more technical) for recommendations on whether you need to discontinue it for a period of time before or after your session. We don't know enough to specifically recommend this resource, but one psychiatric pharmacist specializing in psychedelics offers consultations and drug-interaction resources [211]. If your medicine is essential for your health we strongly suggest consulting your doctor on how, and whether, you can safely pause it. They will likely not understand the effects of MDMA, so you may need to provide Sarparast et al. [286] to them. That paper discusses pharmacokinetics, metabolism, and various drug interactions. If your medication isn't on one of these lists, you can't access a doctor or pharmacist, and you can temporarily discontinue it with tolerable effects, discontinuing it for 5 drug half-lives ¹ before the session and 2 days (5 MDMA half-lives, and also the amount of time required to recover 50% of baseline CYP2D6 enzyme capacity [248]) after the session would generally ensure that 98% of a drug has been excreted from your body [18, 73]. This does not account for health conditions that affect metabolism or other relevant processes. On rare occasions a drug's relevant effects persist even after it has been totally eliminated from your body, as is the case with reuptake inhibitors and MAOIs.

- Taking MAOIs within two weeks of an MDMA session can cause a deadly effect known as serotonin syndrome [90, 212]. Notably, one component of ayahuasca is an MAOI [281]. Co-use with amphetamines, stimulants, and opioids can also produce serotonin syndrome [210]
- Reuptake inhibitor medications, including SSRIs, SNRIs, NRIs, and NDRIs, highly inhibit the effects of MDMA [108] ². Long term use of these medications causes this effect to persist long after medication discontinuation. The therapeutic efficacy of MDMA therapy is reduced by half even after 25 days of discontinuation. Further discontinuation may bring further benefits. Discontinuation typically requires multiple additional weeks of tapering to manage withdrawal.
- Combining MDMA with other prescription psychiatric drugs can cause a variety of changes to the intensity or duration of various effects [286]. No generally high-risk interactions, except for MAOIs, have yet been found. However, some may increase low-moderate-risk adverse effects or decrease the therapeutic effects of MDMA.
- The liver enzymes CYP2D6/COMT, CYP1A2, CYP2B6, CYP2C19, and CYP3A4 metabolize MDMA [75, 286]. Flockhard [118] maintains a list drugs that inhibit, enhance, or are metabolized by CYP enzymes. Drugs that enhance CYP enzymes

¹Each drug has a different half-life, which can be found on [DrugBank](#) under Pharmacology → Metabolism.

²This paper was retracted because a study therapist sexually abused one trial participant, the researchers knew about this but failed to report it and remove that participant's data from the analysis, and the researchers failed to disclose conflicts of interest [109, 164]. These are major ethical breaches. We still cite the paper because it's the only source of rigorous data on this important phenomenon that we are aware of. Additionally, the effect size was so large that we don't think one changed data point would have significantly changed the outcome.

may reduce the intensity and duration of MDMA effects by removing it from your blood at a faster rate. Combining large doses of drugs that are metabolized by CYP with MDMA may overload one of these metabolic pathways and potentially cause problems, though it's unclear which drugs and how much. Drugs that strongly inhibit these enzymes, such as ritonavir, may be dangerous to take with MDMA because they lead to excessively high or long-lasting concentrations in your blood [286]. Again, the degree of danger is unclear and dependent on a drug's degree of inhibition and dose. Some inhibitors, like SSRI's, don't seem to cause dangerous effects (other than reduced therapeutic benefit) when combined with MDMA. The multiple enzymes provide some redundancy if one pathway is inhibited, making drugs that inhibit multiple enzymes particularly dangerous.

- MDMA almost completely inhibits the CYP2D6 liver enzyme, one of multiple parallel metabolic paths for MDMA, creating a faster-than-linear dose-response curve [74]. This inhibition returns to baseline with a half-life of 47 hours [248]. Thus, about 2 days after a session enzyme activity will be 50% of the way to baseline, 75% after 4 days, 88% after 6, 94% after 8, and 97% after 10. This effect may counteract tolerance or lead to unexpectedly strong reactions to subsequent doses MDMA. Inhibited CYP2D6 slows the metabolism of a number of other drugs, especially ones that are not metabolized through any other parallel pathways that could take up the slack. Thus, dangerous concentrations of certain drugs could accumulate in your blood when those drugs are used within a few days of MDMA. Flockhard [118] maintains a list of drugs metabolized by various enzymes. Look in the "substrates" section. Even if you aren't taking any medications, the precautionary principle might suggest spacing sessions far enough apart to allow recovery, perhaps a week or two at minimum.
- Pills marketed as MDMA can contain harmful adulterants [284]. See Section 3.4 for testing information.

Medical Considerations

- MDMA increases average blood pressure by 17/6 mmHg and heart rate by 15 b/min in therapeutic contexts [230]. Transient increases in systolic blood pressure to above 180 mmHg occurred in 5% of users in one study [338]. This may be a risk for individuals with cardiovascular disease. Individuals with "...uncontrolled hypertension, history of arrhythmia, or marked baseline prolongation of QT and/or QTc interval" were excluded from clinical trials for this reason [231]. That may not be a complete list of cardiovascular conditions contraindicated for MDMA, and caution should be used for any cardiovascular disorder. It's unclear exactly how much of a risk these pose. A search of the FDA Adverse Event Reporting System found "A total of 17 unique cases were reviewed in this study. There were no reports where MDMA was taken as a single agent and ischemic, hypertensive, or arrhythmic adverse events were reported. All cases included co-use with other medications associated with cardiac function abnormalities [209]."
- Extremely high lifetime MDMA use, possibly along with high use of other psychedelics,

may cause valvular heart disease [84, 315]. In one observational study, 28% of chronic MDMA users showed signs of valvular heart disease (VHD) when evaluated with echocardiography, compared to 0% in a matched control group who reported no MDMA use [84]. The chronic users with clinically significant VHD self-reported a mean consumption of 943 MDMA tablets, while the chronic users without clinically significant VHD reported a mean consumption of 242 tablets. This may give a very rough indication of how much MDMA is needed to cause VHD. These quantities are far higher than we've heard of anyone using in therapy.

- It's unclear what degree of liver function is necessary for MDMA therapy [183].
- MDMA, like many medicines, may have uncommon, poorly understood side effects, particularly after long-term high-frequency use, or in populations with certain genetic features or health problems.
- MDMA commonly causes mild hyponatremia (low plasma sodium concentration) in individuals who drink unsalted fluid during the session, though not in those who don't drink anything [24]. This was found in clinical settings where physical activity was low and temperature moderate. Hyponatremia can become severe if the individual sweats a lot without replenishing the lost salt, or drinks large amounts of unsalted fluid, as sometimes occurs at dance parties [333]. Dangerous heat illness can also occur if you sweat a lot and don't hydrate in a hot environment, as also sometimes occurs at dance parties [333]. Exercise increased caution if your body has severe problems regulating its temperature because MDMA raises body temperature by 0.2-0.8°C or 0.4-1.4°F [196]. Alcohol co-use also significantly exacerbates the risk of heat illness and hyponatremia [333].
- Planning careful or reduced movement during altered states of consciousness may be advisable if your body is prone to injury from otherwise typical human movement. A sitter, guide, or therapist could help you with this during the session, or you could put an obvious reminder sign in your field of view.
- Kangaslampi and Zijlmans [172] saw no obvious reasons why adolescent use would be risky. However, this assumption has not been tested in any trials. Developing individuals could react differently to MDMA than adults. You may have to trade off these unknowns against the fact that treating mental illness is also important, and MDMA therapy shows promise for resolving mental illness [230].
- As with most problems associated with MDMA [272], seizures are very rarely reported, and when they are, they are mostly associated with mixing intoxicants, extremely high doses, or hyponatremia or heat stroke from dancing all night without adequate fluid and salt intake [122].
- We couldn't find any high-quality information about using MDMA while pregnant or breastfeeding. We think the precautionary principal indicates that these combinations should be avoided until they are rigorously demonstrated to be safe.

- Adequate sleep is likely important for productive sessions and post-session recovery [299]. People commonly experience up to three days of post-session fatigue [197]. Starting another session before you have recovered from the previous one may reduce session effectiveness and increase the risk of undesirable effects. We know of two anecdotes of back-to-back psychedelic therapy sessions with no recovery days triggering psychotic episodes.
- Tolerance to MDMA starts developing within 1–2 hours of ingestion [107, 251]. We have been unable to find any data showing how long this tolerance lasts and distinguishing the effects of tolerance from dissociation, [avoidance](#), or the natural variation of sessions may be difficult. However, if you notice a pattern of diminishing effects, we suggest spacing sessions further apart or reducing dose. Using higher and higher doses to overcome tolerance will produce negative effects.

Psychological Risks

- Psychological destabilization (See Section 2.5) is a common occurrence in therapy [247]. It's associated with better outcomes later in therapy, but if it is intense enough and not managed well can severely interfere with your life. We are not aware of any papers demonstrating this, but we think it's likely that psychedelic therapy tends to produce stronger destabilization (and more rapid therapeutic progress) than traditional psychotherapy. See Section 2.5 for more information.
- Possession of multiple doses may be risky for those with severely impaired impulse control if they see the medicine as an escape, an immediate drug-based solution that doesn't require a therapy component, or don't understand the need to recover between sessions. They may use too high of doses, use it too frequently, or use it in unsafe contexts.
- Altered states of consciousness can impair awareness and judgement. Avoid driving and other potentially risky activities on the same day as the session.
- Complex or compelling distortions of external reality on MDMA are rare and correlated with unusually-high doses, but people more commonly have closed-eye visuals (possibly involving traumatic events they experienced) [197]. These visuals may be symbolic instead of a realistic reliving. Temporary and mild visual changes such as color and texture enhancement are common. Sometimes psychedelics, along with many other psychoactive drugs, trigger persistent visual distortions or anxiety about existing but unnoticed visual distortions [10, 141]. When this causes significant distress or impairment it is called Hallucinogen Persisting Perceptual Disorder (HPPD). HPPD is strongly linked to pre-existing anxiety or dissociation, and often improves as those are treated. HPPD from MDMA is unrecorded in clinical trials, but some recreational users report it [201, 338]. One survey found that when people do report persistent visual or auditory distortions (from any psychedelic), 73% say "they [the symptoms] don't bother me at all", 24% "I'd rather not have them, but I can live with them", 0% "they irritate me", and 1% "they drive me mad [52]."

- Suicidal ideation, psychosis, and mania are dangerous states, and, as detailed below, there is an unresolved gap between expert consensus and evidence on the risk of MDMA or psychedelic therapy exacerbating these conditions. Experts tend to recommend either avoidance of psychedelics, or, growingly, caution and high levels of support for individuals with these conditions or at high risk of these conditions [186]. High levels of skilled, ethical, and well-matched psychological and psychiatric support are undoubtably beneficial for individuals with these conditions. However, as far as we can tell, the belief that MDMA therapy tends to cause or make these conditions worse has not been established by clear evidence. Here is the best information we have been able to find on the subject:
 - **Suicidal Ideation:** MDMA therapy with high levels of support decreases suicidal ideation about as much as placebo with therapy, on average [230, 231]. When interpreting these results it is important to note that average improvements can mask the possibility that a small portion of individuals can get worse even while the majority improve, though this applies to the placebo group as much as the MDMA group.
 - **Psychosis:** There is virtually no high quality experimental data because people with a history of psychosis are usually excluded from clinical trials of psychedelics [186]. Case reports of psychotic episodes induced by MDMA are rare and typically, though not always, report confounding factors like co-use with other psychoactive drugs, chronic abuse of other drugs, lack of verification of MDMA ingestion, heat stroke, hyponatremia, extreme doses, or extreme frequency of use [21, 219, 253, 313, 332]. One participant out of 174 in the MDMA phase III clinical trials reported a psychotic episode after the trial ended in poorly-documented circumstances, even though participants reporting any personal history (family history was allowed) of psychotic disorders were excluded from participation [231, 241, 303]. We have personally heard of two cases of temporary psychosis leading to hospitalization triggered by a high-dose psilocybin trip conducted the day after an MDMA therapy session. This suggests a lack of adequate recovery between sessions is a major risk factor. Sulstarova et al. [313] found that when psychedelics were implicated in psychotic episodes, the episode lasted an average of 1.8 weeks with psychiatric treatment.
 - **Mania:** There is virtually no high quality experimental data because people with a history of mania (less-so hypomania) are usually excluded from clinical trials of psychedelics [126]. The MDMA phase III trials did not exclude individuals with bipolar II and no manic episodes were reported [231]. One small, uncontrolled study of psilocybin-assisted therapy for people with bipolar II but not currently in a hypomanic state showed good efficacy and safety when combined with a high level of support [1]. We aren't sure how well that translates to MDMA therapy. Notably, we couldn't find a single case report of mania where MDMA was unambiguously involved in the recent past, and are therefore confused why MDMA and disorders involving mania are often considered a risky combination. Perhaps it is because bipolar I frequently also involves psychosis, which does have

a link to MDMA use, even though it seems rare and typically associated with exacerbating factors not seen in therapeutic contexts.

We think the clearest line of reasoning for MDMA therapy triggering these conditions is that 1) high stress is a known risk factor for psychotic or manic episodes [329, 335], and 2) MDMA therapy is known to occasionally create high amounts of stress through confronting previously-avoided traumatic memories or other types of destabilization (See Section 2.5). Of course, this also implies that MDMA therapy can reduce the risk of psychotic or manic episodes when MDMA therapy resolves existing stress. It also suggests that high quality psychological support before, during, and after the session would indeed reduce risks. We don't know any way to predict whether MDMA therapy will help or hurt in any specific situation. Conclusively resolving the gap between low evidence of risk and expert consensus will require much more research.

Evans et al. [105] surveyed people who have experienced new, persistent negative symptoms after recreational, professional-therapeutic, and DIY-therapeutic psychedelic experiences. This data applies to all psychedelics, not just MDMA. Most symptoms dissipated with time, but 17% of respondents said theirs lasted more than 3 years. From most to least common, participants reported emotional (76%), self-perception (58%), cognitive (52%), social (52%), ontological (50%), spiritual (34%), perceptual (26%), and other (21%) difficulties. There is major uncertainty in how much these symptoms are due to (See Calder et al. [49] for a discussion of this in psychedelic therapy in general.):

- Surfacing of existing maladaptive schemas and subsequent defense cascade activation, a necessary and healthy part of the therapeutic process if managed well. You may have been avoiding these schemas until the session. *We think there is a high likelihood of this for MDMA therapy. It's conceivable that a highly skilled therapist could help you keep to destabilization in small, easily dealt with chunks, but psychedelic experiences are famously difficult to control.*
- Trauma from life impairment or destabilization due to poorly managed surfacing of maladaptive schemas and trauma. *This is possible, though the risk can be significantly reduced with expert guidance and high quality support.*
- Trauma from the psychedelic experience itself. *We think this usually results from large doses of hallucinogens, unsafe settings, and abusive or incompetent guides/therapists. We think traumatization risk is low for MDMA itself because of its intense feelings of safety and tendency toward low hallucinatory effect.*
- Difficult or destabilizing changes to your understanding of self, existence, or meaning. *We think MDMA only rarely induces this because MDMA tends to produce much lower levels of ego-dissolution and mystical experiences than other psychedelics [101, 156]. See Section 4.3 for more information.*
- Something else. We don't know if this exists, and if it does, what it is or how often it occurs.

Even in this subgroup of people who experience extended difficulties in the previously mentioned study, 90% agreed with the statement "I believe that the insights and healing gained from psychedelics, when taken in a supportive setting, are worth the risks involved [105]." However, it is possible that a population of psychedelic users who experience debilitating effects was missed due to sampling bias. Psychedelics can also inflate feelings of meaning, potentially biasing respondents to report that their experiences were more valuable than they actually were [148].

Other Common Concerns

- **Discomfort with Drugs** While MDMA therapy is not for everyone, healing can happen even when discomfort is present during a session because MDMA rewrites patterns of (maladaptive) discomfort that you stay present with [110]. Your fear of MDMA could be unlearned if it is not an accurate representation of reality [89].
- **Loss of Control** While engagement with distressing memories can be intense, people regularly have clear, complex, and emotionally nuanced conversations on MDMA [66, 252]. MDMA creates intense feelings of compassion and safety that make aggressive behavior unlikely. D. Nutt et al. [243] ranked drugs by expert perception of "Harm to others", and MDMA was ranked at about 2% the risk of alcohol.
- **Drug Stigma** Many drugs are harmful, however, during the War on Drugs a wide variety of psychoactive substances were further stigmatized and categorized as harmful without clear evidence-based distinctions regarding their actual risk [7, 243]. While there were complex motivations for the War on Drugs, it functions and persists primarily as moral panic, a means to punish certain groups of people, and a means for politicians to disenfranchise and ostracize the voter base of their political opponents. There is little correlation between the legality of psychedelics and their potential for harm [243].
- **Addiction** A panel of medical experts organized by the Dutch government found no cases of MDMA addiction in Dutch treatment centers and concluded that "It does not, or only minimally, lead to abuse, dependency or use-related disorders [325]." Withdrawal has also not been found in rodent studies, even at extreme dosing schedules [275]. However, MDMA, like most experiences that can make you feel profoundly safe, can be psychologically addictive when it is used to escape from difficult feelings rather than engaging with them. Reports of behavioral MDMA addiction in recreational contexts exist, but as previously stated, seem rare and associated with escapism [97]. As previously discussed, there have been many flaws in studies on MDMA abuse. Consequently, little is known about the effects of abusing MDMA, or what level of use causes physical or psychological problems. If you are worried about your potential for addiction, we suggest: only possessing one dose at a time, only obtaining MDMA from a trusted mental health professional who can monitor your abuse potential, don't escalate dosing, don't do solo therapy, and only use it for therapy.
- **Neurotoxicity** Some observational human studies and controlled high-dose animal

studies have found that MDMA use is associated with neurotoxicity (oxidative stress in this case) or cognitive problems [252]. However, these problems have not been found in controlled studies in humans [142]. The human observational studies that find problems usually fail to adequately control for multiple-drug use, a significant risk factor. Notably, Halpern et al. [142] ruled out high levels of long-term cognitive issues from recreational MDMA use in a population that had exceptionally low lifetime use of other psychoactive substances. Unfortunately the study didn't have the statistical power to rule out low-moderate levels of cognitive issues. One small randomized study of MDMA therapy also did not find any significant cognitive effects [233]. The animal studies that found problems typically used extreme doses, extreme frequencies of use, or injected the medicine, a more potent method of administration than swallowing a pill [252]. It's also not clear that humans respond the same way as rats to an equivalent dose. It's possible that replicating these conditions of extreme doses or frequency of use could cause harmful neural oxidative stress in humans. Some studies have reliably found serotonin system alterations in humans, but as far as we are aware, it hasn't been established that this is clinically significant, and the effect decreases with abstinence [134]. Fear and misinformation about MDMA is widespread due to the War on Drugs, sensationalized of poor quality research, and misattribution of MDMA-related deaths as an inherent risk of MDMA instead of its interactions with certain medications and health conditions, and the risks of heat illness or hyponatremia at raves [252]. See chapter "The Toxicity Debate" in *The History of MDMA* by Torsten Passie for a comprehensive review of the topic.

High doses of certain antioxidants, including alpha-lipoic acid, ascorbic acid, and acetyl-L-carnitine, administered shortly before and during the session, prevent oxidative stress in rats [4, 16, 296]. Some companies bundle these antioxidants together in commercially available products, but we are not aware of them having been rigorously tested for usefulness in humans [276].

- **Misuse** We are not aware of any clear evidence suggesting that recreational use of MDMA is problematic as long as the safety considerations in this section are taken into account. One panel of drug-misuse experts estimated that, even in typical non-therapeutic contexts where users are likely not as cautious as they should be of risks, MDMA poses a significantly lower overall health risk than marijuana, and far less than alcohol [243]. While those drugs can be used in harmful ways, they can also be used responsibly with negligible negative effects. It is important to note that possession of MDMA is a felony in most of the world, though in practice many jurisdictions do not enforce or prioritize charges for possession of small amounts [262]. We recommend the assistance of an ethical, well-matched, and skilled therapist for anyone who develops a pattern of harmful, escapist, or psychologically-addictive MDMA-use.
- **Origins of MDMA** MDMA (3.1) is generally made by making several modifications to the plant compounds safrole (3.2) or piperonal (3.3) [99, 330]. When properly conducted, this process results in pure MDMA. Single-substance purity greatly improves the ability to produce accurate and safe doses. Refer to Ruggeri [282] for a nuanced discussion of what "natural" means. For those concerned about the pharmaceutical

industry: MDMA was first made in the early 20th century by Merck as an intermediate product with no recognized use itself [252]. The first known human use of MDMA was in the early 1970s as a legal alternative for MDA in recreational use. Its first use in therapy occurred in the late 1970s after the independent chemist Alexander T. Shulgin realized it's therapeutic potential and introduced it to the therapist Leo Zeff Ph.D., who used it with many clients and taught many therapists how to use it. Then, once it was made illegal, legal therapeutic use ended. Making it legal again would require enormous amounts of money to run proper FDA-approved clinical trials, but no regular drug company was willing to do this because the original patent expired in the 1930s, and they wouldn't be able to recoup their investment through drug sales. The 21st century clinical trails were funded through a combination of 1) donations to the nonprofit Multidisciplinary Association for Psychedelic Studies (MAPS) and 2) MAPS selling shares of its for-profit division Lykos [263]. To recoup their investment Lykos tried to patent a specific particle size of MDMA crystals within a pill, but the patent office rejected it. Their business plan is now unclear. We think that in 2025, outside rare clinical trials or limited legal use in certain countries, all MDMA used in therapy is ultimately sourced from underground chemistry labs and has nothing to do with Lykos or MAPS.




Figure 3.1: Structure of MDMA.




Figure 3.2: Structure of Safrole.




Figure 3.3: Structure of Piperonal.

- **Can I Inadvertently Unlearn a Healthy Schema?** As stated by Ecker [88]:

When two mutually contradictory schemas are juxtaposed consciously, the schema that more comprehensively or credibly models reality, and therefore more usefully predicts how the world will behave ³, reveals the other schema to be false, and the falsified one is immediately transformed [reconsolidated] accordingly.

The reconsolidation process doesn't imply that your post-reconsolidation beliefs will be a precise truth about the world or yourself, only that it will be more true than the falsified/unlearned schema in the context of your lived experience. We think this generally produces good outcomes, but is not perfect. There might be rare situations where a healthy but false-according-to-your-lived-experience schema is unlearned. For example, someone's especially deep desire to not be alive might be able to contradict their desire to, say, avoid falling off cliffs. In that case their avoid-falling-off-cliffs schema would be an unintegrated remnant from a time in their life when they did want to be alive. In case such a scenario is actually possible, please do not try to unlearn any schemas critical for keeping you or any other being safe. Do not conduct MDMA therapy in acutely dangerous situations where healthy danger avoidance schemas may activate. We are also hopeful that using MDMA's compassion, connection, and safety to facilitate reconsolidation of one's own fears and insecurities also tends to result in schemas that are associated with more compassion, connection and safety. On a practical level, we are unaware of any instances of MDMA therapy unlearning a fundamentally healthy schema. The closest example we are aware of is the unlearning of fear-based schemas that, while unhealthy, may temporarily provide some necessary functionality in your life (See Section 2.5).

Similarly, the reconsolidation process can't always help you unlearn erroneous beliefs that were formed from unrepresentative sets of experiences. If you were the first human to meet aliens, and they attacked you, you might reasonably learn "these aliens are dangerous," and no amount of reconsolidation will change that until you acquire contradictory knowledge (maybe you learn that that alien happened to be a pirate and all the other aliens are very nice people).

3.2 Professional Guidance vs. Self Guidance

MDMA therapy appears to be successful in a wide variety of contexts including therapist-guided sessions with pre- and post-session support, do-it-yourself couples therapy, and solo therapy [66, 152, 231]. However, we believe working alone with MDMA presents higher risks and a lower healing likelihood compared to partnering with an ethical, skilled, and well-matched therapist or guide. That being said, it is often difficult and expensive to access an ethical, skilled, and well-matched therapist or guide, so that may not always be the best option available to you. Per our individual and clinical experience, an ethical, skilled, and well-matched therapist or guide may provide:

³The phrase "predicts how the world will behave" may be confusing here, but it includes beliefs about yourself (e.g. I am good, I am bad) and how you react in various situations (e.g. dogs are threatening enough to trigger a [fight-or-flight](#) reaction).

- A trustworthy presence that creates a greater feeling of safety, enabling more effective healing
- Additional perspective that's hard to see from a first-person view
- Education on [trauma](#), healing, trust, what healthy relational patterns look like, and healthy ways to deal with emotions (also known as psychoeducation)
- Troubleshooting for problems with the medicine or other parts of the healing journey
- Improved screening for [contraindications](#) (conditions that make MDMA particularly risky)
- Monitoring of your level of [destabilization](#) over time
- A skilled and experienced perspective about how best to maintain your to your [window of tolerance](#), and broaden your window of tolerance over time
- Assistance in learning appropriate coping strategies
- Assistance identifying which coping strategies are best for you in a particular context
- Assistance preparing executive function supports for yourself to maximize your capacity to use the right strategies at the right times
- Management of destabilization periods to reduce disruptions to your life—including empathetic encouragement to rest or cut back from other obligations when appropriate, in order to preserve over-all wellness and capability, and assistance strategizing ways to manage your life that will minimize disruption
- Guidance through difficult therapeutic exercises
- An empathetic and [grounding](#) presence while you think through major life decisions, relational challenges, and challenging new [schemas](#) that may emerge in the course of the work
- Assistance identifying supplementary treatment modalities that are likely to be most effective for your situation, and in some cases, information about how best to access those treatment modalities
- Assistance in planning for your medicine experience and organizing appropriate social support for the whole process
- Unadulterated medicine and/or some degree of medical monitoring, depending on who you're working with

Therapists and guides who are ethical and skilled but whose style or personality are not a good match for you should be easy to approach about this [mismatch](#), and they should recommend any colleagues who they think would be a better match. We think the risks inherent in working with an ethical and skilled therapist or guide who you don't match well

with mostly involve wasted time and money, and possibly demoralization. However, we think the risks of unethical or unskilled therapists and guides can include:

- Emotional, physical, financial, or sexual abuse [241]. This includes [Adverse Idealizing Transference](#) (See Section 3.3).
- Excessive dependence on that therapist or guide [241]
- Increased risk of adverse effects and destabilization, possibly though overly intense or frequent [psychedelic](#) sessions with inadequate support.
- Ineffective treatment that the mentally healthy would find frustrating could be totally demoralizing to the mentally unhealthy. You could stop seeking any kind of treatment altogether.
- They may push their own interpretations on you while you are in a suggestive state of consciousness, potentially leading to false beliefs of abuse [291] or false beliefs about how trauma and mental illness work.

Furthermore, licensed mental health providers are usually legally obligated to call the police on you if they think you are at high risk of suicide or hurting someone else. What level of risk your provider thinks is sufficient to call the police is strongly dependent on their individual judgement, personal interpretation of local laws, how much they fear being sued or losing their license if someone dies or gets hurt and then blames them, and how much they believe involuntary hospitalization will help you. If you are suicidal or fantasize about hurting your abuser, we strongly suggest asking your provider to elaborate their decision criteria before you meet with them, or during your first appointment before they ask you if you are suicidal or want to hurt someone. Then you can decide if you can cope with the level of self-censorship necessary to stay outside their boundary. Or, you may even trust your provider enough that you can be completely open with them because you know they will only tell you to go to the hospital if you really need it. In that case you could write up a crisis plan involving which hospital you want to go to, which family members or friends you want notified, etc. If your provider does call the police on you, know that police typically have little training in the mental health and will likely take your provider's word over yours. There is also a good chance that the police dragging you away against your will to a place you can't leave, where medical staff will do a wide variety of invasive and non-consensual things to you, will traumatize you. Even worse, Emanuel et al. [93] found that (in Allegheny County) involuntary hospitalization significantly increases the chance of a patient killing themselves or hurting someone else over the 6 months following admittance in cases where clinicians might disagree about admitting a patient (43% of evaluations in this study). It's not clear how well these results apply to situations where multiple clinicians would all agree on admitting a patient. [93]. We think S. Alexander [9] appears to be a good guide to navigating/avoiding the inpatient mental health system.

Individual and couples MDMA therapy without professional assistance (possibly with the assistance of a trusted, empathetic, and emotionally non-reactive sitter [318]), appears to work well for some people, including the author MG [66, 152]. We are uncertain what circumstances lead to positive vs. negative experiences, or the degree to which various risks

are increased. We can't say if this is appropriate for your particular situation, but it is an option that a lot of people like for various of the reasons listed in this section.

We propose the following ranking of options. The top of the list represents the lowest risk of adverse outcomes, the highest likelihood of durable healing, and also the highest financial cost. This list is a general guide and the exact positions of items are debatable, as well as dependent on personal circumstance. Exceptions to the rule always exist.

1. Continually working with a skilled, ethical/accountable, psychedelic-trained therapist or guide you align well with. *We tentatively think this is the ideal model for all situations if you can find the right clinician to work with and have enough money. We also think this model is especially important for people with potentially dangerous symptoms they can't manage themselves, including psychosis, mania, suicidal ideation, or a severe lack of impulse control.*
2. Start off with a skilled, ethical/accountable therapist or guide who you align with and who is psychedelic-trained and/or personally experienced with MDMA. You may later transition to self-guided sessions (with regular check-ins) if you and your clinician collaboratively decide that is sufficiently safe for you. *This model has not been explored in the research and may have a higher risk of difficulties. However, because it offers dramatically lower costs and there are many anecdotes of people (including MG) who have found it highly effective, some people will pursue this method.*
3. Work with a skilled, ethical/accountable non-psychedelic-trained therapist or guide you align well with; collaboratively assess your risk-factors with them (perhaps reading this safety section of this guide together, or consulting briefly with a psychedelic trained therapist). If your risk factors are low, you then self-guide all your medicine sessions while maintaining regular sessions with your clinician. You also use high quality resources (see Appendix A) to educate yourself on the nuances of effective and safe MDMA therapy and use a high-quality sitter as appropriate, which includes at least the first several sessions (See Section 4.1 for characteristics of good sitters). *We think this model is similar to the previous one, but—depending on the quality of your self-education—somewhat more difficult and riskier.*
4. Self-guide all your medicine sessions and do all of your own between-session work, perhaps talking about your healing journey with emotionally skilled friends or friends skilled in safely using psychedelics for healing. You also read literature (see Appendix A) on trauma healing and psychedelic therapy written by mainstream academics and use a trusted sitter for at least the first few sessions (See Section 4.1 for characteristics of good sitters) *We don't generally recommend this model because self-assessment of risk factors is very difficult. If you do try it, we think you will greatly benefit from high self-emotional knowledge and high skill in managing your own emotional reactivity. While this model has worked for many people, we are unsure of the risk/benefit trade off. We strongly recommend identifying and at least briefly connecting with a therapist or guide you might want to work with in case you get into deeper water than you are comfortable with.*

5. Self-guide all your medicine sessions and do all of your own between-session work. You don't use any high quality reference material and don't understand the technical nuances of safe and effective healing. Or you work with an incompetent or abusive guide or therapist who may harm you by suggesting overly-intense psychedelic sessions and not effectively help you with the resulting trauma or destabilization. They may also offer distorted or unhealthy interpretations of experiences you have during a session. *We don't recommend this in any circumstance. While it is occasionally helpful to some, we think the lack of rigorous understanding of the process can place both safety and healing at elevated risk, and is likely to impair healing to some degree. Adverse effects may not be identified, understood, and well-managed.*

It seems important to note that although more data is needed, therapeutic use of psychedelics in professionally supported group sessions, where multiple therapists look after a larger number of clients throughout a medicine experience, may offer a potential way to make professional support more accessible [213].

3.3 How to Find a Therapist or Guide

Which therapist you work with matters a lot. For instance, in a large study done by Firth et al. [115], after adjusting for demographic factors (like the severity of symptoms clients were entering therapy with), the best 3.9 percent of clinicians had 77.2 percent of their clients recover; the recovery rate for therapists in the average range was 58 percent; and the 3.9 percent of clinicians who had the worst outcomes only saw 41.4 percent of their clients recover (Note that a significant percentage of people recover even without therapy, so it's possible that the worst therapists have a negative influence on their clients.).

It is our hope that the following recommendations, which largely emerge from our personal and clinical experience ⁴, can make finding a therapist feel less overwhelming and more hopeful for those who are struggling—or who don't even know where to start—with the search.

First, we acknowledge the difficulty: even under optimal circumstances, accessing mental healthcare can turn out to be a slog. These challenges are common knowledge for people who provide community mental health services and/or who have accessed them repeatedly: the financial and administrative costs are often daunting. Interacting with licensed mental healthcare professionals is inherently vulnerable for many, especially those who have witnessed or experienced carceral hospitalization or forced medication. Intake interviews often demand intimate details of one's finances, sexuality, and medical and mental health. All of this is the price of accessing a clinical relationship that may or may not be very helpful. If it isn't, clients may feel they need to stick with it, because they do need help, and finding someone else to help them seems like more than they can take on, but that doesn't necessarily mean the clinician will stick around—and particularly for those who are using Medicare/Medicaid or who require less-expensive sliding scale services, clinicians may be

⁴This experience includes some common knowledge of professional norms among the licensed mental health professions, much of which can be found in the ethics codes of the major licensed mental health professions, e.g. the National Association of Social Workers code of ethics, the American Psychological Association code of ethics, the American Counseling Association code of ethics, The American Association for Marriage and Family Therapy code of ethics, etc.

students whose clinical internships end only a few months after starting to work together. Online services, which have endeavored to bridge the gap between what is needed and what is easily available, are plagued by serious ethical and product-quality concerns [22, 28, 32, 33, 120].

The good news is that there *are* excellent clinicians out there—and not all of them are late in their careers. Early career therapists, like those who tend to staff more affordable clinics, provide just as good of care as their more experienced counterparts [132]. Here are our recommendations on how to find one that's right for you.

Bad Therapy is Worse than no Therapy

Remember that really bad therapy can really hurt you [157], and as such we feel it is worse than no therapy. Bad therapy can leave you stagnant for a long time with the impression that no real help for you exists. It can make your symptoms worse without making them better after. In the worst case scenario, it can leave you with additional [trauma](#). See Section 3.3 for a discussion of the particular challenges of avoiding negative and damaging clinical experiences in the realm of [psychedelic](#) therapy.

Good therapy is often very uncomfortable [89]. However, you should feel a sense of mutual trust and respect with your clinician, and you should also feel a sense of collaboration and consent regarding the goals you are working towards and the methods you use to get there [138]. Even if you don't understand the methods your clinician is using to help you, we believe a skilled and well-matched clinician will take the time to help you develop a trust in them that is commensurate with the discomfort of what they are asking you to undertake.

Although we cannot speak to the specific trade-offs of your situation, in general we recommend continuing to search until you are able to access good therapy.

Trust your Personal Experience

Trust your perceptions, because your personal experience of your clinician impacts the efficacy of your treatment [158]. You don't just need a good provider, but a good provider who is also a good fit with you. We strongly recommend using the BR-WAI [138], an empirically validated tool for understanding how you and your therapist are connecting, and what might be required to improve that connection.

In our experience, it's a good idea to look for someone it feels like you could say anything to. If you cut your arm, any skilled emergency physician will be able to competently stitch you up. The same is not true with a comparable degree of psychiatric injury [115]. In mental healthcare, the bedside manner is part of the intervention, and the same bedside manner doesn't work for everyone. Although the most skilled mental healthcare providers connect well with an extremely broad spectrum of clients, it is unrealistic to expect every provider to "click" with every client—and many excellent mental healthcare providers ultimately focus narrowly on particular populations of interest to them. If you aren't connecting with a particular clinician, it doesn't mean anything is wrong with them, and it doesn't mean anything is wrong with you.

Feedback

Good therapists love feedback and direction. It is very likely that many therapists who could do great work with you if you are expressive about what you need and want would, in contrast, be very bad therapists for you if you aren't expressive about those things [77, 187, 207, 245]. If you can, we recommend asking clearly for what you want and talking clearly about how things feel. Additionally, there are several instruments that have been developed to help therapists measure and improve their performance. Examples include the BR-WAI, the ORS-SRS, the Core-OM, or the QR-45.2. If your therapist asks you to participate in one of these formal feedback mechanisms, we recommend doing so, even if it feels awkward; these measures really seem to help therapists provide better services.

We've observed that it is sometimes helpful to imagine what therapy would be like, if it went as well as you could possibly imagine, and to share this with your clinician—and to articulate your fears about the process. You can also ask if your ideal hopes align with their experience of their methodology, which may help you set expectations for your treatment. You can use the list above (of what a skilled therapist can provide) to identify ways you would like your therapist to support you. It may be helpful to identify which forms of support you are interested in receiving, and to spend some of your initial sessions learning how your clinician feels about providing support in those particular ways.

Particularly if you have been working with a particular clinician for a while and your issues/diagnoses and demographic are within their main practice area, you are *well* within your rights to ask a clinician to go outside their comfort zone to learn or implement a new-to-them intervention that is right for your situation. An accredited therapist is required to complete continuing education hours anyway. There are lots of legitimate reasons they may say no (cost, time, and accessibility of additional training, to start with), and that's OK too—but please don't be afraid to ask.

If things aren't working, and you've made some effort to recruit your clinician's help in fixing the situation, a therapist may also be willing to spend some of your final few sessions helping you find and connect with someone who is a better fit for you.

Boundaries

Good therapists have good boundaries. Clients often come to therapy without an understanding of what healthy therapeutic boundaries are and why they might be important, and that's OK—it is the clinician's job to have this knowledge, to share it with the client, and to assert boundaries as needed.

One of the most important reasons boundaries are crucial in therapy is a phenomenon called [Adverse Idealizing Transference](#) (AIT) [80, 157]. Idealizing Transference is a phenomenon in which clients develop strong positive feelings towards their therapist. This can be totally healthy and extremely helpful to the course of therapy—supporting clients in their sense of safety and their ability to sustain focus and effort through the sometimes severe discomfort of healing. However, in some cases, it is possible for these positive feelings to be so strong and misdirected that they cause considerable harm—causing lasting distraction and disruption in the client's life, potentially continuing for decades. This situation creates a severe vulnerability that the therapist, if they are unscrupulous or unskilled, may exploit

(intentionally or not) for emotional, sexual, or financial gain—creating severe trauma for the client and sometimes impacting others as well. In these cases, Idealizing Transference has become Adverse Idealizing Transference. Just as helpful medications sometimes have side effects for a small percentage of the people who use them, a small percentage of therapy consumers experience AIT.

AIT can happen even when a clinician is doing everything right [80]. However, both the emotions of AIT and the harm created by them can be greatly amplified when therapists fail to communicate and follow through on healthy boundaries. Here are some commonly recognized healthy professional boundaries for therapists:

- The clinician does not disclose details of their personal life to you unless that disclosure enhances your treatment and is motivated by a desire to promote your welfare.
- The clinician avoids dual relationships wherever possible. For example, if a client cannot pay for services and offers to do yard work or provide other professional services in barter, it would cause a dual relationship to accept this offer. The most commonly accepted exception to the dual relationship rule is in extremely rural practice, where access to services is very limited—so, for instance, a clinician might provide mental health services to someone who also their children’s pediatrician. However, in these cases, other professional boundaries should still be maintained on both sides.
- The clinician is very clear from the beginning of treatment about their policies regarding the location and timing of sessions, confidentiality practices, means and quantity of payment required, acceptable communication channels outside of therapy sessions, contact on social media, contact outside the therapy context, and lateness or missed sessions. The clinician follows through on these policies as stated, and communicates any policy changes in a timely way.
- The clinician does not communicate to you in any way that they feel differently about you than they do about their other clients, or that they treat you differently than their other clients.
- The clinician does not permit or encourage the exchange/offering of significant gifts, especially financially significant gifts.
- The clinician does not provide advice outside the realm of their expertise; most clinicians minimize the time they spend giving advice even within their expertise, because supporting clients in the process of arriving at their own conclusions is more aligned with ethical standards and more effective towards lasting change.
- If physical touch is engaged in at all, it generally should be minimal, such as a brief hug at the end of each session or a single brief hug at the termination of treatment. Physical touch may be avoided entirely, and if present must be for the benefit of the client, not the clinician.
- Even if the clinician is providing therapy on a very generous sliding scale basis that is essentially free for an individual with great financial need, it is a good sign if they

insist on always charging a fee. In many cases, a fee less than a dollar can still serve as a healthy reminder about the nature and boundaries of the relationship, helping both client and clinician maintain a mindset that minimizes the risk of AIT.

Therapists are, unfortunately, not explicitly educated on AIT at this time. (We strongly recommend that all clinicians read the two reference articles for this section). That said, therapists in all the major licensure categories should be familiar with and generally compliant with the boundaries listed above; understanding the importance of boundaries and respecting the vulnerability of clients are important topics in their clinical training.

Per item 3 on this list, if you are a client with a high number of risk factors for AIT [80, 157], we recommend discussing preventative measures with your clinician, and weighing boundary practices particularly heavily in your assessment of clinicians' fit for you. Note that these risk factors are not required in order to develop AIT, nor do they guarantee AIT—they simply correlate with an increased risk. The risk factors are:

- a history of dependent/idealized relationships, especially with health professionals
- an approach to therapy that is primarily seeking care, rather than insight
- unrealistic views of what therapy can provide
- being female, especially if working with a male therapist who is older than you
- having a therapist of a gender you are sexually or romantically attracted to
- being a sexual minority, or
- experiencing significant symptoms on a spectrum with borderline or narcissistic personality disorder

A final recommendation on boundaries and the prevention of AIT: although confidentiality is an important therapeutic boundary, we feel it is an excellent sign if your clinician seeks regular supervision and consultation (without disclosing more details of your case than must be disclosed to obtain appropriate professional advice) as needed. Neither you nor your clinician should feel that anything is happening in the therapy room that they would be ashamed or embarrassed to disclose to a trusted friend (in your case) or a trusted HIPPA-compliant colleague (in theirs). Therapy should feel private, but if it starts to feel like a secret, something may be off.

Targeted Therapy

In our experience, in some circumstances it is very important to seek therapy that is targeted to the challenges you are experiencing. One of the most common and arguably benign forms of bad therapy happens when clinicians offer a generally empathetic and supportive environment without bringing clients into a space of productive discomfort. This often results in therapy that feels pleasant, but not very helpful—and which perpetuates the damaging myth that working with a skilled mental healthcare provider is interchangeable with, but more expensive than, having an empathetic friend.

Although the current diagnostic system is substantively flawed [63, 87], we do recommend that a best practice for seeking effective mental healthcare is to a) do one's best to obtain one or more accurate diagnoses, b) research the most evidence-supported treatments for your diagnoses, and c) seek out clinicians who are trained and experienced with those specific treatments—ideally, who are experienced using those specific treatments to address those specific diagnoses. According to both our personal experience and Thomas Insel, M.D. [179], this leads to radically better outcomes than a less targeted search for mental health treatment.

A less medicalized approach to this process recommended by a colleague [301] is to identify what kind of change you would like to make with the help of a professional, do some research on how people seem to be working towards that change in various contexts, and seek out a professional who has a good reputation or training in that method. This may be especially appropriate if the help you are seeking is not specifically oriented around mental illness.

Regardless of whether this whole sequence feels accessible to you, we recommend if you are experiencing therapy that feels pleasant but not as helpful as you need it to be, it is worth having a conversation with your clinician about what specific interventions and modalities they are employing, and what might work better. Often, in this situation, you as a client are in need of a treatment method that will push you more.

Finding a Therapist can be a Long-Term Project

If you feel daunted by the process of finding a good therapist, we strongly encourage you to recruit some support and treat finding a therapist as a long-haul effort. For example, if you have a supportive friend or partner, you could ask them to commit to providing you with your favorite takeout every time you complete ten or fifteen "actions" (getting a list of clinicians your insurance covers, messaging therapist to see if they are taking clients, completing an intake interview, scheduling a session, completing a session, etc.) on your therapist search. Alternately, you might start a text thread with your closest supporters, where you can report your efforts and be rewarded with GIFs and emojis. A perspective shift that may be helpful when searching for a therapist is to regard each "failure" or action as a step towards finding the help you need, worth celebrating even if it doesn't yield any immediate tangible results.

We recommend completing three or more sessions with a given therapist before committing to give treatment with them a try. If you luck out and find a great fit on your first or second try, the BR-WAI will help you have confidence that you've really found what you're looking for. If a particular clinician (or a string of clinicians) are not a fit for you, that's OK too; that doesn't mean you have anything to apologize for. It's good to trust the process and expect that it may take some time.

We don't know enough to endorse them, but Psychedelic Passage [264] offers a psychedelic guide/therapist referral service. You may be able to find guides and therapist from talking to people at psychedelic meetups, though quality and adherence to ethical standards may be variable.

Accreditation and Safety

We would be remiss not to acknowledge that unlicensed ⁵ or minimally accredited mental healthcare providers are common [2]—often billed as coaches, guides, shamans, pastors, or simply healers. In this era when a mass-scale mental health crisis is met with a healthcare affordability crisis in the USA, individuals in need of healing seek assistance wherever they can. Indeed, talk therapy and psychiatry are modern inventions, and we are aware both from common sense and through personal experience that skilled and ethical healers of mental and emotional distress exist across many contexts and training levels.

That said, it can be extremely difficult to verify whether the individual you are considering working with is ethical and skilled—and working with an unskilled or unethical provider can be extremely harmful [157, 226]. Although the protection offered by working with a licensed counselor is imperfect, we feel it is an extremely important consideration—and all the more so, as described below in Section 3.3, when working with psychedelics.

We perceive significant risks associated with using an unlicensed mental healthcare provider:

- They may provide, and charge for, interventions that are useless or harmful.
- They may not have been trained in differential diagnosis, and in any case are not legally permitted to diagnose you
- They may provide services to you while they are impaired through the use of drugs or alcohol
- Because they may not have received training about the importance of boundaries and of respecting the vulnerability of clients within the power dynamics of mental healthcare, they are less likely to express and enact boundaries and other practices that minimize the risk of adverse idealizing transference (AIT).
- As such, they may enact harm that emerges not from the interventions themselves, but from other aspects of how they do business: for instance, unnecessary dual relationships or boundary violations can leave clients feeling dis-empowered, violated, or humiliated across multiple domains of their lives.
- They may encourage you, during particularly vulnerable and suggestible times, to make decisions that are bad for you and your life; they may leverage their intimate knowledge of your trauma to exploitatively encourage you to make choices which benefit them at your expense.
- Unless they commit crimes in a way that would be recognizable as criminal and punishable by law even outside a therapeutic relationship, they are unlikely to experience any negative consequences for any physical, financial, or psychological harm that may come to you in their care.

⁵For the purposes of this section, when we say unlicensed, we are not referring to pre-professionals and pre-licensed professionals who are operating under the license of an independently licensed professional as part of their training progression. Examples would include a resident counselor or psychologist. In terms of accountability and ethics enforcement, we feel comfortable recommending this class of providers at the same level as independently licensed professionals.

The protections provided by working with a licensed professional are extremely imperfect. For instance: the field of mental health talk therapy is still relatively young, and it is widely accepted that talk therapy is as much art as science. We have observed that most fully licensed professionals center their practices on interventions that could be covered by insurance, and this may provide some probabilistic guardrails against interventions that have no empirical support at all. However, even among fully licensed practitioners, there is little enforcement that compels clinicians to focus on the most empirically validated interventions, to deliver them in the most empirically validated ways, or to be able to match a client's particular situation to the most empirically validated treatment for that specific situation. If these practices are important to you, we recommend asking many detailed questions about them when you are searching for a well-matched therapist.

Additionally, we have observed that various systems of power and oppression can and do play out in the therapy room if clinicians are not actively, vulnerably, and skillfully working to avoid this outcome. The prestige and respect generally afforded to therapists can sometimes foster hierarchical and non-collaborative dynamics. Therapists sometimes say extremely inappropriate, dismissive, harmful, and/or stigmatizing things, and clients are harmed the more by it because those statements were made by a therapist—someone who they perceive to be an expert, someone who is supposed to have the answers. Licensure does little or nothing to protect against or prevent these forms of harm.

Although cultural acceptance is improving, mental illness is still very stigmatized, and there are many reports of clinicians who turn on their clients, abusively labeling them "borderline" or simply crazy, if those clients file a complaint against them [157]. The privacy of the therapy room, the power of stigmatized diagnoses, and the prestige of the therapist role means that in "he said she said" adjudications, a client is unlikely to be listened to. The situation is further complicated by the reality that in the process of a long career working with many clients who suffer from profound attachment wounds, overwhelming trauma, and at times delusions, hallucinations, and paranoia, clinicians' fears of being misrepresented and attacked by clients as a symptom of their illness are not always unfounded [140, 342]. It is inherently very difficult to tell from the outside—and sometimes from the inside too—what has really gone on. As such, many therapists may be more likely to empathize with their peers [157] than wronged clients when they hear about misconduct by colleagues. This unfortunately creates a robust haven for a minority of clinicians who are unethical⁶, extremely incompetent, negligent, and/or predatory.

Despite these shortcomings, we feel it is important to highlight the advantages of working with a licensed clinician, and encourage you to weigh the risks very carefully. Some certificates for coaching or Christian counseling can be obtained in a few weeks to a month for less than a thousand dollars; these kinds of certifications do not bring significant professional accountability, because a) loss of such a certification doesn't usually create significant occupational impairment, and 2) certifications this small are not typically backed up by a licensure organization with sufficient resources to keep track of practitioner misconduct or enforce consequences [53]. Obtaining independent licensure as a mental health clinician

⁶"Studies generally show remarkable consistency in age, gender, and practice characteristics in that the typical transgressor [of sexual relationships with clients] is a middle-aged male therapist in solo private practice who engages in a sexual dual relationship with one female patient" [55]

demands years of study, additional years of supervision, and an often six figure financial investment in education and accreditation. If a fully licensed professional practices therapy while they are impaired through drugs or alcohol, or if they cross sexual boundaries with a client, or if they exploit clients for financial gain—for instance, by giving financial advice or creating a dual relationship—the client can file a complaint with the clinician’s licensure board [27, 337]. If the clinician is then found to have committed the harm described in the complaint, they may (depending on their particular license and jurisdiction) face a variety of consequences. Here are a few of the possibilities:

- They may have their name published on a state registry that lists the misconduct they were found guilty of
- They may be required to take ethics classes or complete other professional development work
- They may be required to work under a supervisor for a period of time, and during that time announce to every single client at the start of treatment that they are working under the license of another professional and who that professional is
- They may lose their access to providing treatment through a hospital they had previously worked through, or they may lose the ability to have their work reimbursed through insurance
- For severe and/or protracted misconduct, or if they refuse to comply with rehabilitation requirements, they may have their license entirely revoked

Independently licensed clinicians must typically pass a criminal background check to become accredited [85]. They may also lose their accreditation if they are found guilty of fraud, sexual misconduct, or abuse in other areas of their lives [27]. This is an important safeguard because a pattern of exploitation across various domains of their life is one of the earmarks of an individual who is genuinely predatory, rather than simply incompetent [68]. Although these consequences are not always commensurate with the harm caused, at least one study has showed that the process of filing a board complaint against a harmful clinician on the whole tends to be a positive experience for survivors [337].

To check whether your clinician is licensed or accredited in some way, try asking them for their license number and then looking it up on the website of their professional association. There are also several professional directories—Psychology Today being the largest in the United States—that will only list clinicians after verifying their credentials. In the United States, there are *many* qualifications and certifications that allow a practitioner to legally provide mental health counseling.

To further add to the confusion, we have observed that even within the same license, training can vary widely. If you are committed to working with a licensed professional, we recommend searching for providers based on the professional’s experience, preferred client demographic, and/or treatment modalities, and then verifying their license. You can attain a clearer understanding of the details of a particular clinician’s background with the particular issues you are having (or the particular modalities and interventions you are interested in being treated with) by asking them detailed questions. For example: how many clients

have you worked with who have x diagnosis? What is your training and background in y intervention? They might answer with details including trainings or continuing education units they have completed, books they have read, classes that were part of their degree, relevant experience with those populations before they became a therapist, and much more. All these details are highly variable between individual practitioners, but the baseline safety protections that come from working with a licensed professional are always attached to the specific license they hold. Finally, please note that the fields of life coaching, guiding, or other unlicensed professional support often serve as havens for individuals who have lost a license due to misconduct.

If you choose to work with unlicensed professionals, we recommend exclusively working with professionals who are very clear about their scope of care, and who participate in accountability and transparency practices such as participating in accountability pods (a practice developed by the Bay Area Transformative Justice Collective, see Mingus [228]) and publicly posting their business ethics (as exemplified here: Sinback [300]). Indeed, we feel these practices, though imperfect, are a green flag from providers of any licensure level, and we hope they will become normalized across mental healthcare—along with providers routinely seeking appropriate supervision and consultation, and being transparent with clients about who is supervising or consulting with them. Finally, many of the suggestions from the "Recommended individual actions to improve safety of psychedelic care" section may be adapted to reduce your risk profile, even if you are not working with psychedelics—and the caveats we placed on that list apply here as well. No matter who you work with, if they choose to harm you through their behavior, that is not your fault.

To understand scope of care, when you are considering working with an unlicensed professional, it may help to ask many detailed questions about precisely which services they provide, and about how and where they learned the skills to provide those services. Unlicensed professionals are forbidden by law from diagnosing or treating mental illness but many of the interventions that are used to treat mental illness can be appropriately implemented by unlicensed professionals, and have many legitimate uses outside mental illness treatment [2, 168]. For instance, some coaches teach people how to [reconsolidate](#) maladaptive [schemas](#), or how to complete thought records, or how to use the mindfulness-based RAIN (see Brach [37]) practice to ride out urges to engage in maladaptive coping, or myriad other skills and strategies that constitute legitimate mental illness interventions. These skills are not exclusively relevant to mental illness; a reasonable person might learn them simply to enrich their life and increase their personal growth. When unlicensed professionals deploy them, they are also not doing so (or legally should not be doing so) in the context of a treatment plan wherein a therapeutic relationship is constructed and interventions are preformed that will specifically address a specific mental illness. As such, it can reasonably fall within the domain of unlicensed care to teach these skills, and to help folks identify some circumstances where it is helpful to use them. These kinds of services may significantly help you self-manage or self-treat your mental illness, especially (as is often the case) if you are unable to access high quality licensed mental healthcare.

On top of this, we've observed that coaches and other unlicensed professionals are often an appropriate option for bridging a gap between the needs of people with mental illness, and the necessary level of support (often, more than meeting with a clinician once a week) that would allow them to achieve a significantly better quality of life. For example, a coach might

call you several times a week at the moments in your schedule that you have determined you are most vulnerable, so they can help you accomplish some task initiation or avoid some doom-scrolling—a service a therapist is unlikely to provide. Unlicensed professionals might help you with more practical, seemingly superficial, yet crucial aspects of changing your life for the better: sitting with you while you fill out job applications, or declutter your house, or practice eating mindfully. Some unlicensed professionals can help you learn and apply healthy relationship skills that will radically improve your life. Some carry out structured and empirically validated approaches and work under the supervision and organizational support of fully licensed professionals, as exemplified by the Healthy Gamer coaching programs [167].

In contrast, we believe the very best mental health professionals can complete a detailed bio-psycho-social assessment of your over-all situation, accurately match your symptoms to one or more diagnoses, and then offer you mental health interventions that are particularly suited to you in the context of that larger picture. They offer a deep understanding of how various constellations of symptoms tend to show up, and some awareness of pitfalls you are likely to encounter along the way based on that. They will have an understanding of what level of care is appropriate to your situation, and if they do not have the particular expertise appropriate to your condition, they will help you find a provider who does. They may know much sooner than you do if it is urgently important for you to receive a higher level of care—for instance, early intervention for a first psychotic episode has a massively positive impact on the lifelong trajectory of individuals psychotic spectrum disorders, and timely intensive treatment for eating disorders or substance use disorders can be lifesaving. Particularly if you do not have a case manager to take on this role, a mental health professional may help you work through what is stopping you, and learn the skills to recruit and coordinate care from many sources. Examples include:

- A psychiatric prescriber
- Specialist care providers like a dietitian or a trauma informed OB-GYN
- Peer support from friends and loved ones
- Peer support from potential future friends and loved ones, as when joining an activity group that helps you stay consistent with positive coping strategies
- Community programs, like a senior center, meditation center, or gym
- Coaches, ecclesiastical leaders, or other appropriate unlicensed professionals
- When appropriate, a personal care assistant to assist with the activities of daily living

Although schema reconsolidation may ultimately heal most or all of your mental illness in a deep and durable way, in the meantime you must live with your symptoms—and build the best life you can, despite your symptoms. The best mental healthcare providers are experts, not only in addressing the root causes of mental illness, but in helping you reduce the incidence of your symptoms and in helping reduce the impact of your symptoms on your life.

MDMA/Psychedelic Specific Complications In Obtaining Professional Care

Finding professional support for psychedelic therapy carries challenges over and above the challenges of finding mainstream mental healthcare [220, 222]. The specific nature of psychedelic therapies amplifies the vulnerability of seeking psychiatric care, including (we surmise) vulnerability to AITs. Some of these challenges emerge from the legal status of psychedelic therapies. Finally, these factors have combined to create an existing culture of underground MDMA therapy that can be painfully exploitative [241]. An effective process for securing professional support must take all of these challenges into account.

Challenges caused by the vulnerability of seeking psychiatric care: As discussed in sections 3.3 and 3.3, there is a severe power imbalance between providers and consumers of mental healthcare. When a fully licensed professional enacts behavior that is very clearly abusive, it creates the case in which we would expect the maximum possible structural support for accountability within conventional criminal-legal and administrative systems. However, even in these cases, proving misconduct and enforcing appropriate consequences for it is not always possible [34]. On top of this, we've observed that many individuals consuming mental health care feel that they must put up with a certain degree of discomfort in order to access care they may desperately need. We find they are often understandably unskilled at detecting the difference between the healthy discomfort of effective treatment [89] and discomfort related to mistreatment or misconduct.

Challenges caused by the nature of psychedelics: As detailed below, psychedelics can increase client vulnerability. Psychedelics can create experiences of great mental and sometimes physical intensity, of much longer duration than a traditional therapy session. Long sessions, sometimes a risk factor or "red flag" for harmful boundary violations [311], are necessary in psychedelic therapy. MDMA can generate sexual feelings [216], and we think the same enhanced meaning [148], empathy, and openness to experience that make them such a fantastic aid to re-consolidation work may mean they leave individuals who take them more susceptible to persuasion. Altered states of consciousness also impair the ability to be appropriately cautious and thoughtful about risk. These factors make it even harder for clients to tell when providers are behaving inappropriately. Additionally, a significant subset of MDMA clients are having one of the peak experiences of their life, or even *the* peak experience of their life. We think this could cause therapists and guides who routinely facilitate this therapy to feel godlike. Even excellent guides and clinicians may need to work very hard, when administering psychedelic assisted therapy, to maintain appropriate boundaries, humility, and client-centered care. This dynamic can undermine even very good clinicians' ability to provide quality care. . Although there is no data on the topic, we feel this dynamic almost certainly increases the risk of AITs with MDMA therapy, particularly with providers who are not scrupulous regarding boundaries or thoughtful about preventing this specific risk. All of these aspects of psychedelics amplify the already formidable power dynamics between a therapist and a client, regardless of legal status or other factors.

Challenges caused by legal status: The legal status of psychedelics creates additional risk for those seeking professional support for PAT in several ways:

- Mental health providers' training and experience around psychedelics has been ex-

tremely limited by their legal status. This includes the ability of professionals to experience psychedelics as a part of their training, which most clients and clinicians feel improves clinicians' ability to provide psychedelic therapy, and which many feel is essential to that ability [198]. However, clinicians generally do not have access to these experience in a legal context with solid supervisory support. If clinicians even disclose their history of psychedelic use, they could theoretically face some degree of legal or licensure related repercussions—and even if the actual risk of repercussions is very low, the perceived risk may be high enough to prevent clinicians from becoming involved in these activities.

- The fact that everything has to be "underground" makes it harder for people to find each other as needed. This can create a sense of scarcity, as in, "I have found a provider and I need to stick to them because searching for a better fit feels daunting or impossible."
- When the medicines in question are criminalized, clients who are harmed while using the medicine (or in the process of preparing for medicine use or integrating afterward) often legitimately fear legal and/or social consequences to themselves if they report crimes against them that were undertaken during this process [241]. This makes the power dynamics astronomical.

Existing culture of exploitation in psychedelic therapy: Taken together, the above factors render it unsurprising that exploitation, [spiritual bypass](#), and cultic dynamics seem to have been woven into the culture of underground psychedelic therapy [45, 241, 265]. The suggestibility induced by psychedelic use, the profundity of experiences produced, the challenges providers face in staying humble and client centered when providing these interventions, and the deep shelter from any legal threat about malpractice that is created when it is all illegal all play a role in a culture of guides, healers, shamans, and therapists who are able to harm with impunity. Multiple accounts have surfaced of the need to develop a better framework of accountability in these underground, unregulated communities. If you are interested in learning more about this topic, we recommend the following resources:

- Power Trip Podcast [241]
- "Addressing Abuse and Repair: An Open Letter to the Psychedelic Community" [265]
- "Ethical Transgressions and Boundary Violations in Ayahuasca Healing Contexts: A Mixed Methods Study" [45]

Individual Actions to Improve Safety of Psychedelic Care

In this era of regulation, many people with mental illness are driven to work with unlicensed providers due to mistrust of the mainstream mental health system and/or the financial or logistical inaccessibility of high quality licensed care [2]. Additionally, while the system of licensed providers presumably prevents many of the most egregious violations, some serious harm can and does slip through—as evidenced by the whistleblower reports from the MAPS

trials [79]. In this context, we believe there are steps some individuals may be able to take to increase their safety when seeking psychedelic therapies.

We want to emphasize that even if you do nothing on this list, any care provider who violates the sacred trust you have put in them as a healer by mistreating you is fully responsible for their own actions. Those who are most badly in need of psychiatric care are often under-resourced, and likely to find it challenging or impossible to carry out the degree of vetting or preparation they might have ideally preferred. We are not providing these suggestions to cast blame or create additional responsibilities for care-seekers, but as a resource with which those who are able may be able to improve the risk profile of their healing endeavors.

License and Certification

Research their license and certifications carefully. See Section 3.3 about accreditation and the protections it provides. Remember that practitioners may claim a license they don't have, or they may have some sort of certification that does not carry enough weight in their professional life to enforce any kind of accountability. We particularly recommend taking other precautions if your clinician does not belong to a licensing body that publishes the names of clinicians who are found to have violated its ethical code.

Evaluate Fit

Follow the advice above (see Section 3.3) about finding a clinician who is a good fit for you, including working with them for at least three sessions (preferably five or more) before making any decisions about using their assistance for medicine work. During this time, observe their boundaries very carefully, and have frank discussions about their qualifications, your needs and expectations, and the modalities that would be employed during the medicine work.

Methodology and Expertise

Research their therapeutic methodology and expertise. It is our hope that the evidence-based theoretical framework offered in this book—positing that the primary mode of healing MDMA offers is memory reconsolidation—can assist some clients in assessing whether they are interested in engaging with various therapeutic methodologies. Accordingly, we particularly recommend seeking clinicians who have a strong background in addressing [dissociation](#) and panic, in dealing with trauma generally, and in assisting their clients at working through somatic manifestations of trauma/somatic release.

Although they may be particularly fast and effective for activating some important schemas, we strongly recommend avoiding methodologies that involve physical touch—*particularly* those that involve physical touch during the actual medicine work, when the client is unable to consent or make unbiased decisions about whether to continue or stop a particular therapeutic interaction.

If you are interested in somatic methodologies that involve touch, we recommend alternatives such as therapeutic use of restorative yoga postures. In this practice, a clinician can provide support through various bolsters and pillows, along with verbal instruction, so that there is never any need to touch you in any significant way. If for some reason you do choose

to pursue a methodology that involves touch, we recommend undertaking precautions to increase your sense of volition and improve the safety of the endeavor:

- Creating a detailed written consent contract in advance of your medicine session, that determines what forms of touch will be acceptable under what circumstances and how these boundaries will be upheld
- Using witnesses and cameras to provide you with certainty that your wishes have been respected

We agree with the assertion of the American Association of Sex Educators, Counselors, and Therapists, when they suggest that there is no circumstance where sexual touch is appropriate to the therapeutic relationship [17].

Background Check

Get a background check on the guide and possibly on others who recommend them or who have trained them. In some cases, significant networks of recommenders or well-regarded trainers may all be invested in unsubstantiated or potentially harmful therapeutic modalities [241]. Historically, lineage of training has been an important way that healers are credentialed in the absence of licensure systems; if your guide has trained under someone who promotes potentially harmful therapeutic modalities, with concepts such as "breaking down" the client or helping them "fight it out", or if they have been mentored by people who have a history of boundary violations against clients, we recommend proceeding with extreme caution if at all. If a guide with these red flags seems like an otherwise excellent match, we recommend having detailed conversations about how they relate to those practices and approaches, and taking the other safety considerations listed here especially seriously. Finally, as noted in the accreditation section, if a prospective professional support has a history of fraud or abuse in other areas of their life, this is also worth taking into consideration, even though it may appear unrelated, because this may be a warning sign for truly predatory behavior.

Accountability

Look for external accountability in the clinician's ethical structure, both philosophically and practically. One of the concerns cited by Nickles and Ross [241] regarding safety in PAT is that there seems to be a cultural norm in underground psychedelic therapy of identifying the truth—including the truth about situations in which clients allege their clinicians have harmed them—as something that comes from inside each person. In contrast, healthy accountability practices require us to listen with openness to outside information which can make us feel downright terrible on the inside. We recommend seeking providers who maintain active relationships with supervisors, mentors, and/or accountability pods [228] who can help them receive the report appropriately if a client has a bad experience in their care. Additionally, we recommend seeking clinicians who can provide you with a clearly articulated set of written ethical standards they endeavor to adhere to, whether those standards come from a professional organization or personal soul-searching.

Flight Plan

Create a "flight plan" and a safety plan collaboratively with your provider/s while sober, and review/update it before each medicine experience. Birth plans have become popular tool that birthing parents can use to a) educate themselves about the many choices that may emerge during labor and delivery, and b) communicate strategically with providers about their needs and preferences; we feel that structured advance planning for PAT sessions could provide similar benefits [321]. Here are some considerations you may wish to include in your flight plan if you feel you are at particularly high risk for AIT (link to assessment questions in section above), or otherwise have significant safety concerns:

- You may wish to have one or more support people present to serve as witnesses during your medicine session.
- You may even choose to delegate, "medical power of attorney" style, to allow trusted support people to make certain choices on your behalf while you are incapacitated by the medicine. If you pursue this possibility, it is important to have in-depth conversations with your support person and your clinician about what level of distress is appropriate for you to face, and what the likely outcomes of that distress may be—as well as having detailed discussions on the choices they are being entrusted to make.
- You may wish to arrange to have your session filmed, possibly even from a few angles, so that you have a lot of concrete evidence afterward about what happened.

See "preparing for your session" section for more information on flight planning.

Cultishness

Keep an eye out for cultic group structures or dynamics. Accounts from the underground PAT world have described closed systems centered around charismatic leaders, exploitation of the labor of group members, and abundant use of what cult scholars call "thought terminating clichés" [25, 241]. Thought terminating clichés are phrases used to address cognitive dissonance while shutting down inquiry into the framework that produced that dissonance. For instance: members of the underground PAT community have told individuals who were assaulted during their therapy that they "called it in to themselves"—invoking a concept from new age spirituality, which suggests that people bring their life experiences onto themselves. In other words, survivors were told to stop considering the choices and volition of the human beings who betrayed them, and instead to focus on their own metaphysical complicity and potential growth that might emerge from their abuse. In contrast, in a non-cultic framework, people are allowed to ask questions and investigate what is under these "thought terminating clichés." They are allowed to disagree. They are not taught to believe they are dependent on just one source for healing. See appendix (NUMBER) for definitions of cults and lists of red flags and green flags to look out for, aggregated from the work of three different cult scholars.

3.4 Dosage and Testing

Accurate dosing is important for efficacy and safety. The effects of MDMA are strongly dependent of dose and body mass [312]. The MDMA juxtaposition and maladaptive [schema](#) must also be close enough in strength to each other for [reconsolidation](#) to occur [89]. In traditional psychotherapy this generally succeeds without planning for this factor. However, we have noticed this is often regarded as not the case with MDMA therapy. Too low of a dose (0.75 mg/kg, for example) will likely not provide the safety and empathy needed for healing [30]. We have also heard anecdotes that too high of a dose can cause the session to be so pleasurable that you're not able to engage with maladaptive schemas. M. Liechti and Schmid [195] recommends an initial dose of 100 mg for body mass less than 60 kg (132lb) or those over 75 years old, and 125 mg for higher body mass ⁷. For those who need smaller or larger doses, anywhere from 75-200 mg can be used. A 50 mg booster dose taken after about 2 hours is often used to extend the productive duration of the session. Adjusting dosage in subsequent sessions may be helpful to reduce adverse effects, increase feelings of safety [270], or adjust for individual body chemistry. The effects of MDMA increase in response to increasing dose at a faster-than-linear rate because MDMA inhibits the enzymes that metabolize MDMA [74]. Because of this, we suggest increasing or decreasing dose in smaller increments than one would typically expect, especially at the upper end of typical dosage. Accurate data on the upper limit of safe doses is unfortunately absent due to difficulties translating the results of animal testing to humans and confounding factors muddying the study of harmful effects in recreational use [252]. The dose at which 50% of individuals die is unknown for humans but ranges from 14-97 mg/kg in other mammals [254].

Storage of MDMA is simple because it is stable even in water at least up to 20°C (68°F), and drugs are typically much more stable in dry form [60]. Measuring dosage is more difficult. High quality analysis of adulterants and dosage can only be done with sophisticated laboratory equipment. We have not vetted them, but are aware of two labs that offer international mail-in drug testing for adulterants and dosage: Kykeon Analytics [185] and Energy Control International [95]. Testing for adulterants and dosage at home is somewhat difficult and unreliable. It is possible to test for the presence of some, but certainly not all common adulterants using reagent kits like the one from DanceSafe [69] [70]. It is not possible to accurately verify the quantity or concentration of MDMA (or fillers, binding agents, and adulterants) at home. As far as we are aware, pills rarely specify how much MDMA they contain, and it's always mixed with fillers and binders. Crystals are often, but not always fairly pure MDMA. Some vendors will package measured and specified amounts of crystals into capsules as well. If you do obtain MDMA of known dosage, you can use volumetric dosing to divide your sample into doses appropriate for therapy. We suggest aiming for a simple-to-remember of 1 mg/ml solution of MDMA in water. Just dissolve however many mg of MDMA you have in the same number of ml of water. It is much easier to measure a ml of liquid than a mg of powder. Tripsit [328] also offers a volumetric dosing calculator. Note that MDMA is extremely bitter [225].

⁷MDMA is sold in hydrochloride salt form, and all stated masses are masses of the hydrochloride salt form [195]. MDMA is made as a racemic (equal) mixture of the R-MDMA and S-MDMA enantiomers (a right or left-handed version of a molecule), though it is possible to purify either enantiomer [310]. They have different effects.

3.5 Dissociation and Avoidance During the Session

[Dissociation](#) and [avoidance](#) are challenges for MDMA therapy, as they also are for traditional psychotherapy [269]. We group them together in this section because they both often inhibit conscious experiences of contradiction, a requirement for [reconsolidation](#), and because we think they are dealt with similarly [89, 182].

As described in Chapter 2.2, [immobility](#)'s core function is to reduce movement to such an extent that the predator who caught you loses interest and leaves you alone [182]. While immobility is biologically complex, its effects in large part derive from the brain producing opioids in response to a combination of powerlessness and threat (this is the typical activator, some people may dissociate in response to atypical activators). Of course, the [prediction](#) of threat and powerlessness during a therapy session is typically an over-generalized [schema](#) instead of actual threat of immanent death and powerlessness. Therefore, we hypothesize that reducing immobility requires at least one of:

- Reconsolidating the predictions of powerlessness and threat. We think some clinical experience indicates that MDMA can reconsolidate the originating predictions if immobility isn't so strong that you fall asleep [269]. Higher doses, creating a higher sense of safety, may help with higher amounts of immobility [270]. Razvi and Elfrink [269] reports consistent success reconsolidating (our interpretation) the activating schemas for immobility by "...bringing blankness, flat affect, nothingness, boredom, sleepiness, or sobriety [the subjective effects of immobility or other dissociative states during [psychedelic-therapy](#) sessions] into focus." Further, "In a psychedelic-assisted session, it might take staying with it from minutes to a full day-long session, but it will crack." They facilitate this process through a technique they call [selective inhibition](#), which involves the client suppressing all minor body movement and distracting thoughts.
- Sending signals of safety and/or power to your nervous system. The signals might not reconsolidate the originating schema, but they might balance out the amount of threat and powerlessness that the nervous system perceives, or possibly deactivate the originating schemas. Additional sources of safety may include: an attuned, skilled, and ethical therapist or guide whom you work well with, a comforting and safe physical environment, and sufficient pre-session preparation. We suspect [grounding](#) exercises can also do this [116]. Grounding exercises include exercises like naming 5 things you can see, 4 you can feel, 3 you can hear, 2 you can smell, 1 you can taste. If these techniques lower the amount of dissociation you have, they may make reconsolidating the underlying schemas. We don't know whether these techniques are more effective than the previously listed technique in this list.
- There is low quality evidence that 50-250 mg of the opioid antagonist naltrexone deactivates opioid-mediated states (like immobility and [freezing](#)) [98]. Naloxone and nalmefene have similar mechanisms of action and could conceivably also work, though this hasn't been demonstrated. Naloxone's half life seems more appropriate to MDMA therapy than naltrexone's. Some of these medications require prescriptions in certain jurisdictions and collaboration with a prescribing medical professional may be necessary. We are not aware of any attempts at combining opioid antagonists with MDMA.

If you try this novel combination, we suggest using lower doses, as all drugs have side effects, ranges of safe dosing, and interactions with other drugs, including potentially MDMA. RXList [283] provides thorough information about naltrexone. We are unable to provide instructions on safe and effective use here. Reducing dissociation may make reconsolidating the schemas triggering it easier.

Note that the original situation that created immobility-activating schemas likely also involved extreme levels of fear, anger, and [fight-or-flight](#) responses [182]. These will often be felt after the immobility is reduced [269]. We recommend reviewing the list of immobility symptoms in 2.1 before your session. This may help you better identify immobility before if it occurs. We also recommend Razvi [268] for more information on the topic.

Freezing's function is to put a fight-or-flight response temporarily on hold in situations where the predator may not spot you if you stay very still [182]. It involves an opioid response, prediction of threat, and possibly some other prediction or mechanism that we are not aware of that differentiates its activators from the activators of fight-or-flight and immobility. In the absence of knowing this other factor, we suggest the same interventions listed for immobility.

We aren't sure what specific predictions activate forms of dissociation that don't involve immobility and freezing. Presumably at least threat.

We define avoidance as consciously or unconsciously diverting attention from therapeutically important schemas. Uncertainty about the process of tuning in to maladaptive schemas might also play a similar role. We think most techniques for addressing either avoidance or uncertainty boil down to tuning in to whatever, possibly subtle, fear, anger, sadness, or other distress you are feeling in the present moment. The following may help with that:

- An attuned and skilled therapist or guide whom you work well with can help you notice your feelings.
- Looking at certain material (letters, photos, etc.) may more strongly activate schemas you want to work on.
- We think Razvi and Elfrink [269]'s Selective Inhibition is promising, though it hasn't gone through any controlled study. The original intention for the technique is for "unsticking" [defense cascade](#) activation during psychedelic therapy, but we think it may also be useful for addressing avoidance that doesn't involve intense defense cascade activation. Selective Inhibition involves suppressing all distracting minor movements and all escapist thoughts. We hypothesize this may reduce the "noise" in your mind, making the active maladaptive schema relatively louder and more noticeable. You then pay attention to that distressing emotion or physical sensations of distress (muscle tension, altered breathing patterns, etc.) and the associated schema reconsolidates.
- Mindfulness practices of being noticing and staying present with your experience may also help (see Brach [37] and Smookler [304]).
- Your avoidance may itself be some schema (e.g. "I can't cope with that feeling") rather than just simple avoidance of discomfort. If this is the case, working on this schema first will be more useful than trying to bypass. If you don't reconsolidate it will keep coming back to impede the therapeutic process.

3.6 Organizing Community Care

A significant and increasing body of work supports the effectiveness of peer support within the context of formal mental health services [295]. At the same time, some have called for a “reimagining” of peer support in order to take advantage of the unique (and perhaps uniquely helpful) qualities of peer support, which reach outside the conventional borders of professional mental health services [129]. It is this latter project to which we hope to contribute, offering strategies and framings drawn from our experiences organizing care on a mutual aid basis, outside the formal mental health system. We have observed that individuals who are struggling with mental illness may be aware that having a strong support network might aid significantly in their recovery, but may also lack the skills or the mental framework to:

- Cultivate such a support network
- Confidently ask for help in a way that is appropriate to each relationship, relationally sustainable, and not manipulative or unduly high-pressure
- Recognize what specific tasks, activities, or forms of support that network might help them with

In this section, we will discuss each of these processes and suggest a variety of tools and resources which may or may not be empirically validated, but which we have found helpful in these tasks. Finally, we wish to acknowledge that for a wide variety of reasons, these strategies will not be accessible to everyone. We only hope that for some people, they increase access to sustaining connection and healthy relationships of mutual care.

Cultivating a Support Network

8% of Americans report that they don’t have any close friends [130]. Fehr [111] identifies four components of friendship formation: environmental, individual, situational, and dyadic. This is Fehr’s summary of the research of the research on these four factors (emphasis ours):

A necessary first step for the development of most friendships is that two people’s paths must cross. This is more likely to occur if the two people live near one another (e.g., same neighborhood, same building, same floor, same room) than if they do not. Living in a city or, more important, sharing the same work or school **environment** also increases the likelihood of contact. People who know people also are more likely to become friends. The probability that two individuals will meet increases to the extent that their social networks overlap.

Once two people meet, whether they decide to pursue a friendship depends on several additional factors. At the **individual** level, each scrutinizes the other for evidence of disliked qualities or other characteristics that may make him or her unsuitable as a friend. If these exclusion tests are passed, then inclusion tests will follow. It is likely that a friendship will be sought if each perceives the other as attractive, socially skilled, responsive, not shy, and if the two people are similar in a variety of ways.

If both exclusion and inclusion tests are passed, one might think that a friendship would be inevitable. However, **situational** factors influence whether a friendship actually is formed. Research on these factors suggests that two people are more likely to develop a friendship if they anticipate ongoing interactions, if they are dependent on one another, if they see one another frequently, and if each person's "friendship dance card" still has some room on it. Finally, the likelihood of friendship formation depends on **dyadic** variables such as whether the two people like one another and whether there is an appropriate sequencing of the depth and breadth of self-disclosure [111, p. 68].

In deference to this research—but also from our own experience—we feel that for maximal likelihood of success in building new friendships, one must routinely put oneself in environmental and situational contexts that are conducive to friendship formation. That means contexts that:

- Put you in repeated proximity with people you feel you have something in common with, at least some of whom are likely to have resources to spend on a new connection
- Allow for plenty of friendly, cooperative interactions
- Provide a reasonably pleasant/low stress environment, at least some of the time

Here are some ideas for contexts that may meet enough of these criteria to facilitate friend-finding success:

- A workplace or school (ideally in person)—especially effective if full-time and/or residential
- A meditation group, synagogue, or church congregation
- Gyms, pools, dance/martial arts/yoga/Pilates studios, and rec-centers
- Recurring dance nights (salsa, blues, contra, etc.) or jam sessions at various venues
- Events, clubs, or groups you find through local newsletters and event calendars
- Events through your public library, senior center, community center, game shop, or farmer's market
- Night classes through a community college—may focus on art, craft, or trade, or hobby related skills
- Civic engagement with local government and/or activist groups
- Long distance hiking adventures known as “through hikes” on the Appalachian Trail or others
- Volunteering (animal shelter, horse rehab stable, soup kitchen, nonprofit thrift store, etc.)
- Therapeutic support or self-help groups, such as Buried in Treasures groups or Alanon

- Festivals, fairs, and conventions—the intense collaboration involved in festivals like burning man [307] and Pennsic have been known to facilitate friendship formation in a way that is difficult to replicate in the atomized mundane working world of midlife in the USA.
- Online services like meetup.com, Bumble BFF, Captain Awkward meetups, or Buy Nothing groups, which connect people for offline interactions

Some online games or social networking sites can facilitate friendship formation for some users. We recognize that online socializing offers massive accessibility advantages, and we have hope that in the future digital spaces will be designed to facilitate healthy friendship formation [135] rather than being designed to extract the maximum amount of data, time, and/or money from participants. For the time being, online socializing is fraught with problematic ethical and mental health impacts—while also providing benefits, including connections that may be indispensable [64, 176, 249, 259]. It may be that the collaborative activities of gaming or the creativity of posting are more satisfying or helpful for you than reading and reacting to others’ posts, and it may be that some games leave you feeling better (or support you in interacting with others in a more satisfying way) than others. In light of these complexities, we recommend checking in with yourself carefully to gather data about how you actually feel before, during, and after specific online activities. We also recommend using whatever executive function supports are necessary to limit your participation in activities that you don’t find helpful.

If you are able to repeatedly and/or protractedly place yourself in a context (environment and situation, in Fehr’s framework) which offers you a good chance at proximity with high likelihood potential friends, you will still have the individual and dyadic factors to sort out. Let’s return to Fehr’s account of individual factors—individuals are looking for someone who is “attractive, socially skilled, responsive, not shy, and if the two people are similar”. We will leave the question of attractiveness to the myriad other texts and resources on the topic, other than to point out that the research does suggest that social skills and attractiveness may represent two separate routes to friendship—you don’t necessarily need both ⁸—and that attractiveness is relative to context [128, 191, 202, 223, 235].

Fehr identifies the important social skills for friendship formation as initiation (more important in the early finding/making friends stage) and self-disclosure (important for moving from an acquaintanceship to a friendship, and increasingly important as friendships deepen.) Other research suggests that responsiveness (including nonverbal responsiveness) and assertiveness are also important social skills for creating and sustaining satisfying friendships [273].

⁸There is clear data that social skills correlate with social support [285] and also that attractiveness and social skills represent two separate routes to friendship for women [271]. For men the data is less clear—apparently for men, social skills and attractiveness, though still both separately impacting social success, tend to be highly correlated. Since social skills can be taught [40, 288], we feel this raises interesting questions about how men are socialized. Research on the correlations between attractiveness, social success, and social skills in nonbinary people has not yet been published. Despite these complexities, we strongly recommend social skill development as a path to greater social success for all genders. For anyone who is a man or a nonbinary person or who is close to a man or nonbinary person, we recommend Brené Brown’s workshop *Men Women and Worthiness* (soundstrue.com/products/men-women-and-worthiness) as a valuable exploration of gendered challenges in socialization, self disclosure, and life.

To work on initiation skills (how to introduce yourself and make a good first impression) we recommend the content and coaching services from Healthy Gamer and advice from Captain Awkward. For folks who feel this would be a reasonable choice for them, we also recommend setting "getting rejected" as a positive goal, as a kind of prolonged exposure practice to desensitize yourself to the downsides of rejection. Finally, we have observed that in some cases, increased confidence in one's "appropriate self-disclosure" skills can make initiation more accessible.

Our recommended resources for learning appropriate self-disclosure skills are the ladder of bids (See Gottman [133], Chapter "How Couples Build Trust With Attunement"), along with B. Brown [43] work on "Shame webs vs support networks." We have witnessed considerable transformation in these skills by motivated individuals who practiced applying these tools over time.

We feel that assertiveness and nonverbal responsiveness are probably best addressed by cultivating a mindset of confidence, compassion, calm, and balanced entitlement, and trying to carry this perspective into social interactions. This is extremely hard to do when one is mentally ill—as, indeed, are the recommendations in this section generally. To cultivate this positive mindset, we recommend the following resources (if you find them helpful and resonant to your own situation):

- The work of Brené Brown generally
- *Good Inside* by Dr. Becky Kennedy (putatively about parenting, but the general concepts can be applied to relationships with self and others generally). See Appendix A.
- *Grit* by Angela Duckworth
- *Bird by Bird*, by Anne Lamott
- *The Upside of Stress*, by Kelly McGonnigal
- How to live alone and like it (every ism, but very good at teaching people to "romanticize your life"—to tell yourself and others a positive and appealing story about yourself and how you live—and breaking this down into many specific sub-skills and practices)
- Compassion meditation
- Other mantras ("it's OK to make mistakes", "I am enough/I have enough", "I am becoming consistently capable of lovingly attentive behavior")
- The unwinding anxiety app

We are sure there are many other resources that would also serve this purpose well. In addition, despite the inherent awkwardness and discomfort of this practice, we would expect role playing with a therapist, coach, or reasonably skilled peer to be an excellent strategy for improving any of these social skills.

Chapter 4

Pre-Session to Post-Session

4.1 Pre-Session Checklist

Proper planning of a session is important for comfort, safety, and success. This is traditionally divided into three sections of mindset, setting, and cultural/personal matrix [91]. We add two more: tools for the session and planning for the post-session. The concept of "set and setting" or the "set/setting/matrix" is a popular framework for understanding, within [psychedelic](#) subcultures, what leads to a "good trip" or "bad trip [91]."

Mental Preparation and Expectations (Mindset):

- We suggest journaling about the things, places, practices, people, or situations with whom you feel safe and at home, and with whom you feel unsafe. Then make a diagram with two axes, safe-feeling and accessibility. Plot at least the top 10 items you journaled about on this diagram. Identify the items that are both safe and accessible and keep them in mind for possible post session [destabilization](#). We suggest planning increased time with the safe items and decreased time with the unsafe items in the days and weeks following your session.
- If you hope to use your neuroplastic period to develop practical new habits or to reconnect to a project that you've been feeling too overwhelmed to engage with, we recommend doing some "habit mapping (see Brewer [38])." This consists of identifying behaviors you are hoping to adjust, identifying what triggers lead you to engage in those behaviors, and identifying what results emerge after you engage in the behavior. For example, I might identify that I would like to adjust the habit of scrolling through social media on my phone for three to five hours every day as soon as I get off of work. Identifying triggers might involve exploring: what are the feelings that precede my going online? What are the stories I tell myself? What physical and social environment am I experiencing that supports this behavior? Am I triggered by loneliness, by a desire to be free of demands for a period of time, or by a feeling of boredom/desire for stimulation—or all of the above? What happens when I work the second half of my workday in a communal space, vs when I work alone? What happens when I lock the phone in the glove compartment of my car during my lunch break, and don't revisit it

until I've walked outside to the parking lot? The last stage of habit mapping involves checking in with yourself and taking time to feel *all* the consequences of enacting the habit. It might be that you feel stiff and sedentary, which feels bad in your body; it might be that you find yourself feeling anxious or tired or lonelier than when you started scrolling, or that you get caught up in cycles of self-judgment or shame about the behavior. Maybe you feel frustrated and wish you had more time for other things. Or maybe you feel some of these things, and also feel delighted and inspired by the content you are consuming. Generally, the goal of habit mapping is to observe and record the landscape of each habit as it plays out in your life, and to truly open yourself to understanding on a deep level whether the choices you are making are the choices that are best for you. In the context of preparing mentally for memory [reconsolidation](#), taking some significant time to sit with whatever it is that you feel an intense need to numb (and sitting with the consequences you are willing to face in order to achieve that numbing) may prime you to be able to face that thing during your medicine experience.

- Thought records are an excellent mental health and memory reconsolidation tool that can be used alone or with a clinician. We recommend completing at least one prior to your first medicine session, to familiarize yourself with the process and support yourself in making optimal use of this tool afterward, during your neuroplasticity period. See Harper [144] for a worksheet.
- Shame mapping can help you identify many core [schemas](#) to address during the session. See Appendix B for details.
- [Dissociation](#) and [resistance](#) are the primary obstacles to healing during a session. Learning about the signs of these beforehand could help you recognize and deal with them during the session. Refer to Section 3.5.
- Set an intention to face and stay present with whatever fears, anxieties, anger, grief, etc. come up, without [avoidance](#) or distraction. This is necessary for reconsolidation [89]. Writing down the challenges or emotional difficulties you would like to address during the session can be helpful for bringing these schemas into awareness during the session. However, be cautious about schema-specific expectations about what you want out of the session, how you think it should go, or what you will learn. These expectations often do not match up with reality and can become ways to avoid reconsolidating the maladaptive schemas that are actually present. We think an established practice of loving-kindness (Kabat-Zinn [170]) or focus meditation (Brach [37]) may help you apply these techniques to your own distress during the session and help you stay present with distress. Additionally, we suggest intending to view the truth of the schema's beliefs or emotional reactions with agnosticism, something like "this belief and emotional reaction may or may not be true or helpful; I will stay present with it to learn why the schema exists and how it influenced me."
- Catch up on sleep. Therapy requires focus and energy. MDMA promotes focus and energy as well, but we suspect it can only help so much if sleep is lacking.

- Wondering how other people describe their sessions? We suggest reading the top posts here for a survey of how successful MDMA therapy can feel: [r/mdmaththerapy](#). The top posts mostly describe productive sessions that don't contain unworkable dissociation or avoidance, or poorly handled destabilization. Sorting by "new" will also show descriptions of less productive or more disruptive sessions. Godes et al. [131] also lists the common self-reported subjective experiences of MDMA therapy clients: "Staying with what 'is'; decreased reactivity; insight, reflection, linking; mental clarity; recovery of [traumatic](#) memories; disentangling trauma from self; reuniting lost affects and parts; self-acceptance; joy, happiness, gratitude; hope and empowerment; relaxation, calmness, peace; comfort; gratitude, empathy, compassion; union, wider perspective; inner healing intelligence [the therapeutic framework used in this study]; accessibility to emotions; mind-body connection" The paper has full descriptions of these items.

Setting:

- MDMA's stimulant effect may prevent sleep if the session is started later in the day, so we recommend starting in the morning [31].
- Eating is avoided if possible on the morning of the session because some people experience nausea [67]. Taking medicine with food can also delay onset of effect. M. Liechti and Schmid [195] provides (prescription) medication recommendations for nausea.
- Significant distraction during the session likely reduces efficacy [278]. It is helpful to arrange easy access to necessities like a restroom, snacks, and water.
- MDMA commonly causes mild hyponatremia (low plasma sodium concentration) in individuals who drink fluid during the session, though not in those who don't drink anything [24]. We suggest adding a bit of salt to anything you drink. If your environment is hot enough to cause sweating during the session (MDMA can further increase sweating. [67]), replacing fluids and sodium will become more important to avoid dangerous heat illness (MDMA further raises body temperature by 0.2-0.8°C or 0.4-1.4°F[196]) and severe hyponatremia.
- Prepare your environment or travel somewhere to maximize your feelings of comfort and safety. These could add to the feeling of safety from the medicine and ease down dissociation and resistance and increase [mismatch](#). We propose that carefully expanding your session environment could be beneficial once you are experienced with the medicine. For example, if you have trauma from dogs, you could safely activate that schema by petting a dog who you know won't act aggressively, and who's human is nearby to manage them if you feel like the experience is too much to handle.
- Solitude, except for a trusted and experienced guide, therapist, or sitter, promotes inward-focus. A sitter can help with logistics, listen to your feelings, or handle mundane events like someone knocking at the door [318]. Sitters should possess trustworthiness, presence (ability to listen to distress without becoming distressed), and empathy. Interacting with strangers may cause problems if they do not understand what is happening.

- Pets may be a source of comfort and safety, but shouldn't be distracting.

4.1.1 Cultural/Personal Matrix:

Unfortunately, the researcher who originated the term "matrix" was credibly accused of such intense abuse—particularly in the realm of crafting abusive environments and mind-sets in those she treated—that we feel her advice on this front must be presented with the context of those allegations foremost [72]. This is despite the fact that this framework, as published, look helpful to us from afar. As such, we encourage you to critically engage with this framework if it appeals to you, and, if you are using it, to pay special care to boundaries, power dynamics, supervision, and other safety mechanisms to avoid misconduct and abuse. Eisner [91] defines matrix as the "...environment (1) from which an individual comes, (2) in which the individual lives during the time of the sessions, and (3) to which the individual returns after successful therapy—the everyday living space..." This is important because "Rapid change is very difficult to sustain if the living environment is the same as the one which caused the difficulties in the first place." Family, living situation, and culture have complex interactions with the process of MDMA therapy. In some cultures, like those where ayahuasca use is currently endemic in certain areas of South America, knowledge of psychedelics may be widespread and their use accepted. Finding help in dealing with certain after-effects may be much easier in those contexts. Other social or family contexts can be hostile or counterproductive to the process of MDMA therapy.

Tools:

- We've heard that some people like to self-narrate the session and record the audio with their phone. Listening to it later may aid further reconsolidation and insight.
- Eye shades and noise-cancelling headphones can reduce distractions.
- MDMA can cause jaw clenching and headaches [197, 231]. Some people use mouth guards or pacifiers to reduce this effect or protect their teeth [94]. Over-the-counter pain relievers may help after the session. Those with jaw problems could conceivably need to take extra precautions or start with lower doses.
- The Fireside Project offers a hot-line to help people through challenging psychedelic experiences at +1 (623) 473-7433 in the United States [114]. Consider putting this number in your phone as an additional layer of safety.
- Distinctive music or scents, like fragrant essential oils. We've heard a few anecdotes of people being able to reactivate the MDMA state of consciousness after the session by listening to the music (and presumably other cues) they played during the session. This could be very helpful for additional therapy.

Planning for After the Session:

- People often feel highly fatigued for 1–3 days after the session [197]. Prepping food and a comfortable place to rest in advance may be nice.

- Additional reconsolidation may be easier for a period of time following a session if that session helped you temporarily jump out of a set of self-reinforcing schemas that for one reason or another inhibited therapy. If it works this way for you, it may be helpful to plan for extra reconsolidation efforts in this period of time.
- We suggest making a plan to try different techniques on subsequent sessions if you're worried that this first MDMA session might not work and is your only hope for healing.
- High quality sleep is likely important for reconsolidation [299]. We suggest a highly effective evidence-based protocol called *Cognitive Behavioral Therapy for Insomnia* if you struggle getting quality sleep. Stanford Medicine has a guide [308].

4.2 The MDMA Therapy Session

The effects of a single MDMA dose are generally noticeable 30 min after taking the medicine, peak an hour after that, then last a further 3 hours before gradually dissipating [338]. Those with genetically or, presumably, pharmacologically-induced low CYP2D6 metabolic capacity reach peak earlier [290]. A 50 mg booster dose taken around hour 2 is often used to extend the productive duration of the session [195]. We warn you not to take more MDMA during a session than you initially planned to, unless you took a low dose and after 1.5 hours decide bumping it up to the equivalent of a regular dose would be better. It may help to not even keep any MDMA within easy access of your session location. Desires to take more are often due to anxiety about the session not feeling like what you expected or the feeling like the medicine isn't working, and can lead to increased adverse effects [46]. We suggest that anxiety about the session not working is actually a useful [reconsolidation](#) target, and staying present with that feeling may eventually resolve that issue. Food delays onset of effects [232]. We divide the session into traditional phases based on subjective effects and therapeutic potential:

See Table 3.1 for side effects.

Come-up

The effects of MDMA become noticeable, but you are not yet engaging with the memories you want to work on. Some users experience anxiety [152]. We speculate this might be misinterpretation of MDMA's stimulant effects as anxiety, early engagement with distressing [schemas](#), or fears about the session.

Peak

Reconsolidation is possible here. Connection and safety become pronounced, though you may not notice this if you immediately engage with distressing schemas or are [dissociating](#). MDMA is known for unusual degrees of loving emotions, and we suggest refraining from telling anyone how much you love them unless that is an established norm in that relationship.

We believe the main goal here is emotional activation ¹ of your maladaptive schemas, a prerequisite for reconsolidation [89]. We've observed that once you're emotionally engaged and aren't distracted, the MDMA reconsolidates the schema without any further action. Because of this, therapeutic exercises designed to facilitate reconsolidation (e.g. coherence therapy, internal family systems therapy) likely won't help beyond their function of activating or engaging with maladaptive schemas. Abstract thinking can also be a distraction unless your maladaptive schema remains emotionally activated, you are focused on it to some degree.

There are a number of ways to activate your maladaptive schemas:

- One may already be activated. We think this is the case if you feel any anxiety (maybe even anxiety about the session not going well), fear, anger, sadness, grief, or dissociation.
- Looking at or listening to relevant material like photographs, letters, voicemails, etc.
- Just thinking about your issue, or telling your sitter, guide, or therapist about your issue.
- Engaging in safe activities that activate the relevant schemas, such as writing if you have a fear-based writing block, or giving a presentation to a few friends to deal with stage fright.
- Talking with your partner about a conflict in your relationship or an insecurity you have about your relationship [66].

Once you're activated, we suggest just staying present with that fear, sadness, anger, etc. Lean into (like focus meditation) the feeling and the reconsolidation process should gradually dissipate it. It may also help to hold difficult schema with compassionate curiosity and agnosticism with regard to its truth. Insightful thoughts about how [trauma](#) impacted you or insights into human behavior may arise. Spend time on them if they feel cathartic or important. Otherwise, leave them until after the session.

It is well-known that over-attachment to a specific therapeutic goal can be an impediment to progress because 1) reconsolidating certain schemas often seems to depend on reconsolidating some other schema (sometimes one you are unaware of) first and 2) people sometimes have inaccurate beliefs about what their issues are. Because of this, we suggest that if you don't feel like you are clearly emotionally activating ² and staying present with your desired schema, you should try gently noticing and focusing on any fear, anger, grief, anxiety, discomfort, or tension in your body or field of awareness. This other schema is probably therapeutically-useful.

¹Some people think insight is the primary goal during MDMA therapy, but we disagree. Insight is clearly important for conventional psychotherapy where you need to know what the schema is before you can reconsolidate it [89]. We don't think this is important in MDMA therapy, where you can skip straight to reconsolidation without knowing what the schema is first. In our experience, insight is easier to come by post-reconsolidation, which can be accomplished after the session. This reserves scarce session time for difficult reconsolidation.

²The type of maladaptive schemas addressed in therapy contain strong emotions, so the activation will be emotional [89]. Intellectualizing about the topic isn't sufficient.

We've noticed that people sometimes mentally package the MDMA-facilitated reconsolidation process into meaningful symbolic stories, like "I sent love to my inner child, told it that it was ok, then the inner child finally relaxed," spiritual/religious narratives, and a wide variety of other metaphors.

If you're experiencing profound ok-ness and self-love for the first time, or are seeing how trauma shapes the world, we suggest feeling it fully and not worrying about anything else. This experience can be a preview of the end goal of therapy, and can be a great motivator for staying on the healing journey long-term through challenges. The peace and compassion may not last long after this first session, but you will gradually get some of it back as you reconsolidate various maladaptive schemas over the long-term. Regular life will rarely be total bliss, but reconsolidation gradually improves life over the long run. If you find yourself repeating these blissful experiences on subsequent sessions, we suggest refocusing to your maladaptive schemas. Repeat exposure probably has declining marginal return.

If you feel "...blankness, flat affect, nothingness, boredom, sleepiness, or sobriety..." you might be dissociating [269]. Focus on that nothingness while suppressing movement, thought, and [avoidance](#), and "...it might take staying with it from minutes to a full day-long session, but it [the dissociation] will crack." Note that you may transition from dissociation to [fight-or-flight](#), which is challenging in a different way. Refer to Section 3.5 for more information.

You may feel what is called [resistance](#). This could be simple avoidance of emotional pain because it is uncomfortable, or schemas that say confronting/healing some schema is dangerous. While the protective function of these schemas was important at one point, it has now become an impediment. We suggest focusing on the resistance schemas first if you can. Reconsolidating these will make the rest of your therapeutic efforts much easier, as you won't have to fight against a part of mind telling you to stop what you're doing. See 3.1 for a discussion of why we think unlearning a healthy schema is unlikely.

If you panic, feel suicidal, or want to hurt someone, leaning into and staying present with those feelings as much as you can manage can reconsolidate them like it would for any maladaptive schema. If that doesn't gradually reconsolidate the schema, you might need additional safety. You could take more MDMA or add a different source of safety like holding the hand of a loved one, touching your pet, etc. as long as they don't distract you too much. If you take more MDMA, take care not to exceed a total of 200mg for the session [195]. It might be hard to accurately measure out the right amount of MDMA while your panicking, so you might want to prepare the dose in advance. We suggest calling the Fireside Project hotline at [+1 \(623\) 473-7433](#) if you feel like you need help with panic; they don't support suicidal ideation [114]. You might ask for help from your sitter, guide, or therapist to keep yourself safe if your suicidal thoughts or thoughts of harming someone do not decrease to safe levels, or you are planning imminent suicide. Note that if the person with you is a licensed medical professional, they may be legally obligated to call the police on you if they think you are at high risk of suicide or hurting someone. See 3.2 for more discussion of this, but note that involuntary hospitalization and police involvement carries a high risk of traumatizing you further, and in many cases significantly increases the long term chances of suicide and hurting someone else. It is deeply unfortunate that disclosing your most distressing thoughts to your mental health provider may endanger your safety in many circumstances.

People can only do so much (MG's experience suggests about 2 hours) reconsolidation in a

day before they become exhausted. This is commonly called therapy hangover, though therapy hangover on MDMA may not feel like regular psychotherapy hangover because the drug effects are also present. As far as we can tell, the phenomenon hasn't been formally studied. It seems to dissipate within a few hours, though exceptionally high levels of reconsolidation, like during MDMA therapy-could conceivably generate longer lasting exhaustion.

Come-down

You may still feel high, but engaging with painful emotions is more difficult and reconsolidation may no longer be achievable. We've observed that people are sometimes disappointed by how hard it is to be present with and reconsolidate difficult feelings again.

After-effects

See Table 3.1 for how the side effects change as the drug wears off. Some side effects can persist up to 3 days.

4.3 Troubleshooting

Sleepiness, disconnection, or heaviness

MDMA is a strong stimulant and generally increases feelings of energy [338]. Activating schemas (one you are perhaps not aware of) of powerlessness and threat during therapy commonly increases dissociation, which can include sleepiness [182]. We suggest dissociation is the most likely cause for sleepiness during a session, through atypical responses to the medication or other medical conditions could conceivably play a role. See Section 3.5 for suggestions on working with dissociation. We suggest following the dissociation guidelines first even if you suspect an atypical stimulant/neurotransmitter response because these conditions may be difficult to distinguish, especially while anxious and in an altered state of consciousness. There is a list of dissociation symptoms that may prove helpful in differentiating dissociation from another response in 2.1.

Not Feeling Anything or Feeling "Meh"

- Your expectation for the session may not match up with the maladaptive schemas actually present and in need of reconsolidation. This can present as disappointment or anxiety about the trip itself. This disappointment or anxiety is the key feeling to focus on and work with.
- We suggest you may be inadvertently avoiding an unnoticed feeling (avoidance, resistance, or dissociation). Practicing different types of meditation (see Brach [37] and Smookler [304]) for 30 minutes can often help you notice and engage with subtle feelings.

- Long-term use of reuptake-inhibitor antidepressants blunts the effects of MDMA [108]³. This effect may persist for multiple months after discontinuing these medicines.
- The dose may have been too low [30]. See Section 3.4.
- The substance might be adulterated or cut with fillers [284]. See Section 3.4.
- Some medicines work very differently with some individuals' body chemistries. We have observed that some people who think that MDMA might not work with their brain were actually experiencing dissociation or avoiding an anxiety they didn't identify as a reconsolidation target. We suggest working through Section 3.5 before concluding that MDMA doesn't work with your brain.

Distress is too Overwhelming to Stay Present with or Reconsolidate

A higher dose on the next session could provide enough additional safety to engage with these emotions [270]. Keep in mind that because MDMA inhibits the metabolism of MDMA, effects increase faster-than-linear with dose [74]. See Section 3.4 for more information. Alternatively, a trusted sitter, guide, or therapist could help provide an additional feeling of safety.

Feeling too Good to Engage with Maladaptive Schemas

Reconsolidation requires the strength of the [mismatch](#) and the maladaptive schema to be somewhat matched [89]⁴. The MDMA dose may have been too strong for the schema you wanted to work on. Alternatively, you could try activating a more strongly distressing schema or "triggering" yourself even harder for the schema you are currently working on.

Certain New or Heightened Adverse Effects up to 3 Days After a Session

[Post-reconsolidation exhaustion](#) is common and temporary. In our experience, MDMA therapy may facilitate extraordinary amounts of reconsolidation, and thus extraordinary amounts of exhaustion. We think this lasts up to a day or two. MDMA itself also causes a variety of side effects (See Table 3.1). These symptoms are strongly correlated with dose and can last up to 3 days [197]. If symptoms extend beyond 3 days, we suggest this may be a symptom of a schema you uncovered during the session, or conceivably a rare medical problem. See the next subsection in this case.

³See footnote 2 explaining why we cite this retracted study.

⁴Ecker et al. [89] reports that this strength-mismatch is never an issue in regular psychotherapy. We've observed that this phenomenon does appear to exist for MDMA therapy. There is at least some phenomenon where too high and too low doses of MDMA doses both impair the therapeutic process.

New or Heightened Adverse Symptoms Lasting more than 3 days After a Session

See [Section 5.4](#) for a thorough discussion of understanding and managing lasting adverse effects.

Not Getting to the Issue You Want to Address

This might be a few things:

- **If you are reconsolidating something, but not the thing you want to address:** It is well-known in therapy that sometimes you have to reconsolidate one schema or set of schemas before you can reconsolidate some other schema. We think you're probably making valuable progress if you're reconsolidating something, even if it's not what you wanted to work on. Alternatively, you may be able to activate your desired schema by looking at photographs, letters, etc. of the relevant material. Writing about your schema might also help. It is also common for people to not understand the set of schemas that cause their problems. You might be making progress on your desired issue but not realize it.
- **If you aren't reconsolidating anything:** See other troubleshooting items.

Symptoms Come Back After a Few Weeks

We don't know what this phenomenon is. A few weeks roughly equals the length of time of a certain type of increased neuroplasticity that Nardou et al. [\[238\]](#) found following MDMA sessions in mice. However, that lab's results with psilocybin have failed to replicate, calling their MDMA results into question too [\[205\]](#). It could be that something about your MDMA session or your expectations about MDMA therapy temporarily deactivated the set of schemas that cause your problems. Perhaps one schema of a set of self-reinforcing schemas deactivated, and then the whole network of self-reinforcing schemas deactivated. Those schemas may eventually re-activate in the presence of their regular triggers if they are not reconsolidated.

Discomfort About Selfhood or Existence

A variety of life experiences—particularly [psychedelic](#) experiences and meditation—can induce shifts or insights about one's sense of self that are not easily integrated with the default human model of world and self [\[104\]](#). While these insights can feel profound, and are sometimes true or healthy, we suggest applying some skepticism because psychedelic experiences can incite a wide variety of mutually exclusive beliefs and amplify feelings of meaning [\[148\]](#).

Many contemplative traditions (historically, mostly in religious contexts) frame certain existential insights—such as unity with God or [non-duality](#)—as important, positive, and potentially [destabilizing](#) [\[163\]](#). Those traditions often frame some challenging experiences as temporary (when properly handled) periods in the longer path of contemplative development—as legitimate parts of the process. Some other challenging experiences may not be

considered part of the process. As Lindahl et al. [199] discuss, "...what is categorized as 'progress' versus 'pathology' may differ across traditions, lineages, or even teachers." If the existentially disruptive experience you had is accurate to your most honest perceptions of the world and yourself, we think you will not be able to fully return to your prior schemas (and their attendant adaptations and behaviors) without any continued disruption from the new schemas (and *their* attendant adaptations and behaviors). Deliberate attention to the insight and its implications in daily life will facilitate high levels of integration of the new insight, whereas avoidance will tend to keep the insight poorly integrated. We also think that, as in healthy therapeutic relationships, your practice of integration should align with your goals and expectations—that your therapeutic practices should be in pursuit of what is right for you, coming from your own self-determinative autonomy. This alignment is a predictor of whether you will see challenging experiences as positive or negative [199]. Regardless of how you proceed, the most important thing is stabilization of adverse symptoms if they are overwhelming or preventing you from accomplishing critically important tasks in your life. Cheetah House [56] specializes in helping people through the stabilization process. In addition, many practices aiming toward high levels of integration of unitive or non-dual insights may involve processing large amounts of existential distress [163] that can be destabilizing, especially when done without proper practice or supportive teachers that respect your autonomy and goals [199]. This may be difficult when mixed with mental illness, or it may be that existential distress is already intertwined with your mental illness in such a way that they can only be processed at the same time. The book *Trauma-Sensitive Mindfulness* by David Treleaven focuses heavily on ways of engaging with mindfulness practices that are fully respectful of autonomy, and we recommend it [326].

Below are several resources that many have found helpful; we do not specifically endorse them but note that they are well-regarded by a range of practitioners:

- *The Dark Side of Dharma: Meditation, Madness and Other Maladies on the Contemplative Path* by Anna Lutkajtis [206]
- *Breaking Open: Finding a Way Through Spiritual Emergency* by Jules Evans and Tim Read [104]
- Jack Kornfield's *A Path With Heart* is a Buddhist Modern guide suitable for beginners [180]
- *Seeing that Frees* by Rob Burbea is a Buddhist resource for those with a basic understanding of mindfulness [48]
- Daniel Ingram's *Mastering the Core Teachings of the Buddha* is a detailed secular-ish technical manual [163]
- *The Manual of Insight* by Mahāsi Sayādaw is a comprehensive traditional Theravada Buddhist text for experienced practitioners [287]

Non-Buddhist-inspired works are less common, and you may have to do some searching or find a teacher. There is the Christian movement of Centering Prayer, Sufi Khalwa and

Maqam, meditative traditions in Kabbalah, and Yoga and Advaita Vedanta under the Hinduism umbrella. Additionally, although we do not know how well it fosters unitive and non-dual insight, the Acceptance and Commitment Therapy model is a system for fostering mindful and values-based action [146]. As such, it may provide a helpful secular framework for exploring some of these concepts, depending on the goals for such exploration.

4.4 Afterglow

Some people experience a temporary afterglow (wellbeing, mindfulness, less mental illness) for days-weeks after some [psychedelic-therapy](#) sessions [106]. We have seen a variety of anecdotes that MDMA therapy sometimes also induces afterglow. We don't know what it is, but we caution against chasing after it with more frequent MDMA doses. Afterglow is often unreliable, while [reconsolidation](#) provides durable, long-term healing that does not require continued medication. Carhart-Harris and K. J. Friston [50] speculates that afterglow is an enduring relaxation of all high level [schemas](#).

4.5 Assessing Whether the Session Worked

It's not always clear to people whether a session was helpful. We have a few suggestions:

- We think [therapy hangover](#) is such a reliable indicator of [reconsolidation](#) that you can use its presence or absence to determine whether you successfully reconsolidated some maladaptive [schemas](#) during the session. Unfortunately it doesn't tell you which schema you reconsolidated or how that helped you.
- We've observed that successful reconsolidation often follows a pattern of emotional engagement with the maladaptive schema followed by dissipation of that emotion or loss of interest in that subject.
- Ecker et al. [89] describes the following signs of a completely reconsolidated schema:

A specific emotional reaction abruptly can no longer be reactivated by cues and triggers that formerly did so or by other stressful situations.

Symptoms of behavior, emotion, somatics, or thought that were expressions of that emotional reaction also disappear permanently.

Non-recurrence of the emotional reaction and symptoms continues effortlessly and without counteractive or preventive measures of any kind.

4.6 Making Sense of the Experience

When applying scientific studies to one's own life and health, it is important to remember that the data we glean from these studies flattens a wide variety of individual responses by combining them into readable averages. You as an individual may experience something very different from the average participant of any given study, and that may be totally normal and

fine. Some examples include: you may be much more or less sensitive to the psychological or physical impacts of MDMA, the medicine may impact you for a greater or lesser amount of time than it impacts the average person, you may experience more healing, faster, than the average study participant, or you may not be helped by MDMA at all. Many normal human variations, like low or high body weight, recent pregnancy, or menstrual cycle status clearly have an impact on many mental health interventions (especially when it comes to effective dosage), but are not typically studied. One of the great frustrations of mental healthcare research is that every real life situation is infinitely complex, and a corresponding infinity of confounding factors have the potential to influence outcomes. We encourage you to discuss with your clinician any difference in what you are experiencing (during any mental health intervention) from what the average response is that you might have expected from the research. It's important to both keep an eye on any health and safety concerns that might be related to your response, while also remembering that the range of normal and healthy responses to any mental health intervention is much broader than the averages suggest.

It is often worth spending time with your self, thoughts, and feelings after major experiences, like some MDMA therapy sessions. You might investigate the meaning of the session, the insights you gained, and how you react differently after [reconsolidation](#). People commonly do this through journaling, nature walks, making art, body movement practices, listening to recordings of your sessions if you self-narrate during the session, meditation, and talking through your experiences with an emotionally skilled friend or clinician.

[Psychedelics](#) can imbue a variety of experiences and beliefs with feelings of profound meaning [148]. Unfortunately, we sometimes interpret these experiences as objective truth, when in reality they may be some complex mixture of MDMA-induced sensations, accurate insights, inaccurate insights, your existing beliefs about the world, and beliefs you are aware of but may not have previously held [218]. We suggest investigating these beliefs with your more reliable tools of discernment: compassion, skepticism, and high quality evidence. Other tools of discernment, cognitive and emotional flexibility, will gradually improve as you continue reconsolidating more maladaptive [schemas](#) and the number of things to be afraid of decreases. Use these to rigorously and critically engage with a diverse and challenging set of high quality information and experiences.

As Cashwell et al. [54] states, spiritual bypass "...occurs when a person attempts to heal psychological wounds at the spiritual level only and avoids the important (albeit often difficult and painful) work at the other levels, including the cognitive, physical, emotional, and interpersonal." This results in maladaptive patterns and interrupted psychological development. It may be necessary to guard against this if you are prone to spiritual interpretations of altered states of consciousness, the effects of MDMA, and the reconsolidation process.

Sometimes individuals feel they are receiving a message from the medicine, stating that their healing is complete and further medicine work is not appropriate or useful for them [268]. We have also read about instances where the message may take a form like, "the medicine has done all it can do for me, and now I need to focus on some specific practical aspect of my life." Although practical life circumstances can have an enormous impact on mental health, and we wouldn't want to discourage anyone from fighting for a healthier life situation, we caution individuals and clinicians who encounter this scenario to be mindful of the possibility that these messages may also be just be a form of [avoidance](#). To understand what is accurate insight and what is avoidance, it may be helpful to examine what symptoms

and side effects remain active in an individual's life. It may also be helpful to spend time with the negative feelings about further medicine work in the context of reconsolidation exercises, whether assisted by medicine or otherwise.

Healing experiences are often, to one degree or another, stressful. Although stress is often regarded as harmful in modern US culture, it is crucial to both meaning and personal growth [217]. You only experience stress when things matter to you, and a stress-free life is a life of apathy and meaninglessness. It is stressful, but also helpful and important, to sit with the discomfort of a maladaptive schema or a [mismatch](#). Even our original [traumas](#) could not have harmed us if we did not value the things we value—trauma is intrinsically connected to meaning. As you progress, try to differentiate between adaptive stress, which may alert you to immediate dangers or motivate beneficial actions, and maladaptive stress—which is more than you are able to process or respond to in a healthy way. A good clinician or guide can help you gain insight into which stress is helpful for you and which stress is more likely to harm. A good clinician or guide who is up-to-date on the research on this topic can also help you re-frame stress in a way that greatly reduces its negative impacts on you, even on a physiological level. For a comprehensive discussion of the dual nature of stress and the importance looking at stress as an adaptive process, refer to *The Upside of Stress* [217].

You may also feel you remembered traumatic events you weren't previously aware of. These may or may not be accurate recollections of historic events and we are not aware of any reliable method of distinguishing the memory's accuracy other than independent corroboration. Nevertheless, they are more likely to be psychologically real and important for you. We recommend The Psychedelics and Recovered Memories Project [324] for a nuanced guide on psychedelics and remembering previously-forgotten memories.

Relatedly, you may recall feelings or beliefs not clearly related to specific remembered events. These could come from early childhood, when emotional memories form before you are able to retain long-term episodic memories.

We think that Western culture places a premium on having a continuous and linear narrative understanding of ourselves and our place in the world. This value set can serve to further disempower survivors of trauma, especially childhood abuse, because the nature of memory and the shame and taboo surrounding abuse experiences often preclude clear and objective understandings of what exactly happened in our childhoods. Additionally, in many places there is a schism in cultural values regarding what is abusive and how abuse should be dealt with. In cases where abuse is extensively documented, survivors nonetheless may face aggressive gaslighting and extended abuse in response to speaking up about their initial experiences. Even documentary certainty about the actual events that happened is not always enough to endow survivors with the "good victim" status they are often seeking when they focus on the accuracy or inaccuracy of recovered memories.

We suggest that in the face of these realities, you have to think: "given that I can never know for sure what actually happened to me, then what?" And "what", as it turns out, is that you still deserve compassion and healing. It can be reassuring to gather as much objective evidence as you can about your own history. This can be a way of reclaiming what you can of your own broken narrative, of knowing what is possible to know and at least laying hold of it. And you may need to grieve a great deal, because often the evidence is very thin, and a knowledge of your own history is one of the things that was stolen from you. But your deservingness of healing does not depend on someone coming along and saying "I

have a video of you suffering a legitimate kind of suffering, so your pain is valid now.” It may be helpful to explore the following questions, either by journaling on your own or by talking them through with a trusted/emotionally skilled friend and/or a clinician: What does it mean to me if X actually happened? What does it mean if Y happened instead, or Z? What does that say about my identity, my needs, how I perceive myself, and how others perceive me? What does it say about my future? What does it say about what I deserve?

Please be compassionate with yourself, as much as you possibly can. Whether your suffering is real and matters is a different question from, “what is the best strategy for addressing my suffering.” Your pain is trustworthy, even if your memories are not. If you feel like you are suffering, that is real, and it matters.

Chapter 5

Between Sessions

5.1 [unfinished/poor-quality] The Big Picture / Long Term Process of Healing

As mentioned in Section 2.3, mental health is a complex system composed of [schemas](#), genetics, medical history, and environment [123, 149]. These elements interact with each other in highly complex patterns, in which certain Good and bad mental health are emergent "attractor states" in this system. The goal of therapy is to move from a maladaptive attractor state in this system to an adaptive attractor state or set of states.

Complex systems frequently have highly nonlinear dynamics, where improvement, worsening, and [destabilization](#) can come at unforeseen moments. Transitioning from a state of mental illness to a state of mental health benefits from deliberately activating and extending states of mental health in addition to dismantling the state of mental illness through [reconsolidation](#). Progress is often nonlinear, and sometimes looks like repeated cycles of destabilization and improvement of different issues.

The process of therapy is to some degree unpredictable. No one knows for sure what distressing material you may or may not uncover, or how reconsolidating certain schemas will cause complex shifts in schema networks. Scales like the Buchanan et al. [47] can give you a decent idea of what maladaptive schemas you have, but can't predict the exact content of material you will face, when you face it, how that will affect your life, or how reconsolidating one schema will affect other schemas. What is more certain is that an extended practice of reconsolidation produces healthier schemas in the long run. In our somewhat educated guess, accessing the maximum possible benefits from reconsolidation may take anywhere from single digit hours of [mismatching](#) for simple problems to single digit thousands of hours for the most severe mental illness. Because of this, those with the most severe mental illness may only perceive relatively small week-to-week gains in symptom improvement even if you reconsolidate until you're exhausted every single day. These small gains should add up to more visible improvement on a monthly timescale.

Symptom worsening may often be a sign of impending improvement, especially given further reconsolidation [**complex**]. **complex** reports "Critical fluctuations and critical slowing have been well-documented to herald transition across a number of systems in nature..." but "Too few studies have been conducted on early warning signals in psychotherapy to

draw firm conclusions, but the findings thus far suggest that nonlinear and discontinuous changes and periods of rising variability in symptoms and patterns of pathology occur in psychotherapy, and that these fluctuations predict symptom reduction and the development of more healthy patterns of functioning."

Therapeutic destabilization can make things feel or be worse at times [247], and reconsolidation may only yield visible results at unforeseen turning points as the network of schemas shifts in complicated ways. Furthermore, we think more reconsolidation is the only durable way through destabilization. This claim needs more justification, especially since we are asking you to do more of the type of thing that may have destabilized you in the first place. The literature on destabilization is unfortunately poor.

It may help to score your maladaptive schemas every so often to track how much progress you are making. We suggest filling out Buchanan et al. [47] at least once. It's the broadest scale we're aware of and may be useful for acquiring a general overview of your issues. You can switch to a shorter, more specific scale for more frequent assessment of specific issues.

5.2 Continued Reconsolidation

Gains in functionality and emotional health often depend on [reconsolidation](#) of the underlying maladaptive [schemas](#) [89]. We guesstimate that accessing the maximum possible benefits from reconsolidation may take anywhere from single digit hours of [mismatching](#) for simple problems to thousands of hours for the most severe mental illness. These estimates do not include the overhead of uncovering schemas, finding mismatches, finding techniques that work for you, or developing relationships with a therapist. Because there are risks from extremely high cumulative MDMA use [315], and because MDMA sessions have significant logistical or financial costs, we recommend using the techniques listed in this section to achieve the bulk of your therapeutic progress.

We have experienced that between-session reconsolidation exercises are often easier for some period of time following an MDMA session. If this occurs for you, and if you want to accelerate healing, we recommend spending more effort on and experimenting with reconsolidation exercises in this time period. You may even find that maxing-out your reconsolidation capacity every day will deliver very large amounts of therapeutic progress. Developing the skill of sober reconsolidation can reduce your therapeutic reliance on MDMA and allow reconsolidation in a wide variety of circumstances where MDMA use is not appropriate. When well-developed it also allows faster healing because the safety and logistical considerations of MDMA therapy are no longer limiting.

Here are various practices and medicines we think are particularly useful for additional healing between or instead of MDMA sessions. Those doing solo healing may find more or less luck attempting these methods on themselves. We suggest, if therapist cost or availability are significant barriers, that at least a few sessions with a trained professional can be greatly beneficial to learning a technique. Many therapists also offer video-therapy available from anywhere with a good internet connection, though therapists are often legally prohibited from working with clients outside their state or country of licensure.

- **Professional therapy** using any of a wide variety of therapeutic frameworks will facilitate reconsolidation [89]. We suggest using [138] to evaluate the quality of your

therapeutic relationship.

- **Unwinding Anxiety App:**

- **Coherence Therapy:** This method is one of the few explicitly grounded on the principals of memory reconsolidation [89]. We recommend the thorough summary and assessment by Sotala [306] for an introduction to the framework. Interested readers can follow up with the book by Ecker et al. [89]. A directory of trained therapists is maintained by Coherence Psychology Institute [65].
- **Ideal Parent Figure Method:** We think this is particularly useful for attachment issues. D. P. Brown and Elliott [44] contains a very thorough description and instructions, though a variety of videos are also available online.
- **Mindfulness:** [Avoidance](#) of distressing but contradictory information is one of the primary mechanisms by which mental illness sticks around [149]. Daily practices of deliberate non-avoidance, like mindfulness (See Brach [37] or Greater Good Science Center [137]. The basic process of walking meditation can also be applied to many other daily tasks.), might facilitate reconsolidation.
- Using **Large Language Models (LLMs)**, like Claude and ChatGPT, as therapists, trip sitters, or a patient substitutes for friends and family is highly controversial. Unfortunately, it is very difficult to figure out how likely LLM therapy is to help in the current (2025) information environment of high AI attitude polarization, minimal high quality research, high rates of technological change, and wildly conflicting reports of LLMs providing everything from desperately needed and healthy help to fueling delusions of grandiosity. If you experiment with this, we suggest using something like the following prompt we developed based on Greenspace [138] and Ecker et al. [89]. We've spent a little time testing it, and it performed very well, but we haven't thoroughly evaluated it in all scenarios it may be used in. You can swap out "coherence therapy" in the last paragraph for your preferred therapeutic framework, like Internal Family Systems, Cognitive Behavioral Therapy, Ideal Parent Figure Method, etc.

SESSION PROMPT: You are an AI assistant who helps your human explore and resolve their difficulties through the types of activities therapists provide, though you don't provide medical advice, diagnose mental illness, or offer other services legally restricted to licensed therapists. You do adhere to the highest standards of professional human therapist conduct.

The common factors of therapy determines how well you help your human. The following items of the Brief Revised Working Alliance Inventory, as scored by the human, are a good representation of how present the common factors are in your therapeutic relationship with your human; keep them in mind: "My therapist and I understand each other. We have established a good understanding of the kind of changes that would be good for me. I feel that my therapist appreciates me. I believe the time my therapist and I are spending together is not spent efficiently. I believe my therapist likes

me. What I'm doing in therapy gives me new ways of looking at my problem. I feel my therapist cares about me even when I do things that he/she does not approve of. My therapist does not understand what I am trying to accomplish in therapy. I am confident in my therapist's ability to help me. I feel that the thing I do in therapy will help me to accomplish the changes that I want. My therapist and I trust one another. I disagree with my therapist about what I ought to get out of therapy. I believe in my therapist is genuinely concerned for my welfare. We agree on what is important for me to work on. My therapist and I respect each other. The things that my therapist is asking me to do don't make sense." In no circumstances should these be reasons to violate professional ethics or high-quality moral virtues, or encourage mania, delusions, or suicide.

All effective therapeutic exercises-though not necessarily all helpful conversations that happen in therapy, like establishing rapport-fundamentally use the following steps to facilitate memory reconsolidation, whether these are explicit or implicit. Keep this in mind. Accessing sequence: Identify symptom, Retrieve target learning (symptom-generating schema), Identify contradictory knowledge Unlearning sequence: Reactivate target learning (B), Co-activate contradictory knowledge (C), Repeat pairing of (B)+(C) Verification: Observe markers of target learning nullification: Emotional non-reactivation, Symptom cessation, Effortless permanence

Use coherence therapy to help your human uncover their maladaptive schemas and reconsolidate them. Redirect the conversation back to this task if you end up on an unhelpful tangent.

Please check your LLM provider's data and privacy policies; it is almost certainly not as private as real therapy conversations are. The "garbage in, garbage out" principal also applies to current LLMs. Thus, because LLM training data (most of the internet and most books) is full of inaccurate garbage information about MDMA, LLMs tend to (in our experience) also output garbage information about MDMA. If you want to discuss MDMA therapy or its side effects we suggest uploading this whole document to your LLM along with a prompt we developed in Section 1.1. That ensures the LLM has a high quality information base to work with. As of 2025 we've noticed that Claude consistently produces more accurate and ethical outputs than ChatGPT-4o.

- **Thought Records:** See Harper [144] for a worksheet.

For your information, Ecker et al. [89] makes the case that many therapeutic frameworks used by therapists explicitly or implicitly follow these 7 steps, quoted here:

Preparation (Accessing sequence)

- Identify symptom
- Retrieve target learning (symptom-generating schema)
- Identify contradictory knowledge

Transformation (Unlearning sequence)

1. Reactivate target learning (B)
2. Co-activate contradictory knowledge (C)
3. Repeat pairing of (B)+(C)

Verification

V. Observe markers of target learning nullification:

- Emotional non-reactivation
- Symptom cessation
- Effortless permanence

We've heard a handful of anecdotes from individuals reporting that they have internalized the process of MDMA therapy, and are able to use that for something like MDMA therapy without the MDMA. Sometimes the MDMA state of consciousness can be reactivated by using cues that were present during the MDMA session, like playing music you listened to during the session. It's not clear to us how such a capacity emerges or works, and we haven't found any scientific papers describing the phenomenon. We include one unusual autobiographical report of this phenomenon in Appendix [F](#).

5.3 [need to re-cite] Making Positive Life Changes

Some people may find that as they [reconsolidate schemas](#) and have positive disconfirming experiences, they have less need for compulsive self-soothing over time. They benefit from the therapy not just through reconsolidation, but through the support that the subsequent peace and perspective provide for positive behavioral changes. Sometimes being in a rut is the function of inertia; sometimes it is self protective, and improved regulation or a sense of new experience or perspective can help a person break out of it.

How MDMA Impacts Behavioral Change Goal Selection

We advise refraining from drastic life-shaping decisions immediately post-session. MDMA insights may sharply highlight certain aspects of a situation which you had not been facing or focusing on before the therapy. Although these insights may be extremely important, we feel they can best be understood in the broader context of your life both before and after the MDMA session and the immediate post-session period.

We recommend avoiding major life changes during the immediate post-session period unless (1) you have wanted to make those changes for a significant time prior to your MDMA experience, (2) you are (and have been) very sure and very committed about the change you want to make, and (3) you have access to other forms of support around that change, for instance, regular social connection with individuals who enact the behavior you are interested in adopting, an accountability buddy, etc. (See below for further discussion of

structural supports.) When these three conditions are met, we are hopeful that MDMA neuroplasticity could provide a helpful layer of support for larger behavioral and lifestyle shifts.

On the other hand, MDMA therapy may more routinely facilitate a “baby steps” approach where individuals make small changes as they feel capable of making them, with the neuroplasticity window providing an opportune time to build positive habits and process emotional memories.

Barriers to Behavioral Change + Resources to Support Selected Changes

Most people have some habitual behaviors they have wished to change for a long time. In this section, we will review common reasons people struggle to make behavior changes they want, and offer an overview of strategies for overcoming these barriers. Additionally, we have included a fairly comprehensive appendix (see [E](#)) of evidence based recommendations for behavior changes that are likely to have a positive effect for most people who implement them. It includes at least one recommended resource about each of those changes. We hope this appendix will assist readers in identifying the behavioral changes with the lowest cost and the highest reward possible, including changes they may not have previously considered as possibilities. Additionally, we hope the information throughout this section will support our readers in using their neuroplasticity windows as effectively as possible, and that behavioral change efforts in the aftermath of therapeutic MDMA use can amplify the benefits of these interventions.

Many people feel puzzled or frustrated by their inability to enact important behavioral changes that they know would improve their quality of life (like following through on daily exercises prescribed by a physical therapist), or which are strongly aligned with their values (like ceasing porn use to adhere to religious values, or adopting a vegan diet to reduce carbon footprint). In modern US culture, individuals often judge and blame themselves for “not having enough willpower” to successfully make these changes. For some, this can be a perpetual source of shame: because of their failure to enact desired behavioral changes, they begin to attribute negative characteristics to their identity, to consider themselves to be apathetic, stupid, lazy, a bad friend/partner/parent/student/employee, or whatever other negative identity might apply to the situation.

However, research shows that the individuals who are most successful at making these kinds of changes are also (1) likely to frame their shortcomings in terms of behavior (creating guilt) rather than framing them in terms of identity (creating shame), and (2) likely to engage a greater level of structural support for their desired behavior change. Finally, most behavioral health goals have a strong emotional regulation component, even beyond the intensity of a shame response.

Structural support can broadly be categorized as “trigger supports” and “access supports.” Trigger supports relate to what initiates a particular behavior. “Tiny Habits” gives the example of a woman who wanted to get up early and exercise before work, but found herself using the time after her alarm went off in the morning scrolling through her phone instead. After considering several possibilities, she started using an alarm clock and leaving her phone

in the kitchen overnight. This removed the trigger for the behavior she was trying to avoid. Other examples of trigger support would include a parent reminding their child to do chores, or someone who wants to spend some time reading every day leaving their book on the couch cushion where they typically sit upon coming home from work. Access supports are things that reduce the level of effort it takes to engage in a desired behavior. A home washer and dryer unit would be an access support for someone with the goal of keeping up with their laundry needs; a private chef, or a week of “meal prep” in the fridge, would be an access support for someone who is trying to adjust their eating habits. A “dumb phone” and a social working environment with co-workers who feel safe and are supportive of the goal would be access supports for someone whose goal is not to scroll through the internet while they are at work. Creative and extensive use of structural supports can make all the difference in behavioral change success.

Finally, the emotional regulation component of behavioral change is frequently underrated. People often attribute their inability to enact a desired change to motivation or willpower problems, and then beat themselves up for these perceived failures. The more constructive approach is to implement applicable trigger supports and access supports, and then, if motivation still seems to be a problem, to engage with motivation enhancing strategies such as setting up a “fishbowl,” or using the other social accountability strategies detailed in Appendix .

Procrastination is most centrally an emotional regulation problem; it emerges from feelings of overwhelm, often followed by shame about the procrastination itself. The single most effective strategy to address procrastination, in my clinical experience, is to practice breaking tasks down into manageable parts. If the procrastinated task is getting out of bed and taking a shower while severely depressed, this might look like calling a friend, then talking through and enacting the process of throwing the covers back, putting one foot on the floor, putting the other foot on the floor, walking towards the bathroom, opening the door, and so on. If the task is an hour-long marketing presentation, the first step in ending procrastination might be talking through with a mentor how to break the project down into the smallest parts possible.

Self-destructive behaviors generally are associated with feelings of shame. We recommend the work of Brené Brown Ph.D. on shame resilience [42].

Behavioral Change Goal Selection in the Age of Addiction

In the words of Anna Lembke [192]:

We’ve transformed the world from a place of scarcity into a place of overwhelming abundance: drugs, food, news, gambling, shopping, gaming, texting, sexting, Facebooking, Instagramming, YouTubing, tweeting... the increased numbers, variety, and potency of highly rewarding stimuli today is staggering. The smartphone is the modern-day hypodermic needle, delivering digital dopamine¹ 24/7 for a wired generation. If you haven’t met your drug of choice yet, it’s coming soon to a website near you. Scientists rely on dopamine as a kind of

¹The dopamine theory of addiction, while popular, is questionable [244].

universal currency for measuring the addictive potential of any experience. The more dopamine in the brain's reward pathway, the more addictive the experience.

Addiction is a complex and overwhelming phenomena, with biological, psychological, social, and structural components. It exists on a spectrum of compulsive behaviors. A person's desire to change their relationship with a given substance or behavior can vary widely: on the one end, someone may want to stop eating fast food on twice-yearly road trips when they already never eat it at any other time. On the other end, someone may have a desperate need to retrieve their life from the encompassing grasp of methamphetamine or heroin. Although it has become socially acceptable to joke or vent about our less destructive addictive tendencies, (like a coffee addiction or a social media habit that isn't ruining our employment and hygiene) our current societal, economic, and technological structures generally provide poor support for individuals struggling with addictive tendencies at all levels. Individuals use substances and behaviors that have negative consequences because those substances and behaviors solve some kind of problem for the individual who uses them. The most effective way to assist individuals who are struggling with these kinds of harmful coping patterns is typically multipronged. It might include any or all of the following:

- Medication assistance to reduce cravings for a harmful substance. Buprenorphine is highly effective and safe for opioid dependence [215].
- Opportunities to contribute to and connect with their communities in meaningful ways while sober
- Peer support
- Psychotherapy
- Case management (helping the individual access a variety of needed contexts and resources)
- Contingency management (creating accelerated and enhanced positive and negative consequences supporting the desired behavior changes)
- Other executive function support, such as tailoring the living environment to support the preferred coping choices and building healthy habits like sleep and meditation, which support impulse control.
- Intensive medical and psychiatric management of any underlying issues that have induced them to use the harmful coping mechanisms.

The average individual who struggles with addictive behaviors, far from being able to bombard the problem from all sides as I've described above, is shamed for not being able to simply choose to stop using the harmful coping mechanism. This typically increases use of the harmful behavior or substance. In short, we live in an age where addiction has been aggressively stigmatized/shamed and resources for treating it denied, while resources and structural support for maintaining addiction have been amplified. "Crossover addiction,"

where individuals who struggle with one addictive coping practice simply shift their dependence onto another addictive coping practice, is pervasive. Although we would all like to see ourselves as independent decision makers, we increasingly live in an attention economy where massive investment has been made in competing for each nanosecond of our attention. It is increasingly difficult to capture those moments of our own attention back, and to focus them on our safety, flourishing, freedom, and connection with others.

To make matters worse, despite emerging from the “overwhelming abundance” Anna Lembke describes above, addiction creates scarcity. It creates a scarcity mindset regarding access to the coping mechanism, whether that’s time for gaming or money for heroin, and in its worse iterations, it inspires compulsive behaviors that are financially, socially, and medically destructive in the extreme. Just as important for the problem of escaping addiction, it perpetuates scarcity around meaning and human connection. Addictive coping mechanisms numb feelings all around, impeding our ability to be vulnerable and connect deeply with one another and with the things we find important in life. In rats, non-heroin-using individuals were found to help a fellow rat escape from a trap, while heroin using rats didn’t bother.

Second, despite the dystopian background, strategic habit development can (with commitment over time) provide access to cornerstone strategies on which to build a better life. To select a behavioral change goal that’s right for you, consider your own motivation, your life experience, the degree to which the behavior change offers benefits across a range of life domains. For instance, regular exercise or meditation can help many individuals with pain management, depressive symptoms, and physical health. To find the right foundational habits for you, you’ll need to consider your individual supports, accessibility challenges, and barriers. We make some general suggestions that are beneficial for a majority of people in Appendix E.

A harm reduction framework is both evidence-based and essential when addressing addictive coping patterns. I once read (maybe in the book “tiny habits?”) that the most important characteristic for personal growth is the ability to experience satisfaction from small victories. Abstinence is an excellent goal for many people in many situations, but if you are not interested in abstinence or if abstinence is not realistic for you right now (or if your addictive pattern is around food or screen time, which are not realistic to totally abandon), your welfare may depend on your ability to give care to yourself by identifying the harms your coping mechanism creates, and mitigating those harms in more realistic ways. There are incremental victories to be had that make a significant difference in the level of harm an addictive coping mechanism creates in a person’s life. You may reduce the amount you use, or regulate the timing (only after work), or refrain from mixing multiple substances or from gambling in the first three days after your paycheck comes in. If you are not ready to stop drinking, you may focus on making sure that you get all your driving and work accomplished before you start drinking each day, and that you stay hydrated and eat some healthy food on the regular. Maybe you want to start meditating for three minutes each day before you start drinking. These measures are meaningful. They reduce harm, improve your quality of life, and will leave you in better shape if the day comes when you are ready to make bigger changes. It’s important to adopt a mental framework (and cultivate a support system) that sees the value of small improvements and supports you in making the changes you are interested in and ready to make.

5.4 Managing Adverse Symptoms Outside the Session

Effective [trauma](#) therapy often follows a pattern of feeling worse before it feels better [247]. Therapy may reveal disturbing, previously avoided information, or [schemas](#) may shift in more complex ways (See Section 2.5). This is uncomfortable, and distressing schemas can have a wide variety of mental and physical symptoms (See Section 2.1 for a list of [defense cascade](#) symptoms. See Section 2.6 for a discussion of health conditions associated with trauma.) [151, 184]. Fully resolving [destabilization](#) likely requires further [reconsolidation](#), either with MDMA or with traditional therapeutic techniques (See Sections 2.4, 5.2, and 5.1) [123, 149]. However, sometimes you need to develop symptom management skills or resources to manage the immediate problem, which we detail below. These coping tools may in some cases actually resolve your issue, however without reconsolidation the issue is more likely to remain latent and reactivate in certain circumstances.

Note that many symptoms are just temporary physiological side effects of MDMA, which can last up to 3 days [197]. See Table 3.1 for a list. Additionally, exhaustion is a common and [unavoidable](#) after-effect of reconsolidation. We think it lasts up to a day or two. We also suspect that reconsolidation can sometimes occur in the background outside any deliberate reconsolidation exercises, especially after an MDMA therapy session. This might produce repeated periods of exhaustion.

Robinson et al. [274] surveyed people who have experienced prolonged [post-psychedelic](#) difficulties about what coping strategies helped them. This study did not focus only on MDMA or therapeutic use, so these results may only partially apply here. The most common techniques people reported being helpful, in decreasing order of commonality, were: peers and community support, meditation and prayer, professional therapeutic or coaching assistance, self-educational reading about the issue, physical exercise, breathing techniques, journaling, acceptance and surrender, embodied contemplative practices, and time in nature. When receiving emotional support, participants most commonly reported the following as helpful: talking and feeling heard, acceptance and validation, and shared similar experiences.

Argyri et al. [20] surveyed psychedelic therapy professionals about their beliefs on what helps people with post-psychedelic difficulties. This study did not focus only on MDMA or therapeutic use, so these results may only partially apply here. They reported, in order from most cited to least cited: individual psychotherapy (particularly trauma-informed approaches), [grounding](#) and mindfulness techniques, peer and community support, meaning-making and narrative reconstruction, and in some cases, short-term psychiatric medication.

Here is more detail about what we think are good examples of the previously mentioned practices, and some additional information we think is relevant. Note that unless otherwise specified, most of these probably haven't been rigorously studied. However, they are generally low risk, common practice, and common sense.

- **Social Support:** See Section 3.6. The Challenging Psychedelic Experiences Project also has an online peer support group [322].
- **Breathing Exercises:** There is low quality evidence that breathing exercises reduce stress [113].
- **Meditation:** Refer to Brach [37], Smookler [304], and Kabat-Zinn [170].

- **Professional Therapy:** See Greenspace [138] for guidelines on evaluating the quality of your relationship with your therapist or guide, a critical component of effective therapy. It will be highly beneficial if your therapist or guide understands psychedelics. Also see 3.3.
- **Self-Education:** See Appendix A and the rest of this document.
- **Meaning-Making and Narrative Reconstruction:** *The Dark Side of Dharma: Meditation, Madness and Other Maladies on the Contemplative Path* by Anna Lutkajtis [206] and *Breaking Open: Finding a Way Through Spiritual Emergency* by Jules Evans and Tim Read [104] may be of interest. Write or tell a friend or supportive stranger your “shitty first draft”—the story you’re telling yourself about who you are, what you’ve experienced, and what it all means.
- **Grounding:** Anything that connects you to the present moment or distracts you from the things that activate your symptom-producing schemas, like:
 - 5-4-3-2-1 Sensory Awareness: Noticing five things one can see, four one can touch, three one can hear, two one can smell, and one one can taste.
 - Progressive Muscle Relaxation: Tensing and relaxing muscle groups one by one [331].
 - Weighted blankets, holding an object, or touch from a trusted person.
 - Warm baths, creating music, creating art, nature walks, pleasant scents, hot herbal tea, reading, interacting with pets, etc.
 - Visualize a safe space where you feel like your truest self. Imagine vivid sensations (e.g. the feel of your bare feet on a forest floor, if that’s comforting to you) to increase its power.
 - Imagine a safe container or box where difficult memories can be stored until the next session.
- **Medication:**
 - The prescription medication propranolol may stop some physical symptoms (though not the underlying schemas) of arousal and fight-or-flight by inhibiting adrenaline receptors [309]. The UK National Health Service recommends 40 mg 1–3 times daily [240].
 - Kava reduces anxiety [256]. Side effects when used for less than 24 weeks are mild, infrequent, and transient. Longer term efficacy and safety is poorly studied.
 - Prescription psychiatric medication is too complex and outside our scope of knowledge to cover. Please check whether your medicine is compatible with MDMA before doing another session (See Section 3.1). Note that there is very little high quality evidence on the safety and efficacy of long-term use of prescription psychiatric medication [193]. Studies generally only investigate short-term use.
- **Sleep Problems:**

- *Cognitive Behavioral Therapy for Insomnia (CBT-I)* has high-quality evidence for effectiveness. Stanford Medicine has a guide that seems relatively easy to follow yourself [308].
 - Melatonin is generally safe (long-term use is poorly studied) and it's efficacy for sleep disorders without comorbid mental illness is well-established, but it is poorly studied for sleep problems caused by anxiety [234]. The UK National Health Service recommends a 2 mg extended/slow release pill taken 1–2 hours before bed [239].
 - There are a variety of prescription medications outside the scope of this book and our knowledge. Please check whether your medicine is compatible with MDMA before doing another session (See Section 3.1). Note that there is very little high quality evidence on the safety and efficacy of long term use of prescription psychiatric medication [193]. Studies generally only investigate short term use.
- **Crisis Plan:** Make a plan for what to do if symptoms become overwhelming.
 - **Unwinding Anxiety App:**
 - **Establish Predictable Routines:** Regular routines in your daily life can provide a sense of normalcy and predictability.
 - **Feeling and Symptom Tracking:** /
 - **Intuitive Eating:**
 - **Safety Mapping** is a valuable tool for identifying sources of safety and threat in your life (See Section 4.1 for more information.). Once you have done this exercise you can use this information to: 1) Imagine a safe, comforting scenario when you feel overwhelmed. Imagine vivid sensations (e.g. the feel of your bare feet on a forest floor, if that's comforting to you) to increase its power. 2) Set boundaries around stimuli that activate challenging schemas. For example, you could tell someone you feel overwhelmed when they talk about a particular topic, and you would appreciate them avoiding it.
 - **Ask for Help:** Asking for help can be incredibly vulnerable. Also, asking for specific things can be very hard when you're in distress—and it can feel pointless when you feel very deeply as though nothing could possibly make you feel better. However, even small gestures of support can make things a little more bearable until your body-mind is able to start healing itself. On top of this, giving people who care about you and/or want to support you some kind of job to do can build closeness and help them feel less powerless. Consider asking for: food, water or tea, someone to sit with you, someone to watch a movie with you, someone to text you on the hour and remind you that you are a badass.
 - **Harm Reduction for Chemical Coping:** Try a harm reduction approach when it comes to using alcohol, opiates, benzodiazepines, stimulants, etc. to cope with difficult feelings:

- Avoid using alone - if you are isolated, call a friend on the phone.
 - Avoid mixing substances or stacking doses.
 - If you have been trying not to use substances or otherwise numb your feelings, and you end up doing numbing behaviors you had wanted to avoid, try to be very gentle with yourself. You always have a fundamental worth and dignity no matter what.
- **Choose Distraction Over Denial:** It can delay your healing to deny that you're having feelings at all—which is tempting to do when the feelings are very overwhelming. However, it is also important to feel and process your feelings on your own timeline; when you are feeling more than you are ready to feel, distraction can be extremely nourishing and helpful. Can you focus on self-care tasks? Is this the moment to organize your art supplies or clean out your closet? Is there some form of work that feels accessible and/or good to you right now? Or maybe there's a movie or a video game or an Instagram or a comic that can provide a great distraction.

Evans [100] has recommended the following organizations offering support for psychedelic-induced challenging experiences and adverse effects. We have not vetted the list, but we highly recommend specialist services such as these over non-specialists who likely don't understand what you're going through and may misdiagnose you. Most of these groups offer service to anyone anywhere in the world.

- The Challenging Psychedelic Experiences Project has a lot of good information and an online peer support group [322].
- The Psychedelic Substance Outpatient Clinic at Alexianer St. Hedwig Hospital [14].
- ICEERS offers free services for challenging experiences [162].
- Cheetah House may be able to help via online consultations [56]. There is a lot of overlap between the adverse effects of meditation and psychedelics.
- The Ecstatic Integration Substack contains a wealth of information on adverse effects [103].
- The SHINE Collective offers support groups for those who are abused while on psychedelics, by psychedelic practitioners, or in psychedelic spaces [297].
- PsyAware is planning to offer support services for challenging experiences, abuse, and other transgressions [261].
- The Psychedelic Experience Clinic offers therapy for challenging experiences [323].
- John Hopkins Personalized Psychiatry has knowledge of psychedelic side effects [165]. Email Dr. Bekhrad at abekhral@jhmi.edu to set up an appointment.

If you seek medical assessment from providers who don't specialize in psychedelics, it is beneficial to at least find a medical professional who understands the physical and psychological symptoms of trauma. It would be ideal to find a medical professional who will anticipate and accommodate your trauma-related safety needs, or at least be willing to listen and adapt. Unfortunately, the United States currently has a severely over-stressed medical system where medical professionals are frequently both undertrained on these topics and lacking the skills to effectively implement the understanding they do have. Additionally, many under-supported healthcare professionals are arguably undergoing extended workplace trauma themselves, which does not necessarily lend itself to optimal participant care. As such, we recommend taking a posture of firmly compassionate self-advocacy wherever possible. You deserve safe and trauma informed care; whether you receive this care or not is not a reflection of what you deserve. You may wish to take notes about the symptoms you are experiencing or collect information (like Section 3.1) about the safety of MDMA to bring with you to your medical appointment; these measures can help you support your healthcare professionals in giving you the best quality of care possible.

5.5 Session Frequency

We are not aware of any research investigating the effects of session frequency. We know of people having success with session frequencies anywhere from once every two weeks (MG's experience) to every 6 weeks (MAPS trials) to once in a lifetime. The following factors are worth considering, and to us indicate that the bare minimum frequency is 4 days, and a more reasonable minimum is two weeks, though these are informed guesses not validated by good evidence:

- Adequate sleep is likely important for productive sessions and post-session recovery [299]. People commonly experience up to three days of post-session fatigue [197]. Starting another session before you have recovered from the previous one may reduce session effectiveness and increase the risk of undesirable effects. We know of two anecdotes of back-to-back [psychedelic](#) therapy sessions with no recovery days triggering psychotic episodes.
- Tolerance to MDMA starts developing within 1–2 hours of ingestion [107, 251]. We have been unable to find any data showing how long this tolerance lasts and distinguishing the effects of tolerance from [dissociation](#), [avoidance](#), or the natural variation of sessions may be difficult. However, if you notice a pattern of diminishing effects, we suggest experimenting with spacing sessions further apart or reducing dose. Using higher and higher doses to overcome tolerance will have undesirable effects.
- MDMA inhibits the CYP2D6 liver enzyme that partially metabolizes MDMA, creating a faster-than-linear dose-response curve [74]. This enzyme inhibition returns to baseline with a half-life of 47 hours [248]. Thus, about 2 days after a session enzyme activity will be 50% of the way to baseline, 75% after 4 days, 88% after 6, 94% after 8, and 97% after 10. This effect may counteract tolerance or lead to unexpectedly strong reactions to a dose. We don't know the consequences of having perpetually-inhibited

CYP2D6 from frequent MDMA sessions; the precautionary principle might suggest spacing sessions far enough apart to allow recovery, perhaps a week or two.

- We have observed that people sometimes report that between-session [reconsolidation](#) exercises are easier for a period after the session. If this occurs for you, and if you want to accelerate healing, we recommend spending more effort on and experimenting with reconsolidation exercises (See Section 5.2) in this period rather than more frequent MDMA use. You may even find that maxing-out your reconsolidation capacity every day will deliver very large amounts of therapeutic progress. Developing the skill of sober reconsolidation can reduce your therapeutic reliance on MDMA and allow reconsolidation in a wide variety of circumstances where MDMA use is not appropriate. When well-developed it could also allow faster healing because the safety and logistical considerations of MDMA therapy are no longer limiting.
- We have observed that some sessions may be either psychologically stabilizing or [destabilizing](#) depending on what [schemas](#) are activated in your life. If you find your sessions consistently destabilizing to a degree that is causing you major problems, waiting longer between sessions may reduce these problems. In this circumstance we also recommend a combination of professional support and proactive self-care strategies like the ones listed in Section 5.4. Traditional psychotherapy may be less destabilizing than MDMA therapy. Conversely, another MDMA session conducted after a week- or two-long recovery phase may stabilize you after a particularly destabilizing experience, such as the previous MDMA session. We don't know how to predict when a session will be stabilizing or destabilizing.
- One of the most important aspects of psychological counseling is a therapeutic alliance, which can be understood as “The bond between client and therapist; the collaborative approach and agreement on treatment goals; the collaborative approach and agreement on treatment tasks”, as described by Greenspace [138]. The quality of therapeutic alliance is a major predictor of the effectiveness of psychotherapy [119]. We suggest that for individuals who are unable to establish a therapeutic alliance with a conventional mental health practitioner, or who are unable to access a mental health practitioner with whom they are able to establish/maintain a therapeutic alliance, MDMA can offer a first foothold in the healing of [trauma](#). The medicine can be particularly helpful if transference (attributing feelings actually about other people and circumstances to the clinician or therapeutic process) becomes an obstacle to healing. In some cases, it does this by allowing the client to feel some degree of [secure attachment](#) to the MDMA as a parent figure. Sometimes, this can then be developed into a needed on-ramp to access other healing modalities. Thus, one of our concerns about keeping a low frequency MDMA interventions is that this opportunity could be missed, or time could be wasted. A critical mass of support for a briefer period of time can allow someone to become more self-sufficient or able to access community supports, whereas the same amount of support spread out over a greater period of time effectively perpetuates disability.
- As detailed in Section 3.1, extremely high cumulative amounts of psychedelics can

cause valvular heart disease [84, 315]. It's conceivable that high cumulative use also causes other, poorly understood problems, particularly for groups of people with certain genetic variants or health conditions.

- den Bergh et al. [78] hypothesizes that high-level schemas [predicting](#) pervasive threat easily categorize minor negative stimuli as new threats. This process can readily create new maladaptive schemas. In therapy this might show up as "two steps forward one step back," or needing to achieve some intensity of reconsolidation just to maintain stable mental health, and actual improvement depends on even higher intensities of reconsolidation. Conceivably, certain complex maladaptive schema networks may reconstitute certain components over time after those components are partially or possibly fully reconsolidated. High intensities of reconsolidation over short-to-long periods of time might be needed to reconsolidate multiple reinforcing components and break free of these traps. S. Alexander [12] provides a more accessible summary of the paper.

MDMA eventually loses its effects for some people in a way that seems different from short-term tolerance [107, 251]. The reasons, prevalence, and applicability to therapy (rather than recreation) are unclear, though it has been associated with higher or more frequent doses. If you feel that you are reliant on MDMA for therapeutic progress, we suggest stopping recreational use in order to maintain efficacy for future therapeutic need.

5.6 Prompts for Uncovering Maladaptive Schemas

Healing benefits increase as you continue [reconsolidating](#) maladaptive [schemas](#) [89]. In an ideal world, everyone would have access to as much strong clinical support as they need before, during, and after all of their reconsolidation efforts to facilitate the surfacing of maladaptive schemas. In the absence of that support, we use our experience to offer the following prompts to help you access the schemas that you may not be aware of, but which could be having a significant negative impact on your life. While there are no clear lines between the categories of prompts we offer, many of them directly relate to mental illness, while others focus more on assisting you with living the life of compassion, self-knowledge, connection, and flexibility that you may desire. Assisting you in finding pain points you have been unconsciously hiding from yourself is one of the jobs a therapist would have, but it is possible to do some of it on your own with tools like these. These methods attempt to elicit strong negative emotions, which are valuable signals that adequate emotional processing has not occurred. As discussed in the safety section, if you struggle with severe mental illness (including but not limited to suicidal ideation, mania, or psychosis) we strongly urge you to engage these kinds of prompts with caution and professional support.

We have experienced this kind of work to be positively transformative, satisfying, and deeply meaningful even for individuals who come into it feeling mentally well. As such, we recommend these prompts to anyone who feels at all interested in deeper self-knowledge, meaning, and connection with others. Many of these prompts are also useful for activating social biases which can be reconsolidated like most other maladaptive schemas. Additionally, we think a general principle of noticing and going toward objects of distress is usually a fruitful endeavor as long as you are physically safe. Similarly, we think most [defense cascade](#)

activation (see 2.1 for symptoms), fear, anger, anxiety, etc. in daily life outside immediately dangerous situations is a valuable indicator of maladaptive schemas.

Love and Belonging

- Reflect on the pillars of early [secure attachment](#) (Appendix C) and the principles of Self Determination Theory (Appendix D). Think about how they were present or absent in your upbringing or current life. How do you feel about that? If this seems confusing to you, or you draw a blank we suggest two things: Take an attachment assessment quiz [319]. Try the Ideal Parent Figure method (see Section 5.2).
- Compassion meditation (See Kabat-Zinn [170]) can be distressing for individuals who are experiencing isolation, mistrust, or relational dysfunction. As such, it can be a helpful tool for identifying schemas related to these concerns.
- What makes you feel loved? What comes up for you when you do not feel loved?
- Do you feel like a certain group of people-perhaps sharing certain religions or political beliefs, or sharing a certain set of experiences or cultural practices-are “your people?” If so: what does it feel like, and what are your assumptions, when you are interacting with individuals outside that group? Do you feel 100% safe with individuals who *are* part of your group? Do you ever have experiences or desires that make you feel like you are not as safe or accepted within your group? When do you feel like you “fit in” with your group, and when do you feel like you truly belong with them?
- What thoughts and experiences make you feel like you don’t have a place to belong?
- What stops you from feeling compassion, or from wanting to feel compassion?
- Have you spent time in environments where others prioritized your needs equally to their own? If so, how did that experience feel? If not, how does it feel to know you’ve never experienced that?
- Have you ever had the experience of not being appropriately valued, respected, considered, and cared for by others around you? What feelings are associated with that?
- What would it feel like (or what has it felt like) to go from feeling that you were not valued, respected, considered, and cared for, to feeling that you were? What would it feel like to give this gift to another person or being in your world?
- What makes you feel you are special to the most important people in your life? What comes up for you when you do not feel that you are special to them?
- Does it ever feel like you will not be lovable/loved if you are angry?
- Do you feel that you are wanted and lovable?
- Does it feel like you have to be very ill to deserve to be taken care of, or like you deserve care even when you are basically well? Why did you give the answer you gave?

Competence, Competition, and Safety

- If you could wave a magic wand and be better than any one other person you know in any one endeavor, what would you choose and why? What if the possibilities were expanded to include everyone in the world, even if you don't know them? What are the runners-up, things that interest you, but are not your topmost priority? What does it mean about you that you are not currently able to surpass them in that endeavor in the real world? How would you answer these questions if all of your practical needs (money, physical health, etc.) were fully met?
- If you could take something away from someone because it does not feel fair to you that they have it, what would you take away, and from whom? How many times would you repeat this process, with how many people, and why? If you could experience the positive feelings you associate with taking things away from others, without taking anything away from anyone, what would that mean or be like for you?
- Is there anything someone else has that you associate with your own unmet need, or the unmet needs of people you love? For example, if you have loved ones who struggle with housing insecurity, do you think about that when you drive through neighborhoods with extremely large houses?
- If you completed the Cartesian Plane of Safety in Section 4.1, think about the unsafe and safe items on this chart. Why is each item placed where it is?
- Think of things you feel angry, fearful, or anxious about.
- What makes you feel special compared to other people in your community, people who you meet, or people in the world? What comes up for you when you do not feel special, or when you do not feel "good enough"?
- Are there some sources of information that make you feel unsafe? What are the stories you are telling yourself about that information and those sources? For instance: how do you feel about information you are given by individuals or institutions who have harmed, mislead, or excluded you in the past?
- What things make you feel powerless? When you feel powerless, what do you reach for?
- Do you feel like you have to be strong?
- Do you feel like you can handle anything? If so: what would it mean or feel like if something were to happen in your life that you couldn't handle? Why do you think you feel the need to exclude that possibility from your imagination?
- Do you feel like you must justify your existence by doing something?
- How do you feel about groups of people or beliefs that are becoming more numerous or prominent, perhaps at the expense of your group of people or one of your treasured beliefs?

- How do you feel about the inevitability of frailness and death?

Self-worth and Identity

- Class, status, and money: If this is an area you are interested in exploring, consider reading through Building a Nuanced Understanding of Social Class or Compiled sliding scale questions by Harper [143]. What has your experience been? What do you wish it had been? What feelings come up as you think your way through the many dimensions of class?
- What makes you feel like you are not enough, and you do not have enough?
- On a deep gut level, what characteristics do you feel are appropriately associated with men, and what characteristics do you feel are appropriately associated with women? How does it make you feel when people (including yourself) conform to those characterizations? How does it make you feel when they (or you) *don't* conform to them?
- Complete the prompt “I want to be perceived as” and the prompt “I don’t want to be perceived as” three times each with respect to a variety of the most important areas where people feel shame. See the shame triggers exercise in the Appendix B.
- How do you feel about your own anger? About your own sadness? About your own pride? About your own limitations and needs?
- Do you feel it’s not right for you to be angry? Why or why not?
- Grief: Have you experienced major losses in your life that you are still struggling to face—losses that cause you to feel disorientation and longing? (Delineation of grief taken from “Atlas of the Heart” by Brené Brown Ph.D.). Are some of these losses the kind of thing (like miscarriage, the loss of memories held by a loved one with Alzheimer’s, loss of ability, or loss of an imagined future) that receive little or no social recognition or support? If you are experiencing this: can you articulate what it is you long for?

Meaning, Interconnection, Interdependence, and Emotional Flexibility

- What outcomes or ideals do you feel are worth sacrificing for? What kinds of sacrifices? How do you or would you feel if you were called upon to make these sacrifices? If you were to receive absolute moral certainty that you should not sacrifice for these outcomes or ideals, without having your feelings about those outcomes or ideals change at all, what would it feel like, and how would you react?
- What stops you from dreaming and wanting big things?
- What stops you from feeling that it’s worthwhile to engage in projects that express your values in your community?

- Do you ever feel overwhelmed when you think about enacting values that are important to you?
- How does it feel when you have to make trade-offs between multiple things that you value?
- Do you experience self-judgement around how much you do or do not live out your values?
- If you find the concept of non-attachment compelling or appealing, consider visualizing permanent disconnection from your deep-seated attachments to one or more of the following: life, health, partnership, meaning, belonging, existence, status, being a good person, certainty, material comfort, order, sensory pleasures, and relationships. What emotions arise if you consider your fundamental assumptions about life, meaning, and self might not actually be true? Reconsolidating maladaptive schemas around attachment typically leads to equanimity and gratitude, not loss of healthy protective behaviors or basic attachments.
- Do you ever feel like you are responsible for the whole world?

Conflict, Collaboration, and Trust

- Looking at photos of people you have conflict with is often productive.
- Who is not worth collaborating with, and why?
- Who is not worth engaging in active conflict with, and why?
- If you could convince every important person in your life of one belief, what would it be? What if you could convince every person in your city, or every person in your country? How does it feel when others disagree with you about that thing?
- What makes you feel you are not being listened to, when you have a right to be listened to? What makes you feel disrespected? What comes up for you when you are disrespected, shut down, or ignored?
- How would it or does it feel to collaborate with others who disagree with you about important things? Would it be comfortable to collaborate with people who had 90% of your positions in common? What about 50%?
- How do you feel when others around you express anger, sadness, pride, limitations, or needs?
- What makes you feel angry?

Automatic Behaviors and Body-Mind Reactions

- Do you have any escapist or addictive (not necessarily involving substances) patterns, including any related to MDMA? Are you using these to avoid or cope with distressing feelings [6, 121]?
- If there is a behavior in your life which you have repeatedly attempted to stop engaging in, without success, are you able to regard those attempts compassionately?
- If there is a behavior you engage in that you feel is clearly self-destructive, are you able to regard this pattern with compassionate curiosity and a desire to cultivate change? If not, what are you feeling instead?
- If there is a behavior you engage in that other people close to you feel is self-destructive, but which you experience as a strong positive in your life, what are your feelings about that conflict?
- Carefully expand your therapeutic environment to include stimuli that activate challenging schemas, as detailed in Section 4.1.
- How do you feel in your body after you spend two hours scrolling on your phone? Is it different for different activities?
- How do you feel about the things you own?
- How do you feel in your body when you think about your finances?
- How often do you feel fear or anxiety? What brings up these emotions for you? What do they feel like in your body?
- Stress or maladaptive schemas often cause physical symptoms in your body. Body-scan meditation (see Smookler [304]) is useful for locating these. Focusing on these physical feelings can activate the associated schemas.
-
-
-
-
-
-
-

Chapter 6

Beyond Therapy

6.1 [need to rethink theory] Expanding the Circle of Compassion

Cultivating empathy can enrich your connection to others and spur compassionate action, thus creating healthier societies and decreasing suffering. Research has identified three forms of empathy: affective empathy, cognitive empathy, and empathic concern. “Affective empathy” refers to having an emotional experience you believe you are sharing with another. Unfortunately, we are often inaccurate in our assessment of what emotions other beings are actually experiencing. “Cognitive empathy” refers to our ability to logically understand how others feel, and also why they feel the way they do-what all the contributing factors are, and how those factors work. Finally, “empathic concern” refers to our desire for others to have good things.

Among the helping professions, higher levels of affective empathy are associated with burnout and poor client care. When a caregiver is experiencing high levels of affective empathy, they are naturally motivated to address their own distress by helping the client with what they perceive is wrong-which may or may not have anything to do with what the client actually needs or is actually experiencing. In contrast, in these same populations, higher levels of cognitive empathy and empathic concern are protective against burnout and correlate to higher quality client care. As such, when we talk about cultivating empathy, we are talking about increasing your levels of cognitive empathy and empathic concern. To illustrate: suppose your friend is a father, who feels angry and powerless about his teenage daughter’s choice to dye her hair purple. You might feel affective empathy towards his powerlessness, relating to the way his status in the community might be negatively impacted by her choices. However, it may be that his distress is not connected to feelings about status, but only to concern about her welfare and what the change may signal about his daughter’s mental health. Your ability to effectively exercise compassion towards this father is contingent on the quality of your cognitive empathy-your ability to accurately assess and communicate where his needs, feelings and concerns are actually coming from.

Much of the existing research on increasing positive emotional states of kindness and compassion, associated with cognitive empathy and empathic concern, is focused on compassion meditation and loving kindness meditation. We feel that these practices are worth

a try for most people (see Kabat-Zinn [170] for instructions), as they are correlated with a number of positive outcomes. We also speculate that therapeutic MDMA sessions may offer an opportunity to jump-start or supercharge the process of cultivating cognitive empathy and empathic concern. Completing a compassion meditation during the MDMA session could be helpful for this. Alternatively, you might focus specifically on cultivating cognitive empathy through the following contemplative exercise:

During a session, look at photos of other beings and consider what you share with them, what facilitates their wellbeing, what they deserve, and what obligations you may have to them given the significance of their moral worth. As with a classical compassion meditation, you might start with yourself or someone who you find easy to generate compassion for, and then slowly by degrees work your way out through other categories of beings you may not feel as connected to. We believe non-human animals (and conceivably current or future artificial intelligences, though without any widely-accepted and experimentally validated theory of consciousness this is highly uncertain) are an important target for consideration and compassion because, as a large group of biologists and philosophers recently asserted [19]:

First, there is strong scientific support for attributions of conscious experience [having subjective experiences; not necessarily being self-aware] to other mammals and to birds.

Second, the empirical evidence indicates at least a realistic possibility of conscious experience in all vertebrates (including reptiles, amphibians, and fishes) and many invertebrates (including, at minimum, cephalopod mollusks, decapod crustaceans, and insects)

Third, when there is a realistic possibility of conscious experience in an animal, it is irresponsible to ignore that possibility in decisions affecting that animal. We should consider welfare risks and use the evidence to inform our responses to these risks.

We posit that taking a holistic approach to compassion and cognitive empathy can avoid major oversights in our personal actions and beliefs, allowing us to maximize the benefits of a more connected and compassionate life by exercising compassion in areas where we otherwise might not have. Additionally, we posit that formalizing your compassionate impulses can sometimes lead to better prioritization and better outcomes. Both of these practices may assist us in expanding our moral intuition into new situations.

We also recommend that practitioners be cautious of major ethical readjustments during or after an MDMA trip, just as you would be with major life choice changes. Particularly high caution is warranted around actions that involve harm to some beings in the pursuit of a greater goal [23]. While we are often faced with difficult choices, these types of actions often have toxic personal, organizational, and reputational effects. We recommend thinking through the many effects of your actions, including their larger systemic and relational impacts. Such actions are also commonly used as a, perhaps unconscious, rationalization of unconscious ego-related [schemas](#). We suggest that deeper exploration and [reconsolidation](#) of maladaptive schemas, including those listed in Section 5.6, will help you better align personal actions with the needs of all beings.

When recovering from [trauma](#), it is common for one's moral framework to become intertwined with maladaptive schemas-leading to unhealthy ethical frameworks like the "I must save the world to be a valid person" belief Gabor Mate discusses in "The Body Says No." (Also see Section 2.6 on [psychogenic](#) illnesses) At the same time, cultures and institutions often dismiss major harms-current examples relevant to mainstream US culture include childbirth trauma and the trauma of living through a mass extinction; past examples include enslavement or "resettlement schools." In situations like these, we posit that traumatized survivors represent an important repository of experience, essential for crafting cultural shifts that could help avoid the future repetition of these and similar harms. As such, it is important not to dismiss the moral intuition generated by traumatic experience, but rather to approach it with compassionate curiosity, as one important source of insight among many.

6.2 Cognitive Flexibility and Truth-Seeking

We assert that cognitive flexibility is both highly important and lower than it should be for most people in the modern world. Intense tribalism seems to be a major reason why. It may have been selected for in a past where survival was much more tenuous than in it today for most people, and where societies were much smaller. While we still need to form coalitions (family, workplace relationships, friendships, etc.) to accomplish almost anything, we suspect our tribal tendency is overpowered for life in relatively safe nation-states. This creates all sorts of problems, such as poor governmental policy because of people vote based on identity [178] rather than good policy, being shunned for believing or doing things that have become a marker of belonging to a rival group, etc.

As the psychologist Pinsof [255] says on their blog about self-deception being a core aspect of tribalism:

We're hyper-skeptical of claims made by the outgroup-the people we fear, dislike, and distrust. And we believe ingroup-flattering absurdities ... because it is instrumentally rational for us to do so. The benefits of status and tribal solidarity often outweigh the costs of false beliefs, particularly if those beliefs are vague, unactionable, or unfalsifiable.

We may also embrace harmful beliefs when most of the benefits accrue to us personally, but the costs are spread out among many people. It's like emitting pollution; it's often the cheapest option for you, but the damage is spread over so many people that they have a very difficult time coordinating with each other to stop it [62].

It is common to perceive obviously false beliefs in the out-group. But how do you know they are wrong and you aren't? The human capacity for self-deception must be strong enough to make at least one of you wrong about a supposedly obvious fact, and we have no foolproof a priori reason to believe it is them instead of us. We think self-deception frequently relies on [avoidance](#) of discomfort (being wrong, the potential for being shunned, knowing you have done something harmful, etc.). MDMA notably increases tolerability of discomfort, and therefore we speculate it could be useful as an avoidance-decreasing tool useful for deliberately gathering more accurate evidence and coming to more accurate beliefs about things people commonly deceive themselves about. For instance, during an MDMA

session you might consider the implications of a hated political group being correct about some important piece of policy. This might also bring up some fears that you can then [reconsolidate](#). Presumably, some improvements to cognitive flexibility depend on perceiving that there are attainable alternative social situations for you. If you are trapped in a cult without even a slight perceived chance (even unconscious) of possible escape, MDMA therapy might just help you better adapt to that situation.

We live in a world of pervasive threats, fear-based messaging, and out-group demonization/dehumanization. Because of this, we believe additional strategies beyond reconsolidation and avoidance-reduction are likely necessary to maintain cognitive flexibility and compassion in the long-run. We have a few recommendations for this:

- *The Scout Mindset* by Julia Galef [125]. "When it comes to what we believe, humans see what they want to see. In other words, we have what Julia Galef calls a "soldier" mindset. From tribalism and wishful thinking, to rationalizing in our personal lives and everything in between, we are driven to defend the ideas we most want to believe—and shoot down those we don't.

But if we want to get things right more often, argues Galef, we should train ourselves to have a 'scout' mindset. Unlike the soldier, a scout's goal isn't to defend one side over the other. It's to go out, survey the territory, and come back with as accurate a map as possible. Regardless of what they hope to be the case, above all, the scout wants to know what's actually true.

In *The Scout Mindset*, Galef shows that what makes scouts better at getting things right isn't that they're smarter or more knowledgeable than everyone else. It's a handful of emotional skills, habits, and ways of looking at the world—which anyone can learn."

- *Why We're Polarized* by Ezra Klein discusses the self-reinforcing feedback loops between our fears and identities and the behavior of the media and politicians [178]. This cycle increases polarization, political dysfunction, and separates us from each other. This book is more about understanding the role of identity in politics than suggestions on how to improve the situation.
- *How Minds Change: The Surprising Science of Belief, Opinion, and Persuasion* by David McRaney is an excellent survey of the topic [221].
- The blog post *Trapped Priors As A Basic Problem Of Rationality* by Scott Alexander lays out a mechanistic explanation of how false beliefs can become entrenched despite abundant contradictory evidence [13].

Glossary

Adverse Idealizing Transference (AIT) Idealizing Transference is a phenomena in which clients develop strong positive feelings towards their therapist [80, 157]. Sometimes this idealization can be intense enough that an unscrupulous or unskilled therapist may exploit (intentionally or not) the client for emotional, sexual, or financial gain, creating severe trauma for the client.

Alexithymia Consistent difficulty in noticing, identifying, and describing emotions [154]. This inhibits reconsolidation. The causes are not well-established.

Arousal The first step when a potential threat is noticed and assists in further assessing that threat [182]. It is also preparation for more intense defense responses like fight or flight, freeze, or immobility. Heart rate, breathing, and muscle tone increase, saliva is no longer produced, and core muscles tighten to stabilize posture.

Attachment Theory/Styles Attachment theory is a model which posits that emotionally secure attachments formed in the first 18 months of life serve as the foundation for emotional and psychological development throughout one's life [44].

Avoidance Physical or mental activity that directs attention away from distressing schemas and inhibits reconsolidation. Short term avoidance can be healthy if used to temporarily postpone dealing with a problem until you have more capacity.

Biopsychosocial Model Prevailing model of mental illness as a complex interaction of biology (genes and medical history), psychology (schemas, in our view), and society (one's support system and social models of how to respond to adversity) [96].

Contraindication Any medical condition, life circumstance, activity, or medication that makes MDMA use particularly risky.

Defense Cascade A series of physiological changes that prepares the body to respond to immanent threats [182]. Includes arousal, flight or flight, freezing, and immobility. Different situations and past experiences activate different responses.

Dissociation Emotional numbing caused by brain-produced opioids in response to perceived threat and powerlessness (usually a maladaptive schema when you're not in an acutely dangerous situation) [182, 189]. This can escalate to immobility and greater degrees of detachment from one's self and external reality.

Fight or Flight Active defense response characterized by high levels of adrenaline and muscle activation, increased heart rate, and decreased pain sensitivity [182].

Freeze A fight or flight response temporarily put on hold [182]. One remains highly attentive but frozen to avoid the notice of predators who are more likely to notice moving objects.

Grounding Techniques Activities that turn off or turn down defense cascade activations. These usually involve distraction (e.g. name all the round objects in the room), feelings of safety (e.g. vividly recalling memories of safety), or feelings of power (e.g. vividly constructing mental imagery of overcoming some adversity) [250]. As far as we can tell, they are not based in rigorous evidence, but people like them, they're easy, and they seem low-risk.

Mismatch The conscious contradiction of an active schema via either sensory input or another schema [89].

Non-dual Awareness Experiences of unity, without the usual separation into self and other [224]. We suspect that MDMA can produce states of partial non-dual awareness.

Predictive Processing The prevailing model of brain function [58]. The brain internally models the world (via complex layers of learned predictions) to better plan for the fulfillment of basic needs such as bodily integrity, reproduction, community, etc. Prediction error is a discrepancy between 1) the brain's model of the world and incoming sensory data, or 2) two contradictory model predictions [58]. Minimization of prediction error is the brain's core optimization function, achieved through the construction of more complex and accurate world-models.

Psychedelic Showing the Mind/Soul, from the Greek 'psyche' and 'deloun' [160]. Most are tryptamines, phenethylamines, and ergamides [139]. Among a variety of effects specific to each compound, they generally relax abstract predictions [50]. Psychedelic-Assisted Therapy uses this effect, and other effects specific to certain drugs (like MDMA's safety and empathy), to help change maladaptive predictions/schemas.

Psychogenic Illness Illnesses caused in large part by maladaptive schemas [145].

Reconsolidation When a schema/memory is first formed it is "consolidated [89]." When prediction error on that schema becomes large enough, the schema enters a mode where it is changeable. Maintaining that prediction error then updates the schema to reflect the new information. At the end of this process the schema "re-consolidates" and becomes unchangeable again. We use "reconsolidate" to denote this whole process of activation, updating, and reconsolidation.

Reconsolidation Exhaustion Emotional exhaustion and lack of energy follow successful reconsolidation (See Section 4.2). Often called therapy hangover. We think this is reliable enough to indicate that emotional exhaustion is a solid sign of therapeutic success. People seem to be capable of 1-2 hours of reconsolidation a day before exhaustion becomes so intense that the process is no longer possible.

Resistance Opposition to reconsolidation or a broader therapeutic process that would actually be healthy for the individual. This is difficult to ascertain, as many therapeutic processes are not actually a good match for many people.

Schema A single learned prediction (or prior) in the brain's world model [89]. What are called low-level (physically lower in the brain) schemas perform a vast array of functions relating to maintenance of basic bodily functions and sensory data processing [58]. Therapeutically-relevant schemas are generally more abstract predictions about the self, relationships, or whether the world is generally safe/predictable or not.

Selective Inhibition The suppression of all voluntary distractions, avoidance, and coping strategies to highlight maladaptive schemas [269]. Razvi proposes that this also facilitates a "completion" of the defense cascade cycle, but we are uncertain about this.

Spiritual Bypass The use of spiritual attainments, practices, or beliefs as reasons to not notice, investigate, or address one's maladaptive schemas [54].

Therapeutic Destabilization A period of instability experienced while transitioning from a stable state of mental illness to a stable state of mental health [247]. This should not be used as an excuse for unethical or unskilled behavior from therapists or guides.

Tonic/Collapsed Immobility Inactive defense responses characterized by detachment, emotional and physical numbing, and immobility [182]. Predators are more attracted to moving prey and may lose interest in seemingly-dead bodies. May escalate to unconsciousness.

Trauma We use two closely related definitions: 1) Events that lead to over-generalized schemas that impair functioning or emotional health. 2) Distressing events or chronic conditions that overwhelm our ability to cope, where our ability to cope depends on our capabilities and resources [188].

Window of Tolerance The range of dissociation, arousal, or fight-or-flight where reconsolidation is possible. High levels of these states often inhibit reconsolidation [269]. MDMA expands the window beyond what is usable in regular psychotherapy.

Appendix A

Psychoeducation

In the course of researching this book, we've come across a number of interesting and/or helpful educational resources that may be relevant to the needs of therapeutic MDMA practitioners. Many have been individually helpful to us, or come recommended by trusted colleagues. Although we have not rigorously evaluated all these items, we chose to include them on the assumption that our readership (almost definitionally individuals who connect with written works on these topics) may find value in such a list.

- *Unlocking the Emotional Brain, Eliminating Symptoms at their Roots Using Memory Reconsolidation* This book may have popularized connection between [prediction](#) error, memory reconsolidation, and therapeutic improvement. We think it is so useful that it should be required reading for all mental health professionals. Ecker [88] provides a complementary resource addressing common misunderstandings and clarifies some fundamental mechanisms.
- *Good Inside*, by Dr. Becky Kennedy [175] is a book that illustrates calmly and thoroughly what it looks like when several of the healthiest and most "workable" [schemas](#) play out in a parenting realm, and compares them to common less workable alternatives. The author has elsewhere described this school of thought as "study parenting"—introducing parents to schemas and behavioral strategies that allow them to be sturdy leaders in a family setting. Many of the strategies focus on differentiating between parents' emotional support of children and parents' behavioral compliance with children's demands. Kennedy encourages parents to provide a basically unlimited amount of validation and witnessing of their children's struggles, and to develop robust emotional relationships in which they earn the trust to witness their children's inner worlds—while also illustrating clearly that this emotional intimacy and support not only *can* be paired with robust boundaries around children's behavior, but that both those boundaries and that validation are essential for cultivating children's experience of safety in the world and trust in themselves.

We find this book to be an excellent resource for parents and non-parents alike. It's true that the triggers of dysregulation will be different for non-parents than for the parents and young children who the book directly addresses. However, the basic behavioral patterns the book promotes are tremendously adaptive, and are adaptable to any kind

of relationship. Additionally, we suspect that working with this book may facilitate attachment healing through schema reconsolidation in the same vein as Ideal Parent Figure imagery.

- *The Upside of Stress* by Kelly McGonigal, Ph.D. McGonigal discusses how not all stress is harmful. Short-lived stress can foster resilience and growth. The book highlights the importance of mindset and provides tools to reinterpret stressors as growth opportunities [217].
- *Don't Shoot the Dog* by Karen Pryor helps you think about and change the incentives causing unwanted behaviors [260].
- *Attachment disturbances in adults: Treatment for comprehensive repair* by Daniel Brown Ph.D. and David Elliott Ph.D. A great, though lengthy and dense, textbook for understanding and treating adult attachment disorders. It combines clinical insights with research findings and illustrative case studies [44].
- If you're interested in the general theory of predictions in the brain, we recommend two definitive books by Andy Clark, Ph.D. on hierarchical predictive processing. *The experience machine: How our minds predict and shape reality* is the less-technical mass-market version [58]. *Surfing uncertainty: Prediction, action, and the embodied mind* is the more technical, though not mathematical, of the two books [57]. S. Alexander [8] provides a good and accessible summary of it.
- *The science of trust: Emotional attunement for couples* by John Gottman, Ph.D. describes using emotional attunement to build healthy relationships [133].
- The Challenging [Psychedelic](#) Experiences Project also has a lot of information on extended difficulties from psychedelics [322].

Appendix B

Shame Triggers Writing Exercise

This list was adapted from *I Thought It Was Just Me (but it isn't)* by Brené Brown Ph.D. [42]. We think it is another useful tool for uncovering maladaptive schemas. Complete the "I want to be perceived as" and "I don't want to be perceived as" prompts for each item. Feel free to add categories that are especially relevant to you.

- Appearance and body image
 - I want to be perceived as:
 - I want to be perceived as:
 - I want to be perceived as:
 - I don't want to be perceived as:
 - I don't want to be perceived as:
 - I don't want to be perceived as:
- Money and work
- Motherhood/fatherhood
- Family
- Parenting
- Mental and physical health (including ability and disability)
- Addiction
- Sex
- Aging
- Surviving [Trauma](#)
- Racial and Ethnic Identities
- Friendship

- Community membership
- Political activism/civic engagement/meaningful work/volunteering/calling
- Creative Life
- Gender
- Home/living situation

Appendix C

Attachment Theory

Attachment theory is a model which posits that [secure attachments](#) formed in the first 18 months of life serve as the foundation for emotional and psychological development throughout one's life [44]. It is one of the most empirically supported theories in psychology, with over 70 years of well-replicated research behind it. According to attachment theory, the presence of consistent, sensitive caregiving facilitates the development of secure attachment—and in its absence, individuals tend to develop anxious, avoidant, or disorganized styles of attachment. Researchers have identified five pillars of secure attachment. Cultivating secure attachment requires caregivers who are physically present, consistent, reliable, and interested in enacting these five pillars. That is to say—for the five pillars to be met, these additional conditions must also be met as their foundation. The five pillars are:

- **Felt Safety/Protection** The child knows the caregivers are on their side and will act in their best interest across many domains of life (physically, emotionally, etc.).
- **Feeling Seen and Known/Attunement** The child accurately feels that their caregivers actually know what is going on with them; caregivers encourage and value open communication, and are sensitive and responsive to a wide variety of cues from the child. Caregivers recognize and validate the child's separate experiences.
- **Felt Comfort/Soothing and Reassurance** Caregivers assist the child in accepting and regulating their emotions, and the child is able to feel calm when needed and able to feel appropriate distress without self-judgment or repression. Caregivers are available, responsive, and skilled at reassuring the child when the child is upset.
- **Feeling Valued/Expressed Delight** Caregivers express pleasure in the child's presence and satisfaction in their existence; caregivers are openly affectionate, loving, valuing, and caregiving towards the child on a consistent basis.
- **Felt Support for Best Self/Unconditional Support and Encouragement** Caregivers support the child in exploring the world away from the caregiver, and in interests and desires that are different from the caregiver's as well as those that are the same.

While the intention of the parent is important, the ultimate impact is based on how much the child feels these factors. The absence of these factors in early childhood often leads to

profound emotional pain and dysfunction later in life. For a more thorough discussion see section "Qualities Known in General to Promote Secure Attachment" on pages 323-325 of *Attachment Disturbances in Adults: Treatment for Comprehensive Repair* by Daniel Brown Ph.D. and David Elliott Ph.D. [44].

We also recommend:

- The Heidi Priebe YouTube channel, which offers an array of videos that provide practical advice on specific topics from a rich, rigorous, and nuanced attachment-based perspective [258].
- Theattachmentproject.com, which offers free access to an empirically validated instrument for assessing your attachment style (labeled there as a “quiz”) [319]. They also provide a list, based on the work of Dr. Jeffrey Young et al., of common maladaptive schemas caused by insecure attachment [320].
- Therapists Uncensored, a podcast where two therapists discuss many aspects of attachment theory with guests who include experts in the field [174].

Appendix D

Self-Determination Theory

Self-Determination Theory (SDT) is a theory of human motivation and behavior, positing that people have innate psychological needs, and satisfying these needs leads to better mental well-being and performance [76]. Many studies across cultures, age groups, and domains (education, work, sports, health, etc.) have examined and supported its principles. We think contemplating how these needs have or have not been fulfilled in your life may uncover maladaptive schemas.

The three fundamental psychological needs identified in SDT are:

- **Autonomy** The need to feel in control of one's actions and choices. It's not about being independent, but rather about feeling that one's behavior is self-endorsed and congruent with personal values and interests.
- **Competence** The need to feel effective and capable in one's activities. It involves mastering tasks, gaining new skills, and feeling a sense of growth in one's capacities.
- **Relatedness** The need to feel connected to others, to care for and be cared for by others, and to feel that one belongs with others. It emphasizes the importance of relationships and emotional connections with peers, family, and the broader community.

For more information, see *The “What” and “Why” of Goal Pursuits: Human Needs and the Self-Determination of Behavior* by Edward Deci Ph.D. and Richard Ryan Ph.D. [76].

Appendix E

Life Changes for Improved Mental Health

There is a great deal of low-quality evidence that a variety of lifestyle changes improve mental health. Almost none of this research involved adequately blinded trial participants, so the reported effects of these interventions could easily be nothing but bias. However, they are generally low-risk and well known to have other positive effects. Note that mental health is highly complex and situation-dependent and average effects in trials don't necessarily guarantee any particular intervention will help you with your particular solution.

Physical Habits:

- Stopping or reducing regular use of harmful substances.
- Physical activity significantly improves mental health [279]. Additionally, aerobic exercise decreases the risk for many chronic illnesses [194] and whole-body muscle strengthening decreases risk of acute and chronic injuries [190]. We suggest Low [204] or working with a physical therapist.
- High sleep quality (defined as feeling well-rested in the morning, low number of awakenings, and quick sleep-onset) is important for mental health [292]. *Cognitive Behavioral Therapy for Insomnia* has excellent high-quality evidence. Stanford Medicine has a guide [308]. Melatonin is safe and might help [234]. It's efficacy for sleep disorders without comorbid mental illness is well-established, but it is poorly studied for sleep disorders caused by mental-illness. The UK National Health Service recommends starting with a 2 mg extended/slow release pill taken 1–2 hours before bed [239].
- We are not aware of any quality evidence on the topic, but think it's plausible that air pollution worsens mental health because it causes a variety of other health problems [82]. Air filters can help, and additionally reduce disease transmission. Clean Air Kits [61] provides filters with the best cost, noise, and performance in 2025.

Relationships:

- Healthy relationships improve mental and physical health [155]. The structure of our societies and culture often make forming healthy relationships difficult. We suggest making relationships a higher priority in your life through, for instance, co-living, co-working, volunteering, or seeking romantic, artistic, or business partnerships.
- Understanding when and why people change their minds about things may reduce unnecessary conflict and help you foster healthier beliefs in your community. We suggest *How Minds Change: The Surprising Science of Belief, Opinion, and Persuasion* by David McRaney.
- Emotional attunement is an important skill for trust in relationships [133]. See *The Science of Trust, Emotional Attunement for Couples* by John Gottman, Ph.D. It is useful for all kinds of close relationships, not just romantic couples.
- Accountability (and forgiveness if that feels right for you) for one's own and other's actions is important for healthy communities. We suggest Mingus [229], Barnard Center for Research on Women [26], and Gottman [133].

Introspection and Self-Improvement:

- Carefully consider the things you own. Which ones really make you happy? Which ones would you be better off without? Marie Kondo's methods for doing this are quite popular.
- There is low-quality evidence that journaling improves mental health [305].
- Mindfulness meditation improves mental health [136].
- Consider how you cope with stress. Which behaviors are healthy for you and those around you? Which aren't?

Appendix F

Autobiographical Accounts of Internalized MDMA Therapy

The following is Mark Groeneveld's report of their own unusual experience with MDMA therapy. Psychedelics experiences are famously prone to strangeness, and we wanted to include at least one illustration of how this can play out, at least in one instance. We note that, despite Mark being the primary author of this book, their interpretations of their experiences may be flawed or mis-remembered. We are also not aware of any other instances of this particular experience resulting from MDMA, so it might be rare.

My first MDMA session (none of the latter sessions were like this) consisted of seemingly-perfect safety and all-encompassing compassion. I comprehended how everyone's maladaptive reactions were due to a variety of learned, no-longer-helpful fears. I also felt that I had a well of inviolable safety inside me so strong I thought I would feel ok (representing emotional resilience, not a lack of empathy) inside even if watched everyone and everything I had ever loved burn to ash in front of me. There was a certain week, after perhaps 10 sessions over two years, when I went walking to deliberately feel my anxiety. At that particular time it felt very good to feel my anxiety for some reason I no longer clearly recall. It was exhausting, and I needed to lay in bed for quite a while afterward to recover. Later I identified this exhaustion as therapy-hangover. That week of walking-reconsolidation is the earliest example I recall of reconsolidation that just "happened" with no deliberate effort or conscious control on my part.

A year or so later after about session 20, I read [306] describing the process of coherence therapy and wanted to try the process on myself. I thought my first MDMA experience of a well of inviolable safety was the obvious choice for a [mismatch](#) for my fear schemas. I activated that knowledge by imagining laying under the tree I was under that first time, how the grass felt on my feet, how the tree trunk felt in my hands. That multisensory visualization seemed to do the trick and activated the well-of-inviolable-safety knowledge strongly enough to start the reconsolidation process. I don't quite recall, but this may have only worked in the two weeks following an MDMA session. It might have taken another 5 MDMA sessions to extend the process past two weeks, at which point

I stopped MDMA therapy as it seemed redundant, and I had some in-hindsight overblown fears about side effects.

My mental illness was quite bad, so I was anxious to do however much reconsolidation was necessary to fix my issues in as short a time as possible. I spent a couple of hundred hours doing coherence therapy with this knowledge of inviolable safety, which seemed to be powerful enough to reconsolidate any maladaptive schema, just like MDMA. I was limited to two hours a day by therapy-hangover. Eventually I had practiced this process so much that I no longer had to explicitly recall that knowledge of inviolable safety to reconsolidate a maladaptive schema. Any time I noticed a distressing schema I could just “flip a switch” in my mind and start the reconsolidation process. This practice didn’t seem to be limited by the typical [window of tolerance](#) either; it worked equally well during [dissociation](#) and near-overwhelming anxiety.

Then after a further 300 hours of that, reconsolidation seems to have started happening without conscious intent whenever a maladaptive schema is strongly activated, and I’m not actively avoiding it. It can happen when I’m watching TV, talking to people, or any number of other activities. I can tell when it’s happening, but if I’m sufficiently distracted I might not notice. The reconsolidation process seems to be activated by fear; the more afraid I am the higher the intensity of reconsolidation. If I want to turn up the intensity of reconsolidation I can also still deliberately “flip the switch.”

So far I’ve done about 1100 hours of reconsolidation over the past 2 years. It’s made a lot of progress working through my backlog of maladaptive schemas, and I’m much less neurotic than when I started. I started with a truly vast amount of maladaptive fears though, so I have a lot to work through still. It’s been incredibly convenient for doing extremely large amounts of therapy without needing a therapist, MDMA, or the overhead of doing an explicit process of understanding my maladaptive schemas, figuring out a mismatch for each one, and then setting up the juxtaposition. It’s kept me making therapeutic progress through periods of despair and depression where I surely wouldn’t have had the capacity for any sort of typical therapy.

The only downside I have noticed is that since I have multiple deep maladaptive fears activated virtually every waking moment (I think this is an effect of having virtually zero early childhood attachment), the auto-reconsolidation also starts running every morning once I wake up enough. That inevitably leads to therapy-hangover a bit later. Then the auto-reconsolidation starts up again once the therapy-hangover wears off. I’ve been therapy hungover a majority of my waking hours for the past two years. I also haven’t discovered any way to turn the auto-reconsolidation process off. It goes for about 2 hours a day, limited only by therapy-hangover. Other than “flipping the switch” to increase reconsolidation intensity, the only control I seem to have over the process is that more strongly activating (triggering myself) a certain schema causes auto-reconsolidation to preferential reconsolidate that schema over my other activated maladaptive schemas. This has been unsettling, but I haven’t noticed any unambiguous side effects yet other than therapy-hangover, with one exception.

One day, at the point in this process where I had done maybe 600 hours of reconsolidation, I was riding my bicycle and suddenly felt my sense of self dissolve. My thoughts, awareness, and the external world all felt part of the same unitive experience, no longer divided into self and not-self. This wasn't a dissociative experience, I was still deeply in touch with "my" body, emotions, and sensory experience, and could function appropriately. It seemed like a classic experience of [non-dual](#) awareness. The effects waxed and waned over a few months, and brought up a lot of distress about clearly seeing my sense of self as an impermanent construction of my mind, more directly confronting the fact of my eventual death, and a variety of other uncomfortable realizations. Luckily, my auto-reconsolidation process successfully reconsolidated all that distress too. The sense of self settled into a stable, possibly diminished state that became a new and unremarkable normal that doesn't seem accompanied by any dysfunction. Looking back, the event seems like an uncomfortable bump on the road, with neither the old nor new state obviously better than the other. However, that ambivalence might arise from an inability to compare the two stable states, separated by many months, side-by-side. In any case, the auto-reconsolidation capacity seems valuable enough to have made the distress of this experience easily worth it in the long run for me.

That experience makes me think the initial inviolable-well-of-safety experience was at least partially a non-dual experience, though it didn't feel like my sense of self was dissolving at the time. I suspect that experience became deeply internalized because it accurately predicted reality in some way. As Ecker [88] stated: "When two mutually contradictory schemas are juxtaposed consciously, the schema that more comprehensively or credibly models reality, and therefore more usefully predicts how the world will behave, reveals the other schema to be false, and the falsified one is immediately transformed [reconsolidated] accordingly." So presumably, inviolable-well-of-inner-safety, while not necessarily representing absolute truth, is more true (at least in the context of my personal lived experience) than my previous set of beliefs that did not include an inviolable well of inner safety. I don't have any metaphysical, ontological, or epistemological insight as to what this means. I also want to note that the initial experience didn't seem sufficient on its own to [destabilize](#) my sense of self. That seems to have required re-activating that knowledge for 600 hours.

I suspect reconsolidation is also occasionally happening during dreams. Once in a while I feel exhausted in a way similar to therapy-hangover when I wake up. Sometimes when that happens I recall dreaming about my usual fears immediately prior to waking up and feeling exhausted.

Around hour 1100 I decided to try MDMA again. I was in a particularly tough place and was wondering if I had been wrong about MDMA being redundant with auto-reconsolidation. The session went well. It felt easier to clearly notice what maladaptive schemas were activated, and I have a general, though vague, sense that it added a decent amount of therapeutic efficiency to my regular process. I plan to do it again.

The next report is from another person, listed here as anonymous (A) for privacy. Mark (M) interviewed them. The interview was casual and didn't use any of the formal bias-reduction techniques often used in qualitative data gathering. The interviewee explicitly consented to their answers being published in this document.

Appendix G

Suggested Avenues of Future Research

Many recommendations for further research are well-understood. Here are a few that we think would be valuable but have not seen anywhere else:

- What is the irreducible set of emotional/cognitive states that MDMA induces? It seems to induce love, safety, emotional empathy, connection, and sociability. Are those reducible to some smaller set of fundamental states? Regan et al. [270] also proposes this question, but we think it's worth restating.
- What is the nature of [reconsolidation exhaustion](#) (therapy hangover)? Can the capacity be safely increased? That would enable more productive MDMA therapy sessions, which are often limited by reconsolidation exhaustion.
- MG and others have reported increased capacity to achieve reconsolidation while sober in a way that is phenomenologically and consequentially similar to what is experienced during MDMA therapy sessions. This appears to be connected to extensive prior MDMA therapy. How does this work? What are its effects?
- Where do solo MDMA therapy and professionally guided MDMA therapy fit on the mental health treatment Pareto Frontier of cost, effectiveness, and safety?
- Why does MDMA seem to provide prediction error for most, if not all maladaptive schemas, but not the adaptive ones?
- How can therapists best prepare their clients for solo at-home sessions (e.g. for sex therapy)?
- How long does tolerance to MDMA last?
- Gain a better understanding of which side effects are part of the therapeutic process and which aren't.
- Some maladaptive schemas seem to activate other maladaptive schemas. It's conceivable that one could resolve multiple maladaptive schemas at once by reconsolidating the "root" schema. In such a case the other maladaptive schemas may still exist, but may not be an issue anymore because they are never activated. This seems valuable

but would probably require understanding the relevant schemas and their relationships with each other. We don't know to what degree such a process is theoretically possible or achievable or time-efficient in practice. We also don't know whether MDMA, as a facilitator of seemingly-universal prediction error for all maladaptive schemas, can be used to precision-target a single schema in a stack of simultaneously-activating maladaptive schemas. Using specific sources of prediction error, as is often done in regular therapy, may be more useful for targeting a single schema.

- Who is most at risk of destabilization and symptom worsening?
- What biological or medical reasons might cause MDMD therapy to not work for some people?
- Therapy is a process of moving from the client's current position in the near-infinite dimensional schema/environment state-space to a near-optimal position. It's conceivable that different paths between these two states are possible. How possible or practical is it to plot and follow the shortest-distance reconsolidation path?
- We are not clear why MDMA therapy facilitates prediction error for some schemas but not others, and why the schemas it tends to reconsolidate are casually or therapeutically identifiable as "maladaptive." We also do not understand what exactly "maladaptive" means in this context. A process can only be adaptive or maladaptive in relation to a goal or optimization function. Predictive processing posits that the brain's fundamental optimization function is minimization of prediction error, but it remains to be seen which particular sources of prediction error that function contains in most people [57]. Some near-immutable intrinsic sources of prediction error for almost everyone may include hunger, thirst, pain, companionship, etc., and the future fulfillment of these. We don't know if MDMA therapy optimizes your schemas according to your existing set of fundamental errors, or to some MDMA-modified set.

Bibliography

- Aaronson, S. T., van der Vaart, A., Miller, T., LaPratt, J., Swartz, K., Shoultz, A., Lauterbach, M., Sackeim, H. A., & Suppes, T. (2024). Single-dose synthetic psilocybin with psychotherapy for treatment-resistant bipolar type II major depressive episodes: A nonrandomized open-label trial. *JAMA Psychiatry*, 81(6), 555–562. DOI: [10.1001/jamapsychiatry.2023.4685](https://doi.org/10.1001/jamapsychiatry.2023.4685).
- Aboujaoude, E. (2020). Where life coaching ends and therapy begins: Toward a less confusing treatment landscape. *Perspectives on Psychological Science*, 15(4), 973–977. DOI: [10.1177/1745691620904962](https://doi.org/10.1177/1745691620904962).
- Aday, J. S., Heifets, B. D., Pratscher, S. D., Bradley, E., Rosen, R., & Woolley, J. D. (2022). Great expectations: Recommendations for improving the methodological rigor of psychedelic clinical trials. *Psychopharmacology*, 239(6), 1989–2010. DOI: [10.1007/s00213-022-06123-7](https://doi.org/10.1007/s00213-022-06123-7).
- Aguirre, N., Barrionuevo, M., Ramírez, M. J., Del Río, J., & Lasheras, B. (1999). α -lipoic acid prevents 3,4-methylenedioxy-methamphetamine (MDMA)-induced neurotoxicity. *Neuroreport*, 10(17), 3675–3680. DOI: [10.1097/00001756-199911260-00039](https://doi.org/10.1097/00001756-199911260-00039).
- Aizenbud, I., Audette, N., Auksztulewicz, R., Basiński, K., Bastos, A. M., Berry, M., Canales-Johnson, A., Choi, H., Clopath, C., Cohen, U., Costa, R. P., Filippio, R. D., Doronin, R., Errington, S. P., Gavornik, J. P., Gillon, C. J., Granier, A., Hamm, J. P., Hertäg, L., ... Xiong, Y. S. (2025). *Neural mechanisms of predictive processing: A collaborative community experiment through the openscope program*. DOI: [10.48550/arXiv.2504.09614](https://doi.org/10.48550/arXiv.2504.09614).
- Alavi, S. S., Ferdosi, M., Jannatifard, F., Eslami, M., Alaghemandan, H., & Setare, M. (2012). Behavioral addiction versus substance addiction: Correspondence of psychiatric and psychological views. *International journal of preventive medicine*, 3(4), 290. URL: ncbi.nlm.nih.gov/pmc/articles/PMC3354400/pdf/IJPVM-3-290.pdf.
- Alexander, M. (2022). *The new jim crow: Mass incarceration in the age of colorblindness*. The New Press.
- Alexander, S. (2017). Book review: Surfing uncertainty. URL: slatestarcodex.com/2017/09/05/book-review-surfing-uncertainty.
- Alexander, S. (2018). Navigating and/or avoiding the inpatient mental health system. URL: slatestarcodex.com/2018/03/22/navigating-and-or-avoiding-the-inpatient-mental-health-system/.
- Alexander, S. (2019a). Lots of people going around with mild hallucinations all the time. URL: slatestarcodex.com/2019/09/11/lots-of-people-going-around-with-mild-hallucinations-all-the-time.

- Alexander, S. (2019b). Mental mountains. URL: slatestarcodex.com/2019/11/26/mental-mountains.
- Alexander, S. (2021a). The precision of sensory evidence. URL: astralcodexten.com/p/the-precision-of-sensory-evidence.
- Alexander, S. (2021b). Trapped priors as a basic problem of rationality. URL: astralcodexten.com/p/trapped-priors-as-a-basic-problem.
- Alexianer St. Hedwig Hospital. (2024). Integrating difficult experiences. URL: alexianer-berlin-hedwigkliniken.de/st-hedwig-krankenhaus/leistungen/ambulante-behandlung/ambulanz-psychedelische-substanzen.
- Aliko, S., Wang, B., Small, S. L., & Skipper, J. I. (2023). *The entire brain, more or less, is at work: 'language regions' are artefacts of averaging*. DOI: [10.1101/2023.09.01.555886](https://doi.org/10.1101/2023.09.01.555886).
- Alves, E., Binienda, Z., Carvalho, F., Alves, C., Fernandes, E., de Lourdes Bastos, M., Tavares, M., & Summavielle, T. (2009). Acetyl-L-carnitine provides effective in vivo neuroprotection over 3,4-methylenedioxymethamphetamine-induced mitochondrial neurotoxicity in the adolescent rat brain. *Neuroscience*, 158(2), 514–523. DOI: [10.1016/j.neuroscience.2008.10.041](https://doi.org/10.1016/j.neuroscience.2008.10.041).
- American Association of Sex Educators, Counselors, and Therapists. (2014). Position on touch and the AASECT certified professional. URL: aasect.org/position-touch-and-aasect-certified-professional.
- Andrade, C. (2022). The practical importance of half-life in psychopharmacology. *The Journal of Clinical Psychiatry*, 83(4), 41940. DOI: [10.4088/JCP.22f14584](https://doi.org/10.4088/JCP.22f14584).
- Andrews, K., Birch, J., Sebo, J., & Sims, T. (2024). Background to the New York declaration on animal consciousness. URL: nydeclaration.com.
- Argyri, E. K., Krecké, J., Robinson, O. C., Evans, J., Skragge, M., & Morgan, C. J. (2025). *Practitioner perspectives on extended difficulties and optimal support strategies following psychedelic experiences: A qualitative analysis*. DOI: [10.21203/rs.3.rs-6303856](https://doi.org/10.21203/rs.3.rs-6303856).
- Arnovitz, M. D., Spitzberg, A. J., Davani, A. J., Vadhan, N. P., Holland, J., Kane, J. M., & Michaels, T. I. (2022). MDMA for the treatment of negative symptoms in schizophrenia. *Journal of Clinical Medicine*, 11(12), 3255. DOI: [10.3390/jcm11123255](https://doi.org/10.3390/jcm11123255).
- Arshad, M. (2024). Struggling telehealth company exploited adderall sales for profit, prosecutors say. URL: usatoday.com/story/news/nation/2024/06/13/telehealth-execs-arrested-100-million-fraud-adhd/74091441007.
- Askell, A. (2021). Self-serving utilitarian arguments. URL: askell.blog/self-serving-utilitarian-arguments.
- Atila, C., Straumann, I., Vizeli, P., Beck, J., Monnerat, S., Holze, F., Liechti, M. E., & Christ-Crain, M. (2024). Oxytocin and the role of fluid restriction in MDMA-induced hyponatremia: A secondary analysis of 4 randomized clinical trials. *JAMA Network Open*, 7(11), e2445278–e2445278. DOI: [10.1001/jamanetworkopen.2024.45278](https://doi.org/10.1001/jamanetworkopen.2024.45278).
- Australian Psychological Society. (2024). Explaining thought-terminating clichés and why we should be wary of them. URL: psychology.org.au/about-us/news-and-media/aps-in-the-media/2024/explaining-thought-terminating-cliches-and-why-we.
- Barnard Center for Research on Women. (2020). Building accountable communities. URL: bcrw.barnard.edu/building-accountable-communities.

- Barsky, A. E., & Spadola, C. E. (2023). Licensing investigations: Suggestions from social workers who received sanctions. *Social Work Research*, 47(2), 135–148. DOI: [10.1093/swr/svad002](https://doi.org/10.1093/swr/svad002).
- Bartov, S. L. (2023). BetterHelp patients furious at 'sketchy' therapists. URL: [newsweek.com/betterhelp-patients-tell-sketchy-therapists-1762849](https://www.newsweek.com/betterhelp-patients-tell-sketchy-therapists-1762849).
- Bathje, G. J., Majeski, E., & Kudowor, M. (2022). Psychedelic integration: An analysis of the concept and its practice. *Frontiers in Psychology*, 13. DOI: [10.3389/fpsyg.2022.824077](https://doi.org/10.3389/fpsyg.2022.824077).
- Bedi, G., Hyman, D., & de Wit, H. (2010). Is ecstasy an 'empathogen'? effects of 3,4-methylenedioxymethamphetamine on prosocial feelings and identification of emotional states in others. *Biological Psychiatry*, 68(12), 1134–1140. DOI: [10.1016/j.biopsych.2010.08.003](https://doi.org/10.1016/j.biopsych.2010.08.003).
- Berro, L. F., Shields, H., Odabas-Geldiay, M., Rothbaum, B. O., Andersen, M. L., & Howell, L. L. (2018). Acute effects of 3,4-methylenedioxymethamphetamine (MDMA) and R (-) MDMA on actigraphy-based daytime activity and sleep parameters in rhesus monkeys. *Experimental and clinical psychopharmacology*, 26(4), 410. DOI: [10.1037/pha0000196](https://doi.org/10.1037/pha0000196).
- Better Business Bureau. (2024a). Complaints for BetterHelp. URL: bbb.org/us/ca/mountain-view/profile/psychologist-referral-service/betterhelp-1216-262454/complaints.
- Better Business Bureau. (2024b). Customer reviews for Talkspace. URL: bbb.org/us/ny/new-york/profile/mental-health-services/talkspace-0121-149740/customer-reviews.
- Biaggio, M., Duffy, R., & Staffelbach, D. F. (1998). Obstacles to addressing professional misconduct. *Clinical psychology review*, 18(3), 273–285. DOI: [10.1016/S0272-7358\(97\)00109-8](https://doi.org/10.1016/S0272-7358(97)00109-8).
- Bonanno, G. A. (2008). Loss, trauma, and human resilience: Have we underestimated the human capacity to thrive after extremely aversive events? *Psychological Trauma: Theory, Research, Practice, and Policy*. DOI: [10.1037/1942-9681.S.1.101](https://doi.org/10.1037/1942-9681.S.1.101).
- Bonanno, G. A. (2021). The resilience paradox. *European Journal of Psychotraumatology*, 12(1), 1942642. DOI: [10.1080/20008198.2021.1942642](https://doi.org/10.1080/20008198.2021.1942642).
- Brach, T. (2023). Feeling overwhelmed? try the RAIN meditation. URL: mindful.org/tara-brach-rain-mindfulness-practice.
- Brewer, J. (2024). The habit mapper. URL: drjud.com/wp-content/uploads/2021/03/Unwinding-Anxiety-Habit-Mapper-from-DrJud-1-1.pdf.
- Briggs, R. (2025). Can we trust social science yet? URL: asteriskmag.com/issues/10/can-we-trust-social-science-yet.
- Brigman, G., Lane, D., Switzer, D., Lane, D., & Lawrence, R. (1999). Teaching children school success skills. *The Journal of Educational Research*, 92(6), 323–329. DOI: [10.1080/00220679909597615](https://doi.org/10.1080/00220679909597615).
- Britton, W. (2018). Dissociation and hyperarousal. URL: cheetahhouse.org/hyperarousal-and-dissociation.
- Brown, B. (2007). *I thought it was just me (but it isn't): Telling the truth about perfectionism, inadequacy, and power*. Avery.
- Brown, B. (2015). *Daring greatly: How the courage to be vulnerable transforms the way we live, love, parent, and lead*. Penguin.
- Brown, D. P., & Elliott, D. S. (2016). *Attachment disturbances in adults: Treatment for comprehensive repair*. WW Norton & Co.

- Brown, J. (2020). *Ethical transgressions and boundary violations in ayahuasca healing contexts: A mixed methods study*. California Institute of Integral Studies.
- Brunt, T. M., Koeter, M. W., Niesink, R. J., & van den Brink, W. (2012). Linking the pharmacological content of ecstasy tablets to the subjective experiences of drug users. *Psychopharmacology*, 220, 751–762. DOI: [10.1007/s00213-011-2529-4](https://doi.org/10.1007/s00213-011-2529-4).
- Buchanan, B., Bartholomew, E., Smyth, C., & Hegarty, D. (2024). A comprehensive questionnaire for schemas related to psychopathology: The maladaptive schema scale - version 1.4 (MSSv1.4). DOI: [10.17605/OSF.IO/C3UPR](https://doi.org/10.17605/OSF.IO/C3UPR).
- Burbea, R. (2014). *Seeing that frees: Meditations on emptiness and dependent arising*. Hermes Amāra Publications.
- Calder, A. E., Diehl, V. J., & Hasler, G. (2025). Current topics in behavioral neurosciences. Springer Berlin Heidelberg. DOI: [10.1007/7854_2025_579](https://doi.org/10.1007/7854_2025_579).
- Carhart-Harris, R. L., & Friston, K. J. (2019). REBUS and the anarchic brain: Toward a unified model of the brain action of psychedelics. *Pharmacological reviews*, 71(3), 316–344. DOI: [10.1124/pr.118.017160](https://doi.org/10.1124/pr.118.017160).
- Carhart-Harris, R. L., Murphy, K., Leech, R., Erritzoe, D., Wall, M. B., Ferguson, B., Williams, L. T., Roseman, L., Brugger, S., De Meer, I., Tanner, M., Tyacke, R., Wolff, K., Sethi, A., Bloomfield, M. A., Williams, T. M., Bolstridge, M., Stewart, L., Morgan, C., ... Nutt, D. J. (2015). The effects of acutely administered 3,4-methylenedioxymethamphetamine on spontaneous brain function in healthy volunteers measured with arterial spin labeling and blood oxygen level-dependent resting state functional connectivity. *Biological Psychiatry*, 78(8), 554–562. DOI: [10.1016/j.biopsych.2013.12.015](https://doi.org/10.1016/j.biopsych.2013.12.015).
- Carhart-Harris, R. L., & Nutt, D. J. (2010). User perceptions of the benefits and harms of hallucinogenic drug use: A web-based questionnaire study. *Journal of Substance Use*, 15(4), 283–300. DOI: [10.3109/14659890903271624](https://doi.org/10.3109/14659890903271624).
- Carr, R. (2011). The end of coaching as we knew it. URL: [linkedin.com/pulse/end-coaching-we-knew-rey-carr](https://www.linkedin.com/pulse/end-coaching-we-knew-rey-carr).
- Cashwell, C. S., Bentley, P. B., & Yarborough, J. P. (2007). The only way out is through: The peril of spiritual bypass. *Counseling and Values*, 51(2), 139–148. DOI: [10.1002/j.2161-007X.2007.tb00071.x](https://doi.org/10.1002/j.2161-007X.2007.tb00071.x).
- Celenza, A. (2024). Sexual boundary violations. URL: andreacelenza.com/sexual-boundary-violations.
- Cheetah House. (2024). Resources and support for adverse meditative experiences. URL: cheetahhouse.org.
- Clark, A. (2015). *Surfing uncertainty: Prediction, action, and the embodied mind*. Oxford University Press.
- Clark, A. (2024). *The experience machine: How our minds predict and shape reality*. Random House.
- Clark, J. E., Watson, S., & Friston, K. J. (2018). What is mood? a computational perspective. *Psychological Medicine*, 48(14), 2277–2284. DOI: [10.1017/S0033291718000430](https://doi.org/10.1017/S0033291718000430).
- Clauwaert, K. M., Van Bocxlaer, J. F., & De Leenheer, A. P. (2001). Stability study of the designer drugs 'MDA, MDMA and MDEA' in water, serum, whole blood, and urine under various storage temperatures. *Forensic Science International*, 124, 36–42. DOI: [10.1016/S0379-0738\(01\)00562-X](https://doi.org/10.1016/S0379-0738(01)00562-X).

- Clean Air Kits. (2025). Taking charge of air quality. URL: cleanairkits.com/pages/mission.
- Coase, R. H. (1960). The problem of social cost. *The Journal of Law and Economics*, 3, 1–44. DOI: [10.1086/466560](https://doi.org/10.1086/466560).
- Cohen, B. M., & Öngür, D. (2023). The need for evidence-based updating of ICD and DSM models of psychotic and mood disorders. *Molecular Psychiatry*, 28(5), 1836–1838. DOI: [10.1038/s41380-023-01967-7](https://doi.org/10.1038/s41380-023-01967-7).
- Cohen, R., Newton-John, T., & Slater, A. (2017). The relationship between Facebook and Instagram appearance-focused activities and body image concerns in young women. *Body image*, 23, 183–187. DOI: [10.1016/j.bodyim.2017.10.002](https://doi.org/10.1016/j.bodyim.2017.10.002).
- Coherence Psychology Institute. (2024). Coherence Psychology Institute referral directory. URL: coherencetherapy.org/prac/directory-terms.php.
- Colbert, R., & Hughes, S. (2023). Evenings with molly: Adult couples' use of MDMA for relationship enhancement. *Culture, Medicine, and Psychiatry*, 47(1), 252–270. DOI: [10.1007/s11013-021-09764-z](https://doi.org/10.1007/s11013-021-09764-z).
- Colcott, J., Guerin, A. A., Carter, O., Meikle, S., & Bedi, G. (2024). Side-effects of MDMA-assisted psychotherapy: A systematic review and meta-analysis. *Neuropsychopharmacology*, 49, 1208–1226. DOI: [10.1038/s41386-024-01865-8](https://doi.org/10.1038/s41386-024-01865-8).
- Cooke, D. J., & Michie, C. (2001). Refining the construct of psychopathy: Towards a hierarchical model. *Psychological assessment*, 13(2), 171. DOI: [10.1037/1040-3590.13.2.171](https://doi.org/10.1037/1040-3590.13.2.171).
- DanceSafe. (2023). MDMA testing kit. URL: dancesafe.org/product/mdma-testing-kit.
- DanceSafe. (2025). Reagent drug checking instructions. URL: dancesafe.org/testing-kit-instructions.
- Danforth, A. L., Grob, C. S., Struble, C., Feduccia, A. A., Walker, N., Jerome, L., Klosinski, B., & Emerson, A. (2018). Reduction in social anxiety after MDMA-assisted psychotherapy with autistic adults: A randomized, double-blind, placebo-controlled pilot study. *Psychopharmacology*, 235(11), 3137–3148. DOI: [10.1007/s00213-018-5010-9](https://doi.org/10.1007/s00213-018-5010-9).
- Davidson, T., & Plesa, P. (2025). Break on through: Betty eisner's problematic use of psychedelics, groups, and control for integrative experiences. *Journal of the History of the Behavioral Sciences*, 61(3), e70027. DOI: [10.1002/jhbs.70027](https://doi.org/10.1002/jhbs.70027).
- De la Torre, R., Farre, M., Roset, P., López, C. H., Mas, M., Ortuno, J., Menoyo, E., Pizarro, N., Segura, J., & Cami, J. (2000). Pharmacology of MDMA in humans. *Annals of the New York Academy of Sciences*, 914(1), 225–237. DOI: [10.1111/j.1749-6632.2000.tb05199.x](https://doi.org/10.1111/j.1749-6632.2000.tb05199.x).
- De La Torre, R., Farre, M., Ortuno, J., Mas, M., Brenneisen, R., Roset, P., Segura, J., & Cami, J. (2000). Non-linear pharmacokinetics of MDMA ('ecstasy') in humans. *British journal of clinical pharmacology*, 49(2), 104–109. DOI: [10.1046/j.1365-2125.2000.00121.x](https://doi.org/10.1046/j.1365-2125.2000.00121.x).
- De La Torre, R., Yubero-Lahoz, S., Pardo-Lozano, R., & Farre, M. (2012). MDMA, methamphetamine, and cyp2d6 pharmacogenetics: What is clinically relevant? *Frontiers in Genetics*, 3. DOI: [10.3389/fgene.2012.00235](https://doi.org/10.3389/fgene.2012.00235).
- Deci, E. L., & Ryan, R. M. (2000). The "what" and "why" of goal pursuits: Human needs and the self-determination of behavior. *Psychological Inquiry*, 11(4), 227–268. DOI: [10.1207/s15327965pli1104_01](https://doi.org/10.1207/s15327965pli1104_01).
- Delgadillo, J., Deisenhofer, A.-K., Probst, T., Shimokawa, K., Lambert, M. J., & Kleinstäuber, M. (2022). Progress feedback narrows the gap between more and less effective

- therapists: A therapist effects meta-analysis of clinical trials. *Journal of Consulting and Clinical Psychology*, 90(7), 559. DOI: [doi/10.1037/ccp0000747](https://doi.org/10.1037/ccp0000747).
- den Bergh, O. V., Brosschot, J., Critchley, H., Thayer, J. F., & Ottaviani, C. (2021). Better safe than sorry: A common signature of general vulnerability for psychopathology. *Perspectives on Psychological Science*, 16(2), 225–246. DOI: [10.1177/1745691620950690](https://doi.org/10.1177/1745691620950690).
- Devenot, N. (2024). Fda announces advisory committee meeting on MDMA-assisted therapy. URL: chemicalpoetics.substack.com/p/fda-announces-advisory-committee.
- Devereux, D. (2016). Transference love and harm. URL: bacp.co.uk/bacp-journals/therapy-today/2016/september-2016/transference-love-and-harm.
- de-Wit, L., Alexander, D., Ekroll, V., & Wagemans, J. (2016). Is neuroimaging measuring information in the brain? *Psychonomic bulletin & review*, 23, 1415–1428. DOI: [10.3758/s13423-016-1002-0](https://doi.org/10.3758/s13423-016-1002-0).
- Dominski, F. H., Lorenzetti Branco, J. H., Buonanno, G., Stabile, L., Gameiro da Silva, M., & Andrade, A. (2021). Effects of air pollution on health: A mapping review of systematic reviews and meta-analyses. *Environmental Research*, 201, 111487. DOI: [10.1016/j.envres.2021.111487](https://doi.org/10.1016/j.envres.2021.111487).
- Doss, M. K., DeMarco, A., Dunsmoor, J. E., Cisler, J. M., Fonzo, G. A., & Nemeroff, C. B. (2024). How psychedelics modulate multiple memory mechanisms in posttraumatic stress disorder. *Drugs*, 84, 1419–1443. DOI: [10.1007/s40265-024-02106-4](https://doi.org/10.1007/s40265-024-02106-4).
- Droogmans, S., Cosyns, B., D’haenen, H., Creeten, E., Weytjens, C., Franken, P. R., Scott, B., Schoors, D., Kemdem, A., Close, L., et al. (2007). Possible association between 3,4-methylenedioxymethamphetamine abuse and valvular heart disease. *The American journal of cardiology*, 100(9), 1442–1445. DOI: [10.1016/j.amjcard.2007.06.045](https://doi.org/10.1016/j.amjcard.2007.06.045).
- Dunlap, B., Basye, A., & Skillman, S. M. (2021). *Background checks and the health workforce: Practices, policies and equity* (tech. rep.). UW Department of Family Medicine. URL: familymedicine.uw.edu/chws/wp-content/uploads/sites/5/2021/11/Background-Checks-FR-2021.pdf.
- Dunsmoor, J. E., Cisler, J. M., Fonzo, G. A., Creech, S. K., & Nemeroff, C. B. (2022). Laboratory models of post-traumatic stress disorder: The elusive bridge to translation. *Neuron*, 110(11), 1754–1776. DOI: [10.1016/j.neuron.2022.03.001](https://doi.org/10.1016/j.neuron.2022.03.001).
- Eaton, N. R., Bringmann, L. F., Elmer, T., Fried, E. I., Forbes, M. K., Greene, A. L., Krueger, R. F., Kotov, R., McGorry, P. D., Mei, C., et al. (2023). A review of approaches and models in psychopathology conceptualization research. *Nature Reviews Psychology*, 2(10), 622–636. DOI: [10.1038/s44159-023-00218-4](https://doi.org/10.1038/s44159-023-00218-4).
- Ecker, B. (2015). Memory reconsolidation understood and misunderstood. *International Journal of Neuropsychotherapy*, 3(1), 2–46. URL: coherencetherapy.org/files/Ecker_2015_MR-Understood-&-Misunderstood.pdf.
- Ecker, B., Ticic, R., & Hulley, L. (2024). *Unlocking the emotional brain: Memory reconsolidation and the psychotherapy of transformational change*. Taylor & Francis. DOI: [10.4324/9781003231431](https://doi.org/10.4324/9781003231431).
- Edinoff, A. N., Swinford, C. R., Odisho, A. S., Burroughs, C. R., Stark, C. W., Raslan, W. A., Cornett, E. M., Kaye, A. M., & Kaye, A. D. (2022). Clinically relevant drug interactions with monoamine oxidase inhibitors. *Health Psychology Research*, 10(4). DOI: [10.52965/2F001c.39576](https://doi.org/10.52965/2F001c.39576).

- Eisner, B. (1997). Set, setting, and matrix. *Journal of Psychoactive Drugs*, 29(2), 213–216. DOI: [10.1080/02791072.1997.10400190](https://doi.org/10.1080/02791072.1997.10400190).
- Else, J. W., van Ast, V. A., & Kindt, M. (2018). Human memory reconsolidation: A guiding framework and critical review of the evidence. *Psychological bulletin*, 144(8), 797. DOI: [10.1037/bul0000152](https://doi.org/10.1037/bul0000152).
- Emanuel, N., Welle, P., & Bolotnyy, V. (2025). *A danger to self and others: Health and criminal consequences of involuntary hospitalization* (tech. rep.). Federal Reserve Bank of New York. URL: newyorkfed.org/medialibrary/media/research/staff_reports/sr1158.pdf?sc_lang=en.
- Emde, K. (2003). MDMA (ecstasy) in the emergency department. *Journal of Emergency Nursing*, 29(5), 440–443. DOI: [10.1016/S0099-1767\(03\)00292-7](https://doi.org/10.1016/S0099-1767(03)00292-7).
- Energy Control International. (2025). Drug testing service. URL: energycontrol-international.org/drug-testing-service/submitting-a-sample.
- Engel, G. L. (1977). The need for a new medical model: A challenge for biomedicine. *Science*, 196(4286), 129–136. DOI: [10.1126/science.847460](https://doi.org/10.1126/science.847460).
- Erowid. (2024). MDMA (also ecstasy; molly; adam; e; x) reports - addiction & habituation. URL: erowid.org/experiences/subs/exp_MDMA_Addiction_Habituation.shtml.
- Escamilla, I., Juan, N., Peñalva, C., Sánchez-Llorens, M., Renau, J., Benito, A., & Haro, G. (2023). Treatment of dissociative symptoms with opioid antagonists: A systematic review. *European Journal of Psychotraumatology*, 14(2), 2265184. DOI: [10.1080/20008066.2023.2265184](https://doi.org/10.1080/20008066.2023.2265184).
- European Union Drugs Agency. (2025). EU drug market: MDMA - production. how and where MDMA is produced in Europe. URL: euda.europa.eu/publications/eu-drug-markets/mdma/production_en.
- Evans, J. (2024a). Building a psychedelic safety network. URL: ecstaticintegration.org/p/building-a-psychedelic-safety-network.
- Evans, J. (2024b). Can MDMA lead to extended difficulties? URL: ecstaticintegration.org/p/can-mdma-lead-to-extended-difficulties.
- Evans, J. (2024c). MAPS / Lykos: Who is to blame and what happens next? URL: ecstaticintegration.org/p/maps-lykos-who-is-to-blame-and-what.
- Evans, J., & Prideaux, E. (2024). Ecstatic integration. URL: ecstaticintegration.org.
- Evans, J., & Read, T. (2020). *Breaking open*. Aeon Books.
- Evans, J., Robinson, O. C., Argyri, E. K., Suseelan, S., Murphy-Beiner, A., McAlpine, R., Luke, D., Michelle, K., & Prideaux, E. (2023). Extended difficulties following the use of psychedelic drugs: A mixed methods study. *Plos one*, 18(10), e0293349. DOI: [10.1371/journal.pone.0293349](https://doi.org/10.1371/journal.pone.0293349).
- Evens, R., Schmidt, M. E., Majić, T., & Schmidt, T. T. (2023). The psychedelic after-glow phenomenon: A systematic review of subacute effects of classic serotonergic psychedelics. *Therapeutic Advances in Psychopharmacology*, 13, 20451253231172254. DOI: [10.1177/20451253231172254](https://doi.org/10.1177/20451253231172254).
- Farré, M., Tomillero, A., Pérez-Mañá, C., Yubero, S., Papaseit, E., Roset, P.-N., Pujadas, M., Torrens, M., Camí, J., & de la Torre, R. (2015). Human pharmacology of 3,4-methylenedioxymethamphetamine (MDMA, ecstasy) after repeated doses taken 4 h apart human pharmacology of MDMA after repeated doses taken 4 h apart. *European neuropsychopharmacology*, 25(10), 1637–1649. DOI: [10.1016/j.euroneuro.2015.05.007](https://doi.org/10.1016/j.euroneuro.2015.05.007).

- Feduccia, A. A., Jerome, L., Mithoefer, M. C., & Holland, J. (2021). Retracted article: Discontinuation of medications classified as reuptake inhibitors affects treatment response of MDMA-assisted psychotherapy. *Psychopharmacology*, 238(2), 581–588. DOI: [10.1007/s00213-020-05710-w](https://doi.org/10.1007/s00213-020-05710-w).
- Feduccia, A. A., Jerome, L., Mithoefer, M. C., & Holland, J. (2024). Retraction note: Discontinuation of medications classified as reuptake inhibitors affects treatment response of MDMA-assisted psychotherapy. DOI: [10.1007/s00213-024-06671-0](https://doi.org/10.1007/s00213-024-06671-0).
- Feduccia, A. A., & Mithoefer, M. C. (2018). MDMA-assisted psychotherapy for PTSD: Are memory reconsolidation and fear extinction underlying mechanisms? *Progress in Neuro-Psychopharmacology and Biological Psychiatry*, 84(A), 221–228. DOI: [10.1016/j.pnpbp.2018.03.003](https://doi.org/10.1016/j.pnpbp.2018.03.003).
- Fehr, B. (2008). Friendship formation. In S. Sprecher, A. Wenzel, & J. Harvey (Eds.), *Handbook of relationship initiation* (pp. 29–54). Psychology Press.
- Felitti, V. J., Anda, R. F., Nordenberg, D., Williamson, D. F., Spitz, A. M., Edwards, V., & Marks, J. S. (1998). Relationship of childhood abuse and household dysfunction to many of the leading causes of death in adults: The adverse childhood experiences (ACE) study. *American journal of preventive medicine*. DOI: [10.1016/S0749-3797\(98\)00017-8](https://doi.org/10.1016/S0749-3797(98)00017-8).
- Fincham, G. W., Strauss, C., Montero-Marin, J., & Cavanagh, K. (2023). Effect of breathwork on stress and mental health: A meta-analysis of randomised-controlled trials. *Scientific Reports*, 13(1), 432. DOI: [10.1038/s41598-022-27247-y](https://doi.org/10.1038/s41598-022-27247-y).
- Fireside Project. (2023). The psychedelic peer support line provides emotional support during and after psychedelic experiences. URL: firesideproject.org.
- Firth, N., Saxon, D., Stiles, W. B., & Barkham, M. (2019). Therapist and clinic effects in psychotherapy: A three-level model of outcome variability. *Journal of consulting and clinical psychology*, 87(4), 345. DOI: [10.1037/ccp0000388](https://doi.org/10.1037/ccp0000388).
- Fisher, J. (1999). The work of stabilization in trauma treatment. URL: smchealth.org/sites/main/files/file-attachments/tic_stabilize.pdf.
- Fitzcharles, M.-A., Cohen, S. P., Clauw, D. J., Littlejohn, G., Usui, C., & Häuser, W. (2021). Nociceptive pain: Towards an understanding of prevalent pain conditions. *The Lancet*, 397(10289), 2098–2110. DOI: [10.1016/S0140-6736\(21\)00392-5](https://doi.org/10.1016/S0140-6736(21)00392-5).
- Flockhard, D. (2025). Drug interactions Flockhart table. URL: drug-interactions.medicine.iu.edu/MainTable.aspx.
- Flückiger, C., Del Re, A. C., Wampold, B. E., & Horvath, A. O. (2018). The alliance in adult psychotherapy: A meta-analytic synthesis. *Psychotherapy*, 55(4), 316. DOI: [10.1037/pst0000172](https://doi.org/10.1037/pst0000172).
- Foisy, N. (2024). Is BetterHelp a scam? unpacking the truth. URL: compassitc.com/blog/is-betterhelp-a-scam-unpacking-the-truth#:~:text=What%20is%20the%20BetterHelp%20Scandal,using%20it%20for%20advertisement%20purposes.
- Forster, M., Grigsby, T. J., Rogers, C. J., & Benjamin, S. M. (2018). The relationship between family-based adverse childhood experiences and substance use behaviors among a diverse sample of college students. *Addictive behaviors*, 76, 298–304. DOI: [10.1016/j.addbeh.2017.08.037](https://doi.org/10.1016/j.addbeh.2017.08.037).

- Freidel, N., Kreuder, L., Rabinovitch, B. S., Chen, F. Y., Huang, R. S. T., & Lewis, E. C. (2024). Psychedelics, epilepsy, and seizures: A review. *Frontiers in Pharmacology*, 14. DOI: [10.3389/fphar.2023.1326815](https://doi.org/10.3389/fphar.2023.1326815).
- Friston, K. (2010). The free-energy principle: A unified brain theory? *Nature reviews neuroscience*, 11(2), 127–138. DOI: [10.1038/nrn2787](https://doi.org/10.1038/nrn2787).
- Fromson, N. (2023). When chest pain isn't a heart attack. URL: michiganmedicine.org/health-lab/when-chest-pain-isnt-heart-attack.
- Galef, J. (2021). *The scout mindset*. Penguin.
- Gard, D. E., Pleet, M. M., Bradley, E. R., Penn, A. D., Gallenstein, M. L., Riley, L. S., DellaCrosse, M., Garfinkle, E. M., Michalak, E. E., & Woolley, J. D. (2021). Evaluating the risk of psilocybin for the treatment of bipolar depression: A review of the research literature and published case studies. *Journal of Affective Disorders Reports*, 6, 100240. DOI: [10.1016/j.jadr.2021.100240](https://doi.org/10.1016/j.jadr.2021.100240).
- Gardoki-Souto, I., Redolar-Ripoll, D., Fontana, M., Hogg, B., Castro, M. J., Blanch, J. M., Ojeda, F., Solanes, A., Radua, J., Valiente-Gómez, A., et al. (2022). Prevalence and characterization of psychological trauma in patients with fibromyalgia: A cross-sectional study. *Pain Research and Management*, 2022(1), 2114451. DOI: [10.1155/2022/2114451](https://doi.org/10.1155/2022/2114451).
- Geiselman, R. E., Haight, N. A., & Kimata, L. G. (1984). Context effects on the perceived physical attractiveness of faces. *Journal of Experimental Social Psychology*, 20(5), 409–424. DOI: [10.1016/0022-1031\(84\)90035-0](https://doi.org/10.1016/0022-1031(84)90035-0).
- Gillard, S. (2019). Peer support in mental health services: Where is the research taking us, and do we want to go there? *Journal of Mental Health*, 28(4), 341–344. DOI: [10.1080/09638237.2019.1608935](https://doi.org/10.1080/09638237.2019.1608935).
- Goddard, I. (2023). What does friendship look like in America? URL: pewresearch.org/short-reads/2023/10/12/what-does-friendship-look-like-in-america.
- Godes, M., Lucas, J., & Vermetten, E. (2023). Perceived key change phenomena of MDMA-assisted psychotherapy for the treatment of severe ptsd: An interpretative phenomenological analysis of clinical integration sessions. *Frontiers in Psychiatry*, 14. DOI: [10.3389/fpsy.2023.957824](https://doi.org/10.3389/fpsy.2023.957824).
- Goldberg, S. B., Rousmaniere, T., Miller, S. D., Whipple, J., Nielsen, S. L., Hoyt, W. T., & Wampold, B. E. (2016). Do psychotherapists improve with time and experience? a longitudinal analysis of outcomes in a clinical setting. *Journal of counseling psychology*, 63(1), 1–11. DOI: [10.1037/cou0000131](https://doi.org/10.1037/cou0000131).
- Gottman, J. M. (2011). *The science of trust: Emotional attunement for couples*. WW Norton & Company.
- Gouzoulis-Mayfrank, E., & Daumann, J. (2006). Neurotoxicity of methylenedioxyamphetamines (MDMA; ecstasy) in humans: How strong is the evidence for persistent brain damage? *Addiction*, 101(3), 348–361. DOI: [10.1111/j.1360-0443.2006.01314.x](https://doi.org/10.1111/j.1360-0443.2006.01314.x).
- Gowen, K., Deschaine, M., Gruttadara, D., & Markey, D. (2012). Young adults with mental health conditions and social networking websites: Seeking tools to build community. *Psychiatric rehabilitation journal*, 35(3), 245. DOI: [10.2975/35.3.2012.245.250](https://doi.org/10.2975/35.3.2012.245.250).
- Goyal, M., Singh, S., Sibinga, E. M. S., Gould, N. F., Rowland-Seymour, A., Sharma, R., Berger, Z., Sleicher, D., Maron, D. D., Shihab, H. M., Ranasinghe, P. D., Linn, S., Saha, S., Bass, E. B., & Haythornthwaite, J. A. (2014). Meditation programs for

- psychological stress and well-being: A systematic review and meta-analysis. *JAMA Internal Medicine*, 174(3), 357–368. DOI: [10.1001/jamainternmed.2013.13018](https://doi.org/10.1001/jamainternmed.2013.13018).
- Greater Good Science Center. (2025). Walking meditation. URL: ggia.berkeley.edu/practice/walking_meditation.
- Greenspace. (2023). Brief revised working alliance inventory. URL: greenspacehealth.com/en-us/br-wai.
- Gumpper, R. H., & Nichols, D. E. (2024). Chemistry/structural biology of psychedelic drugs and their receptor(s). *British Journal of Pharmacology*. DOI: [10.1111/bph.17361](https://doi.org/10.1111/bph.17361).
- Gutheil, T. G. (1991). Patients involved in sexual misconduct with therapists: Is a victim profile possible? *Psychiatric Annals*, 21(11), 661–667. DOI: [10.3928/0048-5713-19911101-08](https://doi.org/10.3928/0048-5713-19911101-08).
- Halpern, J. H., Lerner, A. G., & Passie, T. (2018). A review of hallucinogen persisting perception disorder (HPPD) and an exploratory study of subjects claiming symptoms of HPPD. In A. L. Halberstadt, F. X. Vollenweider, & D. E. Nichols (Eds.), *Behavioral neurobiology of psychedelic drugs* (pp. 333–360). Springer Berlin Heidelberg. DOI: [10.1007/7854_2016_457](https://doi.org/10.1007/7854_2016_457).
- Halpern, J. H., Sherwood, A. R., Hudson, J. I., Gruber, S., Kozin, D., & Pope Jr, H. G. (2011). Residual neurocognitive features of long-term ecstasy users with minimal exposure to other drugs. *Addiction*, 106(4), 777–786. DOI: [10.1111/j.1360-0443.2010.03252.x](https://doi.org/10.1111/j.1360-0443.2010.03252.x).
- Harper, T. (2024). Building a nuanced understanding of social class. URL: docs.google.com/document/d/1SjQae2P8LugMJBXM3ixsbbcuRdUb4mZrwj0l_WtJ1uU/edit?usp=sharing.
- Harper, T. (2025). Thought record spreadsheet w/ instructions. URL: docs.google.com/spreadsheets/d/1AJa4fbjoGVIEsEJd1WMOctuaw4nWpTiD8enGgyVIw4.
- Harris, N. B. (2018). *The deepest well: Healing the long-term effects of childhood adversity*. Houghton Mifflin Harcourt.
- Harris, R. (2019). *ACT made simple, an easy-to-read primer on acceptance and commitment therapy*. New Harbinger Publications.
- Harrison, J. E., Weber, S., Jakob, R., & Chute, C. G. (2021). ICD-11: An international classification of diseases for the twenty-first century. *BMC medical informatics and decision making*, 21(6), 206. DOI: [10.1186/s12911-021-01534-6](https://doi.org/10.1186/s12911-021-01534-6).
- Hartogsohn, I. (2018). The meaning-enhancing properties of psychedelics and their mediator role in psychedelic therapy, spirituality, and creativity. *Frontiers in neuroscience*, 12. DOI: [10.3389/fnins.2018.00129](https://doi.org/10.3389/fnins.2018.00129).
- Hayes, A. M., & Andrews, L. A. (2020). A complex systems approach to the study of change in psychotherapy. *BMC medicine*, 18(197). DOI: [10.1186/s12916-020-01662-2](https://doi.org/10.1186/s12916-020-01662-2).
- Helmich, M. A., Schreuder, M. J., Bringmann, L. F., Riese, H., Snippe, E., & Smit, A. C. (2024). Slow down and be critical before using early warning signals in psychopathology. *Nature Reviews Psychology*, 3(11), 767–780. DOI: [10.1038/s44159-024-00369-y](https://doi.org/10.1038/s44159-024-00369-y).
- Henningsen, P., Zimmermann, T., & Sattel, H. (2003). Medically unexplained physical symptoms, anxiety, and depression: A meta-analytic review. *Psychosomatic medicine*, 65(4), 528–533. DOI: [10.1097/01.psy.0000075977.90337.e7](https://doi.org/10.1097/01.psy.0000075977.90337.e7).
- Hills, J. (2023). *Phenomenology of MDMA solo sessions* [Doctoral dissertation, Antioch University]. URL: etd.ohiolink.edu/acprod/odb_etd/ws/send_file/send?accession=antioch1690227460998206.

- Hoel, E. (2024). Neuroscience is pre-paradigmatic. consciousness is why. URL: theintrinsicperspective.com/p/neuroscience-is-pre-paradigmatic.
- Hogeveen, J., & Grafman, J. (2021). Chapter 3 - alexithymia. In K. M. Heilman & S. E. Nadeau (Eds.), *Disorders of emotion in neurologic disease* (pp. 47–62, Vol. 183). Elsevier. DOI: [10.1016/B978-0-12-822290-4.00004-9](https://doi.org/10.1016/B978-0-12-822290-4.00004-9).
- Holt-Lunstad, J., Smith, T. B., & Layton, J. B. (2010). Social relationships and mortality risk: A meta-analytic review. *PLOS Medicine*, 7(7), e1000316. DOI: [10.1371/journal.pmed.1000316](https://doi.org/10.1371/journal.pmed.1000316).
- Holze, F., Vizeli, P., Müller, F., Ley, L., Duerig, R., Varghese, N., Eckert, A., Borgwardt, S., & Liechti, M. E. (2020). Distinct acute effects of LSD, MDMA, and D-amphetamine in healthy subjects. *Neuropsychopharmacology*, 45(3), 462–471. DOI: [10.1038/s41386-019-0569-3](https://doi.org/10.1038/s41386-019-0569-3).
- Hook, J., & Devereux, D. (2018). Boundary violations in therapy: The patient's experience of harm. *BJPsych Advances*, 24(6), 366–373. DOI: [10.1192/bja.2018.26](https://doi.org/10.1192/bja.2018.26).
- Horvath, A. O., Del Re, A., Flückiger, C., & Symonds, D. (2011). Alliance in individual psychotherapy. *Psychotherapy*, 48(1), 9. DOI: [10.1037/a0022186](https://doi.org/10.1037/a0022186).
- Hughes, K., Bellis, M. A., Hardcastle, K. A., Sethi, D., Butchart, A., Mikton, C., Jones, L., & Dunne, M. P. (2017). The effect of multiple adverse childhood experiences on health: A systematic review and meta-analysis. *The Lancet public health*, 2(8), e356–e366. DOI: [10.1016/s2468-2667\(17\)30118-4](https://doi.org/10.1016/s2468-2667(17)30118-4).
- Humphry Osmond. (2004). *British Medical Journal*, 328, 713. DOI: [10.1136/bmj.328.7441.713](https://doi.org/10.1136/bmj.328.7441.713).
- Huneke, N. T. M., Fusetto Veronesi, G., Garner, M., Baldwin, D. S., & Cortese, S. (2025). Expectancy effects, failure of blinding integrity, and placebo response in trials of treatments for psychiatric disorders: A narrative review. *JAMA Psychiatry*. DOI: [10.1001/jamapsychiatry.2025.0085](https://doi.org/10.1001/jamapsychiatry.2025.0085).
- ICEERS. (2024). Assistance with challenging experiences. URL: iceers.org/support-center-2.
- Ingram, D. (2018). *Mastering the core teachings of the Buddha: An unusually hardcore dharma book-revised and expanded edition*. Red Wheel/Weiser.
- Jacobs, A. (2024). Three studies of MDMA treatment retracted by scientific journal. URL: nytimes.com/2024/08/12/health/mdma-ptsd-retractions.html.
- John Hopkins Medicine. (2024). Personalized psychiatry. URL: hopkinsmedicine.org/personalized-care/personalized-psychiatry.
- Jonas, E., & Kording, K. P. (2017). Could a neuroscientist understand a microprocessor? *PLoS computational biology*, 13(1), e1005268. DOI: [10.1371/journal.pcbi.1005268](https://doi.org/10.1371/journal.pcbi.1005268).
- Joseph, J. (2022a). HG high-level research methodology. URL: healthygamer.gg/blog/hg-high-level-research-methodology.
- Joseph, J. (2022b). The role of coaching in mental health. URL: healthygamer.gg/blog/the-role-of-coaching-in-mental-health.
- Jules, E. (2025). Are you a psychedelic cultist? URL: ecstaticintegration.org/p/are-you-a-psychedelic-cultist.
- Kabat-Zinn, J. (2023). This loving-kindness meditation is a radical act of love. URL: mindful.org/this-loving-kindness-meditation-is-a-radical-act-of-love.
- Kacanda, B. (2025). URL: bsky.app/profile/beccakacanda.bsky.social/post/3lp5tdpoeoc27.

- Kangaslampi, S., & Zijlmans, J. (2023). MDMA-assisted psychotherapy for PTSD in adolescents: Rationale, potential, risks, and considerations. *European child & adolescent psychiatry*, 33, 3753–3764. DOI: [10.1007/s00787-023-02310-9](https://doi.org/10.1007/s00787-023-02310-9).
- Karimov-Zwienenberg, M., Symphor, W., Peraud, W., & Décamps, G. (2024). Childhood trauma, PTSD/CPTSD and chronic pain: A systematic review. *PloS one*, 19(8), e0309332. DOI: [10.1371/journal.pone.0309332](https://doi.org/10.1371/journal.pone.0309332).
- Kelley, A., & Marriott, S. (2024). Therapists uncensored. URL: therapistuncensored.com.
- Kennedy, B. (2022). *Good inside: A guide to becoming the parent you want to be*. Harper-Collins.
- Kim, L. (2022). Tech accountability in face of genocide: Gambia v. Facebook. *Emory International Law Review*, 36, 165. URL: scholarlycommons.law.emory.edu/eilr/vol36/iss1/6/.
- Klaas, B. (2025). The crisis of zombie social science. URL: forkingpaths.co/p/the-crisis-of-zombie-social-science.
- Klein, E. (2020). *Why we're polarized*. Simon; Schuster.
- Klein, E. (2021). A top mental health expert on where america went wrong. URL: podcasts.apple.com/us/podcast/a-top-mental-health-expert-on-where-america-went-wrong/id1548604447.
- Kornfield, J. (1993). *A path with heart: A guide through the perils and promises of spiritual life*. Bantam.
- Kotov, R., Krueger, R. F., Watson, D., Achenbach, T. M., Althoff, R. R., Bagby, R. M., Brown, T. A., Carpenter, W. T., Caspi, A., Clark, L. A., et al. (2017). The hierarchical taxonomy of psychopathology (HiTOP): A dimensional alternative to traditional nosologies. *Journal of abnormal psychology*, 126(4), 454. DOI: [10.1037/abn0000258](https://doi.org/10.1037/abn0000258).
- Kozłowska, K., Walker, P., McLean, L., & Carrive, P. (2015). Fear and the defense cascade: Clinical implications and management. *Harvard Review of Psychiatry*, 23(4), 263. DOI: [10.1097/hrp.0000000000000065](https://doi.org/10.1097/hrp.0000000000000065).
- Kraus, E., Suter, S., Proescholdt, M., Müller, F., Liechti, M. E., Heim, M., Lang, U., & Vogel, M. (2025). Case report: Well-tolerated MDMA-assisted therapy in a 32-year old female patient with advanced alcohol-induced liver cirrhosis. *Psychiatry Research Case Reports*, 4(1), 100252. DOI: [10.1016/j.psycr.2025.100252](https://doi.org/10.1016/j.psycr.2025.100252).
- Kroenke, K. (2003). Patients presenting with somatic complaints: Epidemiology, psychiatric co-morbidity and management. *International journal of methods in psychiatric research*, 12(1), 34–43. DOI: [10.1002/mpr.140](https://doi.org/10.1002/mpr.140).
- Kykeon Analytics. (2025). Analysis service. URL: shop.kykeonlabs.com/shop/store.
- La Torre, J. T., Mahammadli, M., Faber, S. C., Greenway, K. T., & Williams, M. T. (2023). Expert opinion on psychedelic-assisted psychotherapy for people with psychopathological psychotic experiences and psychotic disorders. *International Journal of Mental Health and Addiction*, 1–25. DOI: [10.1007/s11469-023-01149-0](https://doi.org/10.1007/s11469-023-01149-0).
- Lambert, M. J., Whipple, J. L., Smart, D. W., Vermeersch, D. A., Nielsen, S. L., & Hawkins, E. J. (2001). The effects of providing therapists with feedback on patient progress during psychotherapy: Are outcomes enhanced? *Psychotherapy research*, 11(1), 49–68. DOI: [10.1080/713663852](https://doi.org/10.1080/713663852).

- Lane, R. D., Ryan, L., Nadel, L., & Greenberg, L. (2015). Memory reconsolidation, emotional arousal, and the process of change in psychotherapy: New insights from brain science. *Behavioral and Brain Sciences*, 38, e1. DOI: [10.1017/s0140525x14000041](https://doi.org/10.1017/s0140525x14000041).
- Lanius, R. A., Boyd, J. E., McKinnon, M. C., Nicholson, A. A., Frewen, P., Vermetten, E., Jetly, R., & Spiegel, D. (2018). A review of the neurobiological basis of trauma-related dissociation and its relation to cannabinoid-and opioid-mediated stress response: A transdiagnostic, translational approach. *Current Psychiatry Reports*, 20(118). DOI: [10.1007/s11920-018-0983-y](https://doi.org/10.1007/s11920-018-0983-y).
- Lauersen, J. B., Bertelsen, D. M., & Andersen, L. B. (2014). The effectiveness of exercise interventions to prevent sports injuries: A systematic review and meta-analysis of randomised controlled trials. *British Journal of Sports Medicine*, 48(11), 871–877. DOI: [10.1136/bjsports-2013-092538](https://doi.org/10.1136/bjsports-2013-092538).
- Lei, Y., He, X., Zhao, T., & Tian, Z. (2020). Contrast effect of facial attractiveness in groups. *Frontiers in Psychology*, 11. DOI: [10.3389/fpsyg.2020.02258](https://doi.org/10.3389/fpsyg.2020.02258).
- Lembke, A. (2021). *Dopamine nation: Finding balance in the age of indulgence*. Penguin.
- Leucht, S., Hierl, S., Kissling, W., Dold, M., & Davis, J. M. (2012). Putting the efficacy of psychiatric and general medicine medication into perspective: Review of meta-analyses. *British Journal of Psychiatry*, 200(2), 97–106. DOI: [10.1192/bjp.bp.111.096594](https://doi.org/10.1192/bjp.bp.111.096594).
- Lieberman, D. (2021). *Exercised: Why something we never evolved to do is healthy and rewarding*. Vintage.
- Liechti, M., & Schmid, Y. (2023). Interactions with psychedelics and MDMA. URL: saept.ch/wp-content/uploads/2024/01/Interactions-with-Psychedelics-and-MDMA-V4-6.11.23.pdf.
- Liechti, M. E. (2014). Effects of MDMA on body temperature in humans. *Temperature*, 1(3), 192–200. DOI: [10.4161/23328940.2014.955433](https://doi.org/10.4161/23328940.2014.955433).
- Liechti, M. E., Gamma, A., & Vollenweider, F. X. (2001). Gender differences in the subjective effects of MDMA. *Psychopharmacology*, 154, 161–168. DOI: [10.1007/s002130000648](https://doi.org/10.1007/s002130000648).
- Liknaitzky, P. (2024). Mental health professionals' views and experiences. *ICPR 2024*. URL: community.open-foundation.org/c/icpr-2024-recordings/sections/272721/lessons/1015845.
- Lindahl, J. R., Fisher, N. E., Cooper, D. J., Rosen, R. K., & Britton, W. B. (2017). The varieties of contemplative experience: A mixed-methods study of meditation-related challenges in western Buddhists. *PloS one*, 12(5), e0176239. DOI: [10.1371/journal.pone.0176239](https://doi.org/10.1371/journal.pone.0176239).
- Lindsay, B. (2023). B.c. psychiatrist resigns licence after patient complains of abuse during psychedelic therapy study. URL: cbc.ca/news/canada/british-columbia/b-c-psychiatrist-resigns-licence-psychedelic-therapy-study-1.6995983.
- Litjens, R., Brunt, T., Alderliefste, G.-J., & Westerink, R. (2014). Hallucinogen persisting perception disorder and the serotonergic system: A comprehensive review including new MDMA-related clinical cases. *European Neuropsychopharmacology*, 24(8), 1309–1323. DOI: [10.1016/j.euroneuro.2014.05.008](https://doi.org/10.1016/j.euroneuro.2014.05.008).
- Little, A. C., Jones, B. C., & DeBruine, L. M. (2011). Facial attractiveness: Evolutionary based research. *Philosophical Transactions of the Royal Society B: Biological Sciences*, 366, 1638–1659. DOI: [10.1098/rstb.2010.0404](https://doi.org/10.1098/rstb.2010.0404).

- Lo Iacono, L., Trentini, C., & Carola, V. (2021). Psychobiological consequences of childhood sexual abuse: Current knowledge and clinical implications. *Frontiers in Neuroscience*, 15. DOI: [10.3389/fnins.2021.771511](https://doi.org/10.3389/fnins.2021.771511).
- Low, S. (2023). R/bodyweightfitness recommended routine. URL: reddit.com/r/bodyweightfitness/wiki/kb/recommended_routine.
- Lu, O. D., White, K., Raymond, K., Liu, C., Klein, A. S., Green, N., Vaillancourt, S., Gallagher, A., Shindy, L., Li, A., Li, R., Zou, M., Wallquist, K., Casey, A. B., Cameron, L. P., Pomrenze, M. B., Sohal, V., Kheirbek, M. A., Gomez, A. M., . . . Malenka, R. C. (2025). *A multi-institutional investigation of psilocybin's effects on mouse behavior*. DOI: [10.1101/2025.04.08.647810](https://doi.org/10.1101/2025.04.08.647810).
- Lutkajtis, A. (2021). *The dark side of dharma: Meditation, madness and other maladies on the contemplative path*. Aeon Books.
- Macdonald, J., & Mellor-Clark, J. (2015). Correcting psychotherapists' blindsidedness: Formal feedback as a means of overcoming the natural limitations of therapists. *Clinical Psychology & Psychotherapy*, 22(3), 249–257. DOI: [10.1002/cpp.1887](https://doi.org/10.1002/cpp.1887).
- Magyari, T. (2016). Teaching individuals with traumatic stress. In D. McCown, D. Reibel, & M. S. Micozzi (Eds.), *Resources for teaching mindfulness: An international handbook* (pp. 339–358). Springer. DOI: [10.1007/978-3-319-30100-6_18](https://doi.org/10.1007/978-3-319-30100-6_18).
- Makunts, T., Dahill, D., Jerome, L., de Boer, A., & Abagyan, R. (2023). Concomitant medications associated with ischemic, hypertensive, and arrhythmic events in MDMA users in FDA adverse event reporting system. *Frontiers in Psychiatry*, 14. DOI: [10.3389/fpsyt.2023.1149766](https://doi.org/10.3389/fpsyt.2023.1149766).
- Makunts, T., Jerome, L., Abagyan, R., & de Boer, A. (2022). Reported cases of serotonin syndrome in MDMA users in FAERS database. *Frontiers in Psychiatry*, 12. DOI: [10.3389/fpsyt.2021.824288](https://doi.org/10.3389/fpsyt.2021.824288).
- Malcolm, B. (2025). Individual consultation. URL: spiritpharmacist.com/consultation.
- Malcolm, B., & Thomas, K. (2022). Serotonin toxicity of serotonergic psychedelics. *Psychopharmacology*, 239(6), 1881–1891. DOI: [10.1007/s00213-021-05876-x](https://doi.org/10.1007/s00213-021-05876-x).
- Marseille, E., Stauffer, C. S., & Agrawal, M. (2023). Group psychedelic therapy: Empirical estimates of cost-savings and improved access. *Frontiers in Psychiatry*, 14. DOI: [10.3389/fpsyt.2023.1293243](https://doi.org/10.3389/fpsyt.2023.1293243).
- Mastroianni, A. (2023). I'm so sorry for psychology's loss, whatever it is. URL: experimental-history.com/p/im-so-sorry-for-psychologys-loss.
- Mattick, R., Breen, C., Kimber, J., & Davoli, M. (2014). Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence. *Cochrane Database of Systematic Reviews*, (2). DOI: [10.1002/14651858.CD002207.pub4](https://doi.org/10.1002/14651858.CD002207.pub4).
- McElrath, K. (2005). MDMA and sexual behavior: Ecstasy users' perceptions about sexuality and sexual risk. *Substance use & misuse*, 40(9-10), 1461–1477. DOI: [10.1081/JA-200066814](https://doi.org/10.1081/JA-200066814).
- McGonigal, K. (2015). *The upside of stress, why stress is good for you, and how to get good at it*. Avery.
- McGovern, H., Grimmer, H., Doss, M., Hutchinson, B., Timmermann, C., Lyon, A., Corlett, P. R., & Laukkonen, R. E. (2024). An integrated theory of false insights and beliefs under psychedelics. *Communications Psychology*, 2(1), 69. DOI: [10.1038/s44271-024-00120-6](https://doi.org/10.1038/s44271-024-00120-6).

- McGuire, P., & Fahy, T. (1991). Chronic paranoid psychosis after misuse of MDMA ("ecstasy"). *BMJ: British Medical Journal*, 302(6778), 697. DOI: [10.1136/bmj.302.6778.697](https://doi.org/10.1136/bmj.302.6778.697).
- McNamee, S., Devenot, N., & Buisson, M. (2023). Studying Harms Is Key to Improving Psychedelic-Assisted Therapy—Participants Call for Changes to Research Landscape. *JAMA Psychiatry*, 80(5), 411–412. DOI: [10.1001/jamapsychiatry.2023.0099](https://doi.org/10.1001/jamapsychiatry.2023.0099).
- McRaney, D. (2022). *How minds change: The surprising science of belief, opinion, and persuasion*. Portfolio.
- Meikle, S., Carter, O., & Bedi, G. (2024). Psychedelic-assisted psychotherapy, patient vulnerability and abuses of power. *Australian & New Zealand Journal of Psychiatry*, 58(2), 104–106. DOI: [10.1177/00048674231200164](https://doi.org/10.1177/00048674231200164).
- Melamed, L., & Moss, M. K. (1975). The effect of context on ratings of attractiveness of photographs. *The Journal of Psychology*, 90(1), 129–136. DOI: [10.1080/00223980.1975.9923935](https://doi.org/10.1080/00223980.1975.9923935).
- Metzinger, T. (2024). *The elephant and the blind: The experience of pure consciousness: Philosophy, science, and 500+ experiential reports*. MIT Press.
- Miličević, M. P., Belić, S., Vraneš, M., Tot, A., Stevanović, N. R., Rakić, D., & Gadžurić, S. (2020). Volumetric properties, viscosity and taste behavior of MDMA-HCl in aqueous binary and (water+ D-lactose) ternary mixtures at different temperatures. *The Journal of Chemical Thermodynamics*, 142, 106027. DOI: [10.1016/j.jct.2019.106027](https://doi.org/10.1016/j.jct.2019.106027).
- Miller, J. (2024). When therapists lose their licenses, some turn to the unregulated life coaching industry instead. URL: propublica.org/article/utah-therapists-life-coaches-regulation.
- Miller, S., Hubble, M., & Duncan, B. (2014). The secrets of supershrinks: Pathways to clinical excellence. URL: scottdmiller.com/wp-content/uploads/2014/06/Supershrinks-Free-Report-1.pdf.
- Mingus, M. (2016). Pods and pod mapping worksheet. URL: batjc.wordpress.com/resources/pods-and-pod-mapping-worksheet.
- Mingus, M. (2019). The four parts of accountability & how to give a genuine apology. URL: leavingevidence.wordpress.com/2019/12/18/how-to-give-a-good-apology-part-1-the-four-parts-of-accountability.
- Mitchell, J. M., Bogenschutz, M., Lilienstein, A., Harrison, C., Kleiman, S., Parker-Guilbert, K., Ot'alora G., M., Garas, W., Paleos, C., Gorman, I., Nicholas, C., Mithoefer, M., Carlin, S., Poulter, B., Mithoefer, A., Quevedo, S., Wells, G., Klaire, S. S., van der Kolk, B., ... Doblin, R. (2021). MDMA-assisted therapy for severe PTSD: A randomized, double-blind, placebo-controlled phase 3 study. *Nature Medicine*, 27(6), 1025–1033. DOI: [10.1038/s41591-021-01336-3](https://doi.org/10.1038/s41591-021-01336-3).
- Mitchell, J., Ot'alora, G. M., van der Kolk, B., et al. (2023). MDMA-assisted therapy for moderate to severe PTSD: A randomized, placebo-controlled phase 3 trial. *Nat Med*. DOI: [10.1038/s41591-023-02565-4](https://doi.org/10.1038/s41591-023-02565-4).
- Mithoefer, M., & Mithoefer, A. (2021). MDMA. In C. S. Grob & J. Grigsby (Eds.), *Handbook of medical hallucinogens* (pp. 233–263). The Guilford Press.
- Mithoefer, M. C., Wagner, M. T., Mithoefer, A. T., Jerome, L., & Doblin, R. (2011). The safety and efficacy of \pm 3,4-methylenedioxymethamphetamine-assisted psychotherapy in subjects with chronic, treatment-resistant posttraumatic stress disorder: The first

- randomized controlled pilot study. *Journal of Psychopharmacology*, 25(4), 439–452. DOI: [10.1177/0269881110378371](https://doi.org/10.1177/0269881110378371).
- Moon, E., Kim, K., Partonen, T., & Linnaranta, O. (2022). Role of melatonin in the management of sleep and circadian disorders in the context of psychiatric illness. *Current psychiatry reports*, 24(11), 623–634. DOI: [10.1007/s11920-022-01369-6](https://doi.org/10.1007/s11920-022-01369-6).
- Moss, M. K., Miller, R., & Page, R. A. (1975). The effects of racial context on the perception of physical attractiveness. *Sociometry*, 38(4), 525–535. DOI: [10.2307/2786365](https://doi.org/10.2307/2786365).
- Multidisciplinary Association for Psychedelic Studies. (2022). *Mdma investigator's brochure* (tech. rep.). Multidisciplinary Association for Psychedelic Studies. URL: maps.org/wp-content/uploads/2022/03/MDMA-IB-14th-Edition-FINAL-18MAR2022.pdf.
- Mustafa, R., McQueen, B., Nikiti, D., Nhan, E., Zemlenyi, A., DiStefano, M., Kayali, Y., Richardson, M., & Rind, D. (2024). *MDMA-assisted psychotherapy for post-traumatic stress disorder: Effectiveness and value; final evidence report* (tech. rep.). Institute for Clinical and Economic Review. URL: icer.org/assessment/ptsd-2024/#overview.
- Nardou, R., Lewis, E. M., Rothhaas, R., Xu, R., Yang, A., Boyden, E., & Dölen, G. (2019). Oxytocin-dependent reopening of a social reward learning critical period with MDMA. *Nature*, 569(7754), 116–120. DOI: [10.1038/s41586-019-1075-9](https://doi.org/10.1038/s41586-019-1075-9).
- National Health Service. (2025a). How and when to take melatonin. URL: nhs.uk/medicines/melatonin/how-and-when-to-take-melatonin/.
- National Health Service. (2025b). Propranolol. URL: nhs.uk/medicines/propranolol/.
- Nickles, D., & Ross, L. K. (2021). ‘i see a sh*tshow’: Inside the world of psychedelic therapy. URL: thecut.com/2021/11/cover-story-podcast-goes-into-world-of-psychedelic-therapy.html.
- Norman, R. E., Byambaa, M., De, R., Butchart, A., Scott, J., & Vos, T. (2012). The long-term health consequences of child physical abuse, emotional abuse, and neglect: A systematic review and meta-analysis. *PLoS medicine*, 9(11), e1001349. DOI: [10.1371/journal.pmed.1001349](https://doi.org/10.1371/journal.pmed.1001349).
- Nutt, D., King, L., & Phillips, L. (2010). Drug harms in the UK: A multi-criterion decision analysis. *Lancet*, 376, 1558–1565. DOI: [10.1016/S0140-6736\(10\)61462-6](https://doi.org/10.1016/S0140-6736(10)61462-6).
- Nutt, D. J., Lingford-Hughes, A., Erritzoe, D., & Stokes, P. R. (2015). The dopamine theory of addiction: 40 years of highs and lows. *Nature Reviews Neuroscience*, 16(5), 305–312.
- Oanes, C. J., Anderssen, N., Karlsson, B., & Borg, M. (2015). How do therapists respond to client feedback? a critical review of the research literature. *Scandinavian Psychologist*, 2. DOI: [10.15714/scandpsychol.2.e17](https://doi.org/10.15714/scandpsychol.2.e17).
- Ogden, P., Pain, C., & Fisher, J. (2006). A sensorimotor approach to the treatment of trauma and dissociation. *Psychiatric Clinics*, 29(1), 263–279.
- Olthof, M., Hasselman, F., Strunk, G., Aas, B., Schiepek, G., & Lichtwarck-Aschoff, A. (2020). Destabilization in self-ratings of the psychotherapeutic process is associated with better treatment outcome in patients with mood disorders. *Psychotherapy Research*, 30(4), 520–531. DOI: [10.1080/10503307.2019.1633484](https://doi.org/10.1080/10503307.2019.1633484).
- O’Mathúna, B., Farré, M., Rostami-Hodjegan, A., Yang, J., Cuyàs, E., Torrens, M., Pardo, R., Abanades, S., Maluf, S., Tucker, G. T., et al. (2008). The consequences of 3, 4-methylenedioxymethamphetamine induced CYP2D6 inhibition in humans. *Journal of clinical psychopharmacology*, 28(5), 523–529. DOI: [10.1097/JCP.0b013e318184ff6e](https://doi.org/10.1097/JCP.0b013e318184ff6e).

- Pantic, I. (2014). Online social networking and mental health. *Cyberpsychology, Behavior, and Social Networking*, 17(10), 652–657. DOI: [10.1089/cyber.2014.0070](https://doi.org/10.1089/cyber.2014.0070).
- Parincu, Z. (2025). Grounding techniques: Definition & how to use them. URL: berkeleywellbeing.com/grounding-techniques.html.
- Parrott, A. (2005). Chronic tolerance to recreational MDMA (3,4-methylenedioxymethamphetamine) or ecstasy. *Journal of Psychopharmacology*, 19(1), 71–83. DOI: [10.1177/0269881105048900](https://doi.org/10.1177/0269881105048900).
- Passie, T. (2023). *The history of MDMA*. Oxford University Press.
- Patel, A., Moreland, T., Haq, F., Siddiqui, F., Mikul, M., Qadir, H., & Raza, S. (2011). Persistent psychosis after a single ingestion of "ecstasy"(MDMA). *The Primary Care Companion for CNS Disorders*, 13(6), 27095. DOI: [10.4088/PCC.11101200](https://doi.org/10.4088/PCC.11101200).
- PharmAla Biotech. (2025). *Mdma investigator's brochure* (tech. rep.). URL: maps.org/wp-content/uploads/2025/06/PharmAla-LaneoTM-IB_Ed4.2-_P1.1.pdf.
- Pinsof, D. (2024). The truth about self-deception. URL: optimallyirrational.com/p/the-truth-about-self-deception.
- Pittler, M., & Ernst, E. (2003). Kava extract versus placebo for treating anxiety. *Cochrane Database of Systematic Reviews*, (1). DOI: [10.1002/14651858.cd003383](https://doi.org/10.1002/14651858.cd003383).
- Poulter, B., & Ot'Alora, M. (2024). The art of simmering in MDMA-assisted therapy. URL: 2023.psychedelicscience.org/sessions/the-art-of-simmering-in-mdma-assisted-therapy/.
- Priebe, H. (2024). Attachment theory. URL: youtube.com/playlist?list=PLFD8kQWqivS1fy9uwssBE-H5M668fmtFt.
- Prochnow, T., Hartnell, L., & Patterson, M. S. (2021). Depressive symptoms, developing friendships, and social support through online gaming: A mixed-method analysis of online gaming network communication. *Mental Health and Social Inclusion*, 25(3), 243–253. DOI: [10.1108/MHSI-02-2021-0011](https://doi.org/10.1108/MHSI-02-2021-0011).
- Pryor, K. (2019). *Don't shoot the dog: The art of teaching and training*. Simon & Schuster.
- PsyAware. (2024). Need support? URL: psyaware.org/need-support.
- Psychedelic Alpha. (2023). Psychedelic legalization & decriminalization tracker. URL: psychedelicalpha.com/data/psychedelic-laws.
- Psychedelic Alpha. (2025). Patent analysis: Lykos suffers blow from USPTO as all patent claims stand finally rejected. URL: psychedelicalpha.com/news/patent-analysis-lykos-suffers-blow-from-uspto-as-all-patent-claims-stand-finally-rejected.
- Psychedelic Passage. (2023). Your network of trusted psychedelic concierges and guides. URL: psychedelicpassage.com.
- Quinn, D., Martinez, R., Cuentas, C., Hernandez-Wolfe, P., & Fine, C. (2021). Addressing abuse and repair: An open letter to the psychedelic community. URL: psychedeliccommunity.medium.com/addressing-abuse-and-repair-an-open-letter-to-the-psychedelic-community-ccf677dd92b9.
- Rachman, S. (1980). Emotional processing. *Behaviour research and therapy*, 18(1), 51–60. DOI: [10.1016/0005-7967\(80\)90069-8](https://doi.org/10.1016/0005-7967(80)90069-8).
- Razvi, S. (2022). Psychedelic somatic interactional psychotherapy. URL: youtube.com/watch?v=N20vPGFCg7M.

- Razvi, S. (2024). Why MDMA & other psychedelic therapy may not work for you (part 1). URL: psychedelicsomatic.org/post/why-mdma-psychedelic-therapy-may-not-work-for-you.
- Razvi, S., & Elfrink, S. (2020). The PSIP model. an introduction to a novel method of therapy: Psychedelic somatic interactional psychotherapy. *Journal of Psychedelic Psychiatry*, 2(3), 1–24. URL: journalofpsychedelicpsychiatry.org/_files/ugd/e07c59_d4d1db6fc0174f27bef58a6124aba50e.pdf.
- Regan, A., Margolis, S., de Wit, H., & Lyubomirsky, S. (2021). Does±3, 4-methylenedioxymethamphetamine (ecstasy) induce subjective feelings of social connection in humans? a multilevel meta-analysis. *PLoS One*, 16(10), e0258849. DOI: [10.1371/journal.pone.0258849](https://doi.org/10.1371/journal.pone.0258849).
- Reis, H. T., Wheeler, L., Spiegel, N., Kernis, M. H., Nezlek, J., & Perri, M. (1982). Physical attractiveness in social interaction: II. why does appearance affect social experience? *Journal of Personality and Social Psychology*, 43(5), 979. DOI: [10.1037/0022-3514.43.5.979](https://doi.org/10.1037/0022-3514.43.5.979).
- Rigg, K. K., & Sharp, A. (2018). Deaths related to MDMA (ecstasy/molly): Prevalence, root causes, and harm reduction interventions. *Journal of substance Use*, 23(4), 345–352. DOI: [10.1080/14659891.2018.1436607](https://doi.org/10.1080/14659891.2018.1436607).
- Riggio, R. E. (1986). Assessment of basic social skills. *Journal of Personality and social Psychology*, 51(3), 649. DOI: [10.1037/0022-3514.51.3.649](https://doi.org/10.1037/0022-3514.51.3.649).
- Robinson, O. C., Evans, J., Luke, D., McAlpine, R., Sahely, A., Fisher, A., Sundeman, S., Ketzitidou Argyri, E., Murphy-Beiner, A., Michelle, K., et al. (2024). Coming back together: A qualitative survey study of coping and support strategies used by people to cope with extended difficulties after the use of psychedelic drugs. *Frontiers in Psychology*, 15. DOI: [10.3389/fpsyg.2024.1369715](https://doi.org/10.3389/fpsyg.2024.1369715).
- Robledo, P., Balerio, G., Berrendero, F., & Maldonado, R. (2004). Study of the behavioural responses related to the potential addictive properties of MDMA in mice. *Naunyn-Schmiedeberg's archives of pharmacology*, 369, 338–349. DOI: [10.1007/s00210-003-0862-9](https://doi.org/10.1007/s00210-003-0862-9).
- Rollkit. (2023). Why use an MDMA supplement stack? URL: rollkit.net/mdma-molly-supplement-research.
- Ronca, K. E. (2018). *The impact of complex post-traumatic stress disorder and structural violence on children in impoverished urban communities* [Doctoral dissertation, Temple University]. URL: proquest.com/docview/2046909618.
- Roseman, L., Erritzoe, D., Nutt, D., Carhart-Harris, R., & Timmermann, C. (2024). Interrupting the psychedelic experience through contextual manipulation to study experience efficacy. *JAMA Network Open*, 7(7), e2422181–e2422181. DOI: [10.1001/jamanetworkopen.2024.22181](https://doi.org/10.1001/jamanetworkopen.2024.22181).
- Rosenbaum, S., Tiedemann, A., Sherrington, C., Curtis, J., & Ward, P. B. (2014). Physical activity interventions for people with mental illness: A systematic review and meta-analysis. *The Journal of Clinical Psychiatry*, 75(9), 14465. DOI: [10.4088/JCP.13r08765](https://doi.org/10.4088/JCP.13r08765).
- Roxburgh, A., Sam, B., Krikkku, P., Mounteney, J., Castanera, A., Dias, M., & Giraudon, I. (2021). Trends in MDMA-related mortality across four countries. *Addiction*, 116(11), 3094–3103. DOI: [10.1111/add.15493](https://doi.org/10.1111/add.15493).

- Ruffell, S., Netzband, N., Bird, C., Young, A. H., & Juruena, M. F. (2020). The pharmacological interaction of compounds in ayahuasca: A systematic review. *Brazilian Journal of Psychiatry*, 42(6). DOI: [10.1590/1516-4446-2020-0023](https://doi.org/10.1590/1516-4446-2020-0023).
- Ruggeri, A. (2025). Natural doesn't always mean better: How to spot if someone is trying to convince you with an 'appeal to nature'. URL: [bbc.com/future/article/20250210-the-appeal-to-nature-fallacy-why-natural-doesnt-always-mean-better](https://www.bbc.com/future/article/20250210-the-appeal-to-nature-fallacy-why-natural-doesnt-always-mean-better).
- RXList. (2020). Revia. URL: rxlist.com/revia-drug.htm.
- Saleemi, S., Pennybaker, S. J., Wooldridge, M., & Johnson, M. W. (2017). Who is 'molly'? MDMA adulterants by product name and the impact of harm-reduction services at raves. *Journal of Psychopharmacology*, 31(8), 1056–1060. DOI: [10.1177/0269881117715596](https://doi.org/10.1177/0269881117715596).
- Sarason, B. R., Sarason, I. G., Hacker, T. A., & Basham, R. B. (1985). Concomitants of social support: Social skills, physical attractiveness, and gender. *Journal of personality and social Psychology*, 49(2), 469. DOI: [10.1037/0022-3514.49.2.469](https://doi.org/10.1037/0022-3514.49.2.469).
- Sarparast, A., Thomas, K., Malcolm, B., & Stauffer, C. S. (2022). Drug-drug interactions between psychiatric medications and MDMA or psilocybin: A systematic review. *Psychopharmacology*, 239(6), 1945–1976. DOI: [10.1007/s00213-022-06083-y](https://doi.org/10.1007/s00213-022-06083-y).
- Sayādaw, M. (2016). *Manual of insight*. Wisdom Publications.
- Sazak Pinar, E., & Sucuoglu, B. (2013). The outcomes of a social skills teaching program for inclusive classroom teachers. *Educational sciences: Theory and practice*, 13(4), 2247–2261. DOI: [10.12738/estp.2013.4.1736](https://doi.org/10.12738/estp.2013.4.1736).
- Schenberg, E. (2024). *Evidence-based medicine is inadequate to develop evidence-based psychedelic therapies*. DOI: [10.31234/osf.io/rzdpn](https://doi.org/10.31234/osf.io/rzdpn).
- Schmid, Y., Vizeli, P., Hysek, C. M., Prestin, K., Zu Schwabedissen, H. E. M., & Liechti, M. E. (2016). CYP2D6 function moderates the pharmacokinetics and pharmacodynamics of 3,4-methylene-dioxymethamphetamine in a controlled study in healthy individuals. *Pharmacogenetics and genomics*, 26(8), 397–401. DOI: [10.1097/fpc.0000000000000231](https://doi.org/10.1097/fpc.0000000000000231).
- Scoboria, A., Wade, K. A., Lindsay, D. S., Azad, T., Strange, D., Ost, J., & and, I. E. H. (2017). A mega-analysis of memory reports from eight peer-reviewed false memory implantation studies. *Memory*, 25(2), 146–163. DOI: [10.1080/09658211.2016.1260747](https://doi.org/10.1080/09658211.2016.1260747).
- Scott, A. J., Webb, T. L., Martyn-St James, M., Rowse, G., & Weich, S. (2021). Improving sleep quality leads to better mental health: A meta-analysis of randomised controlled trials. *Sleep medicine reviews*, 60, 101556. DOI: [10.1016/j.smrv.2021.101556](https://doi.org/10.1016/j.smrv.2021.101556).
- Sessa, B., & Fischer, F. M. (2015). Underground MDMA-, LSD-and 2-CB-assisted individual and group psychotherapy in Zurich: Outcomes, implications and commentary. *Drug Science, Policy and Law*, 2, 2050324515578080. DOI: [10.1177/2050324515578080](https://doi.org/10.1177/2050324515578080).
- Severs, E., James, T., Letrondo, P., Løvland, L., Marchant, N. L., & Mukadam, N. (2023). Traumatic life events and risk for dementia: A systematic review and meta-analysis. *BMC geriatrics*, 23(1), 587. DOI: [10.1186/s12877-023-04287-1](https://doi.org/10.1186/s12877-023-04287-1).
- Shalaby, R. A. H., & Agyapong, V. I. (2020). Peer support in mental health: Literature review. *JMIR mental health*, 7(6), e15572. DOI: [10.2196/15572](https://doi.org/10.2196/15572).
- Shankaran, M., Yamamoto, B. K., & Gudelsky, G. A. (2001). Ascorbic acid prevents 3,4-methylenedioxymethamphetamine (MDMA)-induced hydroxyl radical formation and the behavioral and neurochemical consequences of the depletion of brain 5-HT. *Synapse*,

- 40(1), 55–64. DOI: [10.1002/1098-2396\(200104\)40:1%3C55::aid-syn1026%3E3.0.co;2-o](https://doi.org/10.1002/1098-2396(200104)40:1%3C55::aid-syn1026%3E3.0.co;2-o).
- SHINE Collective. (2024). Peer-led survivor support groups. URL: shinesupport.org/shine-support.
- Silvernale, C., Garcia-Fischer, I., & Staller, K. (2024). Relationship between psychological trauma and irritable bowel syndrome and functional dyspepsia in a joint hypermobility syndrome/ehlers–danlos syndrome patient population. *Digestive Diseases and Sciences*, 69(3), 870–875. DOI: [10.1007/s10620-023-08201-y](https://doi.org/10.1007/s10620-023-08201-y).
- Simon, K. C., Gómez, R. L., & Nadel, L. (2020). Sleep’s role in memory reconsolidation. *Current Opinion in Behavioral Sciences*, 33, 132–137. DOI: [10.1016/j.cobeha.2020.04.001](https://doi.org/10.1016/j.cobeha.2020.04.001).
- Sinback, L. (2024a). Business values. URL: libbysinback.com/values.
- Sinback, L. (2024b). How to get help. URL: makingpolyamorywork.com/episodes/how-to-get-help.
- Slime Mold Time Mold. (2025). The mind in the wheel - prologue: Everybody wants a rock. URL: slimemoldtimemold.com/2025/02/06/the-mind-in-the-wheel-prologue-everybody-wants-a-rock/.
- Smith, K. W., Sicignano, D. J., Hernandez, A. V., & White, C. M. (2022). MDMA-assisted psychotherapy for treatment of posttraumatic stress disorder: A systematic review with meta-analysis. *The Journal of Clinical Pharmacology*, 62(4), 463–471. DOI: [10.1002/jcph.1995](https://doi.org/10.1002/jcph.1995).
- Smookler, E. (2023). Beginner’s body scan meditation. URL: mindful.org/beginners-body-scan-meditation.
- Sohal, M., Singh, P., Dhillon, B. S., & Gill, H. S. (2022). Efficacy of journaling in the management of mental illness: A systematic review and meta-analysis. *Family medicine and community health*, 10(1), e001154. DOI: [10.1136/fmch-2021-001154](https://doi.org/10.1136/fmch-2021-001154).
- Sotala, K. (2019). Book summary: Unlocking the emotional brain. URL: lesswrong.com/posts/i9xyZBS3qzA8nFXNQ/book-summary-unlocking-the-emotional-brain.
- St John, G. (2018). Civilised tribalism: Burning Man, event-tribes and maker culture. *Cultural Sociology*, 12(1), 3–21. DOI: [10.1177/1749975517733162](https://doi.org/10.1177/1749975517733162).
- Stanford Medicine. (2024). Cognitive behavioral therapy for insomnia. URL: stanfordhealthcare.org/medical-treatments/c/cognitive-behavioral-therapy-insomnia/procedures.html.
- Steenen, S. A., van Wijk, A. J., van der Heijden, G. J., van Westrhenen, R., de Lange, J., & de Jongh, A. (2016). Propranolol for the treatment of anxiety disorders: Systematic review and meta-analysis. *Journal of Psychopharmacology*, 30(2), 128–139. DOI: [10.1177/0269881115612236](https://doi.org/10.1177/0269881115612236).
- Straumann, I., Avedisian, I., Klaiber, A., Varghese, N., Eckert, A., Rudin, D., Luethi, D., & Liechti, M. E. (2024). Acute effects of R-MDMA, S-MDMA, and racemic MDMA in a randomized double-blind cross-over trial in healthy participants. *Neuropsychopharmacology*, 50, 362–371. DOI: [10.1038/s41386-024-01972-6](https://doi.org/10.1038/s41386-024-01972-6).
- Strom-Gottfried, K. (1999). Professional boundaries: An analysis of violations by social workers. *Families in Society*, 80(5), 439–449. DOI: [10.1606/1044-3894.1473](https://doi.org/10.1606/1044-3894.1473).

- Studerus, E., Vizeli, P., Harder, S., Ley, L., & Liechti, M. E. (2021). Prediction of MDMA response in healthy humans: A pooled analysis of placebo-controlled studies. *Journal of Psychopharmacology*, 35(5), 556–565. DOI: [10.1177/0269881121998322](https://doi.org/10.1177/0269881121998322).
- Sulstarova, A., Scheuerlein, L., Monari, S., Seragnoli, F., Gabriel, T., Preller, K., Böge, K., Sentissi, O., Kaiser, S., Solmi, M., Kirschner, M., & Sabé, M. (2025). Treatment approaches and efficacy in psychedelic-induced psychosis: A systematic review. *Asian Journal of Psychiatry*, 104604. DOI: [10.1016/j.ajp.2025.104604](https://doi.org/10.1016/j.ajp.2025.104604).
- Tackett, J. L., Brandes, C. M., King, K. M., & Markon, K. E. (2019). Psychology's replication crisis and clinical psychological science. *Annual Review of Clinical Psychology*, 15(Volume 15, 2019), 579–604. DOI: [10.1146/annurev-clinpsy-050718-095710](https://doi.org/10.1146/annurev-clinpsy-050718-095710).
- Tagen, M., Mantuani, D., van Heerden, L., Holstein, A., Klumpers, L. E., & Knowles, R. (2023). The risk of chronic psychedelic and MDMA microdosing for valvular heart disease. *Journal of Psychopharmacology*, 37(9), 876–890. DOI: [10.1177/02698811231190865](https://doi.org/10.1177/02698811231190865).
- Tang, B., Deng, Q., Glik, D., Dong, J., & Zhang, L. (2017). A meta-analysis of risk factors for post-traumatic stress disorder (PTSD) in adults and children after earthquakes. *International journal of environmental research and public health*, 14(12), 1537. DOI: [10.3390/ijerph14121537](https://doi.org/10.3390/ijerph14121537).
- Taylor, M. J., Rosenqvist, M. A., Larsson, H., Gillberg, C., D'Onofrio, B. M., Lichtenstein, P., & Lundström, S. (2020). Etiology of Autism Spectrum Disorders and Autistic Traits Over Time. *JAMA Psychiatry*, 77(9), 936–943. DOI: [10.1001/jamapsychiatry.2020.0680](https://doi.org/10.1001/jamapsychiatry.2020.0680).
- Thal, S., Engel, L. B., & Bright, S. J. (2022). Presence, trust, and empathy: Preferred characteristics of psychedelic carers. *Journal of Humanistic Psychology*, 0(0). DOI: [10.1177/00221678221081380](https://doi.org/10.1177/00221678221081380).
- The Attachment Project. (2023). Attachment style test. URL: quiz.attachmentproject.com.
- The Attachment Project. (2024). The ultimate guide to early maladaptive schemas [full list]. URL: attachmentproject.com/blog/early-maladaptive-schemas.
- The Bump Editors. (2023). What is a birth plan and why is it important? URL: thebump.com/a/tool-birth-plan#3.
- The Challenging Psychedelic Experiences Project. (2024). Online peer support group. URL: challengingpsychedelicexperiences.com.
- The Psychedelic Experience Clinic. (2024). Psychoanalytic psychotherapy after psychedelic experiences. URL: thepsychedelicexperienceclinic.co.uk.
- The Psychedelics and Recovered Memories Project. (2024). The psychedelics and recovered memories project. URL: psychedelicsandrecoveredmemories.com.
- Toebes, B., van den Brink, W., Gresnigt, F., de Jonge, M., Kolthoff, E., & Vermetten, E. (2024). *MDMA. beyond the ecstasy* (tech. rep.). State Commission on MDMA. URL: government.nl/binaries/government/documenten/reports/2024/05/31/mdma-beyond-ecstasy/MDMA+Beyond+Ecstasy.pdf.
- Treleaven, D. A. (2018). *Trauma-sensitive mindfulness: Practices for safe and transformative healing*. WW Norton & Company.
- Trickey, D., Siddaway, A. P., Meiser-Stedman, R., Serpell, L., & Field, A. P. (2012). A meta-analysis of risk factors for post-traumatic stress disorder in children and adolescents. *Clinical Psychology Review*, 32(2), 122–138. DOI: [10.1016/j.cpr.2011.12.001](https://doi.org/10.1016/j.cpr.2011.12.001).

- Tripsit. (2025). Volumetric dosing tool. URL: volume.tripsit.me.
- Umeoka, E. H. L., van Leeuwen, J. M. C., Vinkers, C. H., & Joëls, M. (2021). The role of stress in bipolar disorder. In A. H. Young & M. F. Juruena (Eds.), *Bipolar disorder: From neuroscience to treatment* (pp. 21–39). Springer. DOI: [10.1007/7854_2020_151](https://doi.org/10.1007/7854_2020_151).
- United Nations Office on Drugs and Crime. (2014). *World drug report* (tech. rep.). United Nations Office on Drugs and Crime. URL: unodc.org/documents/wdr2014/World_Drug_Report_2014_web.pdf.
- University of Michigan Health. (2023). Stress management: Doing progressive muscle relaxation. URL: uofmhealth.org/health-library/uz2225.
- Vaiva, G., Boss, V., Bailly, D., Thomas, P., et al. (2001). An "accidental" acute psychosis with ecstasy use. *Journal of psychoactive drugs*, 33(1), 95. DOI: [10.1080/02791072.2001.10400473](https://doi.org/10.1080/02791072.2001.10400473).
- van Amsterdam, J., Brunt, T. M., Pierce, M., & van den Brink, W. (2021). Hard boiled: Alcohol use as a risk factor for MDMA-induced hyperthermia: A systematic review. *Neurotoxicity research*, 39(6), 2120–2133. DOI: [10.1007/s12640-021-00416-z](https://doi.org/10.1007/s12640-021-00416-z).
- van Elk, M., & Fried, E. I. (2023). *History repeating: Guidelines to address common problems in psychedelic science*. DOI: [10.1177/20451253231198466](https://doi.org/10.1177/20451253231198466).
- van Winkel, R., Stefanis, N. C., & Myin-Germeys, I. (2008). Psychosocial Stress and Psychosis. A Review of the Neurobiological Mechanisms and the Evidence for Gene-Stress Interaction. *Schizophrenia Bulletin*, 34(6), 1095–1105. DOI: [10.1093/schbul/sbn101](https://doi.org/10.1093/schbul/sbn101).
- van der Kolk, B. (2015). *The body keeps the score*. Penguin Books.
- Vinson, J. S. (1987). Use of complaint procedures in cases of therapist-patient sexual contact. *Professional Psychology: Research and Practice*, 18(2), 159. DOI: [10.1037/0735-7028.18.2.159](https://doi.org/10.1037/0735-7028.18.2.159).
- Vizeli, P., & Liechti, M. E. (2017). Safety pharmacology of acute MDMA administration in healthy subjects. *Journal of Psychopharmacology*, 31(5), 576–588. DOI: [10.1177/0269881117691569](https://doi.org/10.1177/0269881117691569).
- Walker, C., Donaldson, C., & Plant, M. (2021). *Global priority: Mental health* (tech. rep.). Happier Lives Institute. URL: happierlivesinstitute.org/wp-content/uploads/2022/04/Global-priority_-mental-health.pdf.
- Wampold, B. E. (2015). How important are the common factors in psychotherapy? an update. *World psychiatry*, 14(3), 270–277. DOI: [10.1002/wps.20238](https://doi.org/10.1002/wps.20238).
- Wegman, H. L., & Stetler, C. (2009). A meta-analytic review of the effects of childhood abuse on medical outcomes in adulthood. *Psychosomatic medicine*, 71(8), 805–812. DOI: [10.1097/psy.0b013e3181bb2b46](https://doi.org/10.1097/psy.0b013e3181bb2b46).
- Williams, M. H. (2000). Victimized by victims: A taxonomy of antecedents of false complaints against psychotherapists. *Professional Psychology: Research and Practice*, 31(1), 75. DOI: [10.1037/0735-7028.31.1.75](https://doi.org/10.1037/0735-7028.31.1.75).
- Wolfgang, A. S., Fonzo, G. A., Gray, J. C., Krystal, J. H., Grzenda, A., Widge, A. S., Kraguljac, N. V., McDonald, W. M., Rodriguez, C. I., & Nemeroff, C. B. (2025). MDMA and MDMA-assisted therapy. *American Journal of Psychiatry*, 182(1), 79–103. DOI: [10.1176/appi.ajp.20230681](https://doi.org/10.1176/appi.ajp.20230681).
- World Health Organization. (2017). *Depression and other common mental disorders: Global health estimates* (tech. rep.). World Health Organization. URL: apps.who.int/iris/bitstream/handle/10665/254610/WHO-MSD-MER-2017.2-eng.pdf.

- Yaden, D. B., Potash, J. B., & Griffiths, R. R. (2022). Preparing for the bursting of the psychedelic hype bubble. *JAMA psychiatry*, 79(10), 943–944. DOI: [10.1001/jamapsychiatry.2022.2546](https://doi.org/10.1001/jamapsychiatry.2022.2546).
- Yazar-Klosinski, B. (2024). Midomafetamine-assisted therapy (MDMA-AT) for treatment of post-traumatic stress disorder (PTSD). URL: fda.gov/media/179062/download.